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Thesis Abstract 
Introduction 
Inflammation and platelet activation play a pivotal role in the pathogenesis of acute 
coronary syndrome (ACS). Mounting evidence indicates that microparticles (MP) are 
potent pro-coagulant molecules modulating inflammatory processes. 
 
Aims 
The aim of my study was to investigate the intracoronary and systemic microparticle 
expression in patients with symptomatic coronary heart disease (CHD) and their 
relationship with markers of inflammation, platelet activation and microvascular 
dysfunction (MvD). 
 
Methods 
Forty eight patients with CHD (37 with ACS [23 patients with ST segment 
myocardial infarction (STEMI) and 14 with non-ST segment elevation myocardial 
infarction (NSTEMI)] and 11 with stable angina (SA) treated with percutaneous 
coronary intervention (PCI) were recruited. Blood samples were aspirated 
sequentially from the right atrium (RA) and the coronary (CO) artery (distal to the 
culprit lesion). AnnexinV+ MP (AnV+MP) from platelet poor plasma were measured 
using fluorescent monoclonal antibodies and flow cytometry. Markers of 
inflammation (hs-CRP, IL-6, TNF-α, serum amyloid antigen (SAA) and platelet 
activation (soluble p-selectin and platelet monocyte aggregates (PMA) were 
measured using ELISA. MvD was assessed by measuring the index of microvascular 
resistance (IMR) and coronary wedge pressure (Pw). 
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Results 
The main novel findings of this study are the demonstration of: 1) differences 
between MP levels in patients with varying severity of CHD i.e. MP levels were 
overall higher in those with ACS (more specifically the highest MP levels were 
observed in the STEMI patients) compared with SA; 2. differential local and 
systemic AnV+ MP expression in human coronary artery disease; 3. differential local 
and systemic expression of inflammatory markers in ACS patients; 4. differential 
local and systemic expression of markers of platelet activation in ACS patients; 5. 
positive correlation between AnV+MP and markers of inflammation, platelet 
activation and myocardial necrosis in ACS patients both in the CO and RA; and 6. 
positive correlation between invasive markers of microvascular dysfunction and 
PMA in human coronary artery disease. 
 
Conclusions 
High levels of AnV+MP occur in the coronary artery of patients with ACS. Levels of 
AnV+MP correlate with severity of the ischaemic lesion since higher MPs were 
detected in the STEMI versus the NSTEMI and SA groups. Markers of platelet 
activation and inflammation in ACS patients, both at the site of the culprit lesion and 
in the systemic circulation, strongly correlated with total and cell specific AnV+MP. 
The interaction between activated platelets and monocytes with endothelial cells and 
the subsequent formation of AnV+MP and PMA during ACS would be compatible 
with a direct pathogenic link between inflammatory and prothrombotic pathways in 
the pathogenesis of ACS and myocardial necrosis. This may suggest a novel role for 
MPs as effectors of the inflammatory response and cellular injury in ACS. Our 
observations also support the hypothesis that PMA formation may be important 
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determinants of platelet activation, inflammation and microvascular dysfunction in 
coronary artery disease. Whether these MP merely reflect the severity of the 
ischaemic lesion, and/or are active participants in the pathogenesis of ACS now 
warrants further study, since these could be important, novel therapeutic targets. 
 7 
Figures 
 
Figure 2.1 Identification of platelet monocyte aggregates with flow cytometry   88 
Figure 2.2 Identification and analysis of AnnexinV+ microparticles with flow cytometric   93 
Figure 2.3 Conversion equation for microparticles number calculation    95 
Figure 2.4 Standard curve for TNF-α and IL-6 concentration calculation   98 
Figure 2.5 Standard curve for soluble P-Selectin concentration calculation   100 
Figure 3.1 Differences of the total AnV+MP and MP subpopulations in the coronary artery between 
the three patient groups         116 
Figure 3.2 Differences of the total AnV+MP and MP subpopulations in the right atrium between the 
three patient groups         118 
Figure 3.3 Correlation between the ischaemic time and microparticles in the coronary artery in the 
non-ST-segment elevation myocardial infarction group     121 
Figure 4.1 Differences of the AnV+ microparticles in the coronary artery between the acute coronary 
syndrome and stable angina groups        134 
Figure 4.2 Differences of the AnV+ microparticles in right atrium between the acute coronary 
syndrome and stable angina groups        135 
Figure 4.3 Correlation between AnV+ microparticles and markers of inflammation and myocardial 
injury in the coronary artery in the acute coronary syndrome     138 
Figure 4.4 Correlation between AnV+ microparticles and markers of inflammation and myocardial 
injury in the right atrium in the acute coronary syndrome     139 
Figure 5.1 Differences in total PMA, CD62P+PMA and soluble P-selectin between the acute coronary 
syndrome and stable angina groups        152 
Figure 5.2 Correlation between AnV+ microparticles and markers of platelet activation in the 
coronary in the acute coronary syndrome group      153 
Figure 5.3 Correlation between AnV+ microparticles and soluble P-selectin in the right atrium in the 
acute coronary group         155 
Figure 6.1 Total PMA and CD62P+ PMA in the coronary artery, aorta and the right atrium 170 
Figure 6.2 Differences of IMR and Pw in patients with NSTEMI and SA   171 
Figure 6.3 Correlation between Pw and IMR with PMA in NSTEMI patients   172 
Figure 6.4 Correlation between Pw and IMR with PMA in SA patients    173 
 8 
Tables 
 
Table 2.1 Cell specific monoclonal antibodies and other reagents used for microparticle 
characterization          96 
Table 3.1 Baseline characteristics, demographics and angiographic data of the study groups 114 
Table 3.2 Differences of microparticles expression in the coronary artery   115 
Table 3.3 Differences of microparticles expression in the right atrium in the three groups  117 
Table 3.4 Differences of the total AnV+MP and MP subpopulations between coronary artery and right 
atrium in the three groups         120 
Table 4.1 Baseline characteristics, demographics and angiographic data of the acute coronary 
syndrome and stable angina groups        133 
Table 4.2 Differences of the AnV+ microparticles between the acute coronary syndrome and stable 
angina groups in the coronary artery and the right atrium     134 
Table 4.3 Differences of the total AnV+MP and MP subpopulations between coronary artery and right 
atrium in the acute coronary syndrome and stable angina groups    136 
Table 4.4 Differences of the inflammatory markers between the acute coronary syndrome and stable 
angina patients in the coronary artery and the right atrium     137 
Table 5.1 Spearman correlations between AnV+MP and markers of platelet activation in the coronary 
artery in the acute coronary syndrome group       154 
Table 6.1 Baseline characteristics, demographics and angiographic data of the non ST elevation 
myocardial infarction and stable angina groups      169 
 
 9 
Table of contents 
FIGURES          7 
TABLES          8 
TABLE OF CONTENTS        9 
ABBREVIATIONS         13 
CHAPTER 1: INTRODUCTION AND THESIS AIMS     15 
1.1 PLATELET ACTIVATION IN CORONARY HEART DISEASE   16 
1.1.1 Role of platelet activation and aggregation in haemostasis    16 
1.1.2 P-selectin and platelet activation       19 
1.1.3 Platelet activation and coronary thrombosis in acute coronary syndrome   20 
 
1.2 PLATELET MONOCYTE INTERACTIONS      21 
1.2.1 Platelet-monocyte aggregate formation       21 
1.2.2 The pathophysiologic significance of platelet-monocyte aggregate formation in coronary heart 
disease           21 
1.2.3 Clinical significance of platelet-monocyte aggregate in coronary heart disease  24 
1.2.4 Differential expression of platelet-monocyte aggregate in the coronary artery and peripheral 
circulation          27 
 
1.3 MICROPARTCLE         29 
1.3.1 Introduction         29 
1.3.2 Microparticle formation        30 
1.3.3 Microparticle composition        31 
1.3.4 Biological effects of microparticles       32 
1.3.4.1 Coagulation        32 
1.3.4.2 Inflammation        33 
1.3.4.3 Endothelial dysfunction       34 
1.3.4.4 Angiogenesis        36 
1.3.5 Clinical significance of microparticle formation in coronary heart disease   37 
1.3.6 Lifespan of circulating microparticles       41 
1.3.7 Microparticles and inflammatory markers      41 
 
1.4 ROLE OF INFLAMMATION IN CORONARY HEART DISEASE   43 
1.4.1 Normal artery structure        43 
1.4.2 Endothelial cells         44 
1.4.3 Smooth muscle cells         45 
1.4.4 Initiation and evolution of atheromatous plaque      45 
1.4.5 Evolution of plaque         47 
1.4.6 Arterial extracellular matrix        49 
1.4.7 Angiogenesis in atheromatous plaques       50 
1.4.8 Plaque mineralization        50 
1.4.9 Arterial stenosis and their clinical implications      51 
1.4.10 Atheromatous plaque inflammation, rupture and thrombosis    52 
1.4.11 Inflammation regulates the thrombogenicity of plaques     54 
1.4.12 Superficial erosion and coronary thrombosis      54 
1.4.13 Diffuse and systemic nature inflammation in atherogenesis    55 
1.4.14 Inflammatory markers and myocardial necrosis in acute coronary syndrome  56 
1.4.14.1 Role of C-reactive protein in coronary heart disease    58 
       1.4.14.2 Role of serum amyloid antigen in coronary heart disease   59 
       1.4.14.3 Role of IL-6 in coronary heart disease     60 
       1.4.14.4 Role of TNF-α in coronary heart disease     60 
 
 10 
1.5 MICROVASCULAR DYSFUNCTION IN CORONARY HEART DISEASE  62 
1.5.1 Introduction         62 
1.5.2 Coronary circulation and coronary blood flow control     62 
1.5.3 Physiologic assessment of epicardial coronary artery stenosis    64 
1.5.4 Fractional Flow Reserve        66 
1.5.5 Role of Collaterals in coronary microcirculation      68 
1.5.6 Coronary flow reserve        70 
1.5.7 Measurement of coronary flow reserve by Doppler flow wire    71 
1.5.8 Limitations of coronary flow reserve       73 
1.5.9 Measuring the index of microvascular resistance and coronary flow reserve with pressure-
temperature sensor wire         73 
1.5.10 Reproducibility and Independence of the index of microvascular resistance from epicardial 
artery stenosis          76 
1.5.11 Clinical implications of measurement of the index of microvascular resistance  77 
1.5.12 Conclusions         79 
 
1.6 AIMS OF THIS THESIS        80 
 
CHAPTER 2: PATIENTS AND METHODS      81 
 
2.1 CORONARY HEART DISEASE PATIENTS      82 
2.1.1 Stable angina patients.        82 
2.1.2 Non-ST-elevation myocardial infarction patients     83 
2.1.3 ST-elevation myocardial infarction patients      83 
2.1.4 Exclusion criteria         84 
2.1.5 Percutaneous Coronary Interventions       84 
 
2.2 IDENTIFICATION OF PLATELET MONOCYTE AGGREGATES   85 
2.2.1 Collection of whole blood for platelet-monocyte aggregate estimation   85 
2.2.2 Preparation of whole blood for platelet-monocyte aggregate estimation   86 
2.2.3 Flow Cytometric identification of platelet-monocyte aggregate    86 
 
2.3 ISOLATION AND ANALYSIS OF TOTAL ANNEXIN V POSITIVE MICROPARTICLE 
AND MICROPARTICLE SUBPOPULATIONS      90 
2.3.1 Preparation of platelet poor plasma       90 
2.3.2 Isolation of microparticles from platelet poor plasma     90 
2.3.3 Labelling of microparticles with Annexin V and monoclonal antibodies   90 
2.3.4 Flow cytometric analysis of microparticles      92 
2.3.5 Determination of absolute microparticle number per ml of plasma    94 
 
2.4 ESTIMATION OF INFLAMMATORY MARKERS AND SOLUBLE P SELECTIN 97 
2.4.1 Collection and Preparation of platelet poor plasma for estimation of inflammatory markers and 
soluble P-selectin          97 
2.4.2 ELISA          97 
2.4.2.1 Estimation of TNF-α and IL-6       97 
2.4.2.2 Estimation of soluble P-selectin       99 
2.4.2.3 Estimation of high sensitive C- reactive protein and serum amyloid antigen  101 
 
2.5 MEASURING THE INDEX OF MICROVASCULAR RESISTANCE, CORONARY FLOW 
RESERVE AND CORONARY WEDGW PRESSURE     102 
 
2.6 RECRUITMENT LIMITATIONS AND PRACTICAL CONSIDERATIONS  104 
 
CHAPTER 3: PHENOTYPIC CHARACTERISATION OF LOCAL AND SYSTEMIC 
MICROPARTICLE EXPRESSION IN PATIENTS WITH ACUTE CORONARY SYNDROME 
AND STABLE CORONARY HEART DISEASE      105 
 
3.1 SUMMARY          106 
 
3.2 INTRODUCTION AND AIMS       108 
 11 
3.3 PATIENTS AND METHODS        109 
3.3.1 Study population         109 
3.3.2 Exclusion criteria         110 
3.3.3 Coronary angiography, coronary angioplasty and blood sampling    110 
3.3.4 MP identification and characterization using flow cytometry    112 
3.3.5 Statistical analyses         113 
 
3.4 RESULTS          113 
3.4.1 AnV+ MP expression in the coronary artery in the STEMI, NSTEMI and SA patients 114 
3.4.2 AnV+MP expression in the right atrium in the STEMI, NSTEMI and SA patients  116 
3.4.3 AnV+ MP expression in the coronary and right atrium in the three groups   118 
3.4.4 MP expression and ischaemic time       121 
 
3.5 DISCUSSION         121 
 
3.6 CONCLUSIONS         124 
 
CHAPTER 4: MICROPARTICLE EXPRESSION IN PATIENTS UNDERGOING PCI FOR 
ACUTE CORONARY SYNDROME AND STABLE HEART DISEASE: CORRELATION 
WITH INTRACORONARY INFLAMMATION AND MYOCARDIAL NECROSIS  125 
 
4.1 SUMMARY          126 
 
4.2 INTRODUCTION AND AIMS       128 
 
4.3 PATIENTS AND METHODS        130 
4.3.1 Study population         130 
4.3.2 Exclusion criteria         130 
4.3.3 Coronary angiography, PCI and blood sampling      131 
4.3.4 Preparation of platelet poor plasma (PPP) MP Cytometric identification and ELISA  131 
4.3.5 MP identification and characterization using flow cytometry    131 
4.3.6 Estimation of TNF-α, IL-6, hs-CRP and SAA       131 
4.3.7 Statistical analyses         132 
 
4.4 RESULTS          132 
4.4.1 High levels of local CO AnV+MP are detected in patients with ACS   133 
4.4.2 Platelet, endothelial and leucocyte MP levels are higher in the systemic (RA) circulation of 
patients with ACS compared with SA       135 
4.4.3 High coronary AnV+MP levels and IL-6 are observed in ACS patients   136 
4.4.4 Coronary inflammatory markers correlate with MP levels and troponin T in ACS  137 
4.4.5 Right atrial IL-6 levels correlate with MP levels and troponin T in ACS   138 
 
4.5 DISCUSSION         139 
 
4.6 CONCLUSIONS         142 
 
CHAPTER 5: MICROPARTICLE EXPRESSION IN HUMAN CORONARY HEART 
DISEASE: RELATIONSHIP TO PLATELET MONOCYTE INTERACTION AND 
PLATELET ACTIVATION        144 
  
5.1 SUMMARY          145 
 
5.2 INTRODUCTION AND AIMS       147 
 
5.3 PATIENTS AND METHODS        149 
5.3.1 Study population         149 
5.3.2 Exclusion criteria         149 
5.3.3 Coronary angiography, PCI and blood sampling      149 
5.3.4 Preparation of whole blood for PMA Cytometric identification    149 
5.3.5 Preparation of platelet poor plasma (PPP) MP Cytometric identification and ELISA  149 
 12 
5.3.6 MP identification and characterization using flow cytometry    150 
5.3.7 Estimation of soluble P-selectin (s P-selectin)      150 
5.3.8 Statistical analyses         150 
5.4 RESULTS          150 
5.4.1 High levels of local CO AnV+MP are detected in patients with ACS   151 
5.4.2 Platelet, endothelial and leucocyte MP levels are higher in the systemic (right atrium) circulation 
of patients with ACS compared with SA       151 
5.4.3 High CD62P+PMA (in both CO and RA) and high CO s-P-selectin were observed in the ACS 
group           151 
5.4.4 Coronary AnV+MP correlate with markers of platelet activation in ACS   152 
5.4.5 Right atrial soluble P-selectin correlate with MP levels in ACS    154 
 
5.5 DISCUSSION         155 
 
5.6 CONCLUSIONS         160 
 
CHAPTER 6: P-SELECTIN ACTIVATED PLATELET MONOCYTE AGGREGATES AND 
MICROVASCULAR DYSFUNCTION IN PATIENTS WITH STABLE ANGINA AND NON-
ST ELEVATION MYOCARDIAL INFARCTION UNDERGOING PCI   161 
 
6.1 SUMMARY          162 
 
6.2 INTRODUCTION AND AIMS       164 
 
6.3 PATIENTS AND METHODS        165 
6.3.1 Study population         165 
6.3.2 Exclusion criteria          166 
6.3.3 Coronary angiography, coronary angioplasty and blood sampling    166 
6.3.4 Measuring IMR and CFR with pressure-temperature sensor wire    166 
6.3.5 Flow Cytometry and PMA methodology      167 
6.3.6 Statistical analysis         168 
 
6.4 RESULTS          168 
6.4.1 Total PMA expression in the CO, AO and RA sites in NSTE-ACS and SA groups  169 
6.4.2 IMR, CFR and Pw in the two groups       170 
6.4.3 Correlations between IMR, Pw and PMA      171 
 
6.5 DISCUSSION         173 
 
6.6 CONCLUSIONS         175 
 
CHAPTER 7: GENERAL DISCUSION AND CONCLUSIONS    176 
 
7.1 GENERAL DISCUSSION        177 
7.2 CONCLUSIONS         186 
 
REFERENCE LIST         187 
 
PUBLICATIONS FROM THIS THESIS       214 
 
 
 
 13 
Abbreviations 
 
Abbreviation Definition 
ACS Acute Coronary Syndrome 
ACT  Activated Clotting Time 
ADP Adenosine di-Phosphate 
AMI  Acute Myocardial Infarction 
AnV Annexin V 
AnV+MP Annexin V+ Microparticle 
AO Aorta 
CD Cluster of differentiation 
CAC Circulating angiogenic cells 
CHD Coronary Heart Disease 
CFR Coronary Flow Reserve 
CK Creatine Kinase 
CO Coronary Artery 
COX-1 Cyclooxygenase-1 
CV  Coefficient of Variation 
CVD Cardiovascular diseases 
CXCL10 C-X-C motif chemokine 10 
EDTA Ethylenediaminetetra-acetic acid 
EMP  Endothelial derived Microparticle 
FITC  Fluorescein Isothiocyanate 
FFR Fractional Flow Reserve 
HDL High Density Lipoprotein 
hs-CRP Highly sensitive C-Reactive Protein 
ICAM-1 Intercellular Cell Adhesion Molecule-1 
INF-γ interferon-γ 
IL Interleukin 
IMR  Index of Microvascular Resistance 
IQR Inter Quartile Range 
LDL  Low Density Lipoprotein 
Left ventricular hypertrophy LVH 
LPS Lipopolysaccharide (Endotoxin) 
mAb Monoclonal Antibody 
Mac-1  Macrophage 1 Antigen 
MMP Monocyte derived Microparticle 
MMPr metalloproteinase enzymes 
MVD Microvascular dysfunction 
MVO Microvascular obstruction 
MPV Mean platelet volume 
MCP-1 Monocyte Chemotactic Protein- 1 
MP Microparticle 
MPO Myeloperoxidase 
NSTEMI Non-ST Elevation Myocardial Infarction 
NF-kB Nuclear Factor Kappa light chain enhancer of activated 
B cells 
 14 
NO Nitric Oxide 
NMP Neutrophils derived Microparticle 
Pa aortic pressure 
PAF Platelet-activating factor 
PAI-1 Plasminogen Activator Inhibitor 1 
PAR Protease-activated Receptors 
PCI Percutaneous Coronary Intervention 
Pd Distal Coronary pressure 
PDGF Platelet Derived Growth Factor 
PE  Phycoerythrin 
PerCP Peridinin-Chlorophyll-Protein Complex 
PerCP-Cy5 Peridinin-Chlorophyll-Protein Complex with cyanine-
5.5 
PF4 Platelet factor 4 
PLT Platelet 
PMA Platelet-Monocyte Aggregates 
PMP Platelet derived Microparticle 
pPCI Primary Percutaneous Coronary Intervention 
PS Phosphatidylserine 
PSGL-1 P selectin Glycoprotein Ligand 1 
Pv Central venous pressure 
Pw Coronary wedge Pressure 
RA Right Atrium 
RANTES Regulated on Activation, Normal T cell Expressed and 
Secreted 
SA Stable Angina 
SMCs smooth muscle cells 
s-P-Selectin Soluble P-Selectin 
SSA serum amyloid-A 
SSC  Side-scatter 
STEMI  ST Elevation Myocardial Infarction 
TF Tissue Factor 
TFPI tissue factor pathway inhibitor 
TGF-β transforming growth factor-β 
TH1 Type 1 T Helper Cell 
TH2 Type 2 T Helper Cell 
TIMI Thrombolysis in myocardial infarction 
Tm Mean transit time 
TNF-α Tumour Necrosis Factor-α 
Trop T Troponin T 
TXA2 thromboxane A2 
VCAM-1 Vascular Cell Adhesion Molecule 1 
VEGF vascular endothelial growth factor 
vWF von Willebrand factor 
  
 
 
 15 
Chapter 1: Introduction 
1.1 Platelet activation in coronary heart disease  
 
1.2 Platelet monocyte interactions       
 
1.3 Microparticle 
          
1.4 Role of inflammation in coronary heart disease 
 
1.5 Microvascular dysfunction in coronary heart disease 
 
1.6 Aims of this thesis 
 16 
1.1 Platelet activation in coronary heart disease 
1.1.1 Role of platelet activation and aggregation in haemostasis  
Platelets are anucleate membrane particles produced from fragmented 
megakaryocytes of the bone marrow. Once they are released into the circulation, 
platelets have a life span of 7 to 10 days. Platelets contain only m-RNA and as such 
have limited ability to synthesize proteins. Platelet production is regulated mainly by 
thrombopoietin, a glycoprotein synthesized in the liver and kidneys (1). Platelets play 
a crucial role in the transformation of the ruptured or eroded atherosclerotic plaque to 
an unstable lesion and the initiation of thrombosis at the site of the complicated 
atherosclerotic plaque (2). Rupture, erosion or ulceration of an atherosclerotic plaque 
exposes the subendothelial thrombogenic extracellular matrix (collagen and tissue 
factor bearing microparticles) to circulating blood. The first step in thrombus 
formation is platelet adhesion to collagen via the platelet glycoproteins GP Iβ (α2β1) 
and GP VI which bind directly to collagen and platelet glycoprotein GPIIβ/IIIα via 
the von Willebrand factor (vWF) which acts as a bridge between platelet’s receptor 
GPIIβ/IIIα and collagen. Von Willebrand factor is synthesized by endothelial cells 
(storage in Weibel-Palade bodies) and megakaryocytes (alpha granules). It assembles 
into multimers that range from 550 to over 10,000 kDa (3). There is considerable 
difference in reactivity between circulating and anchored (in the arterial sub-intima) 
vWF which is the result of the variation of vWF conformation. Most of the vWF 
released from storage enters the circulation in a warped conformation that does not 
allow contact of its platelet-binding domain to vWF receptors on the platelet surface. 
Contrary to the above vWF released from the abluminal surface of endothelial cells 
accumulates in the subendothelial matrix, where it binds collagen through its A3 
domain and platelets through its A1 domain which is exposed (4). vWF multimers 
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act as the adhesive that tethers platelets to the subendothelial matrix. Large vWF 
multimers provide additional binding sites for collagen, and enhance platelet 
adhesion because platelets have more vWF receptors than collagen receptors (5). 
Platelet adhesion to collagen or vWF initiates signalling pathways that result in 
platelet activation which is the next step in platelet plug formation. These pathways 
induce cyclooxygenase-1 (COX-1)–dependent synthesis and release of thromboxane 
A2 (TXA2), and the release of ADP from storage granules. Both TXA2 and ADP 
amplify platelet activation through binding to their platelet receptors. This process 
results in platelet recruitment and further expansion of the platelet plug.  
Thromboxane receptor (TR) is found on platelets and on the endothelium also (6)  
which explains why TXA2 is a potent vasocontrictive molecule. ADP platelet 
receptors are G protein–coupled receptors on the platelet membrane (7). The most 
important ADP receptor is P2Y12 which is the thienopyridine’s target, but P2Y1 also 
contributes to ADP-induced platelet activation. Maximal ADP-induced platelet 
activation requires activation of both receptors. A third ADP receptor, P2X1, is an 
ATP-gated calcium channel. The final effect on platelets of TR and the ADP 
receptors signal is the increase in intracellular calcium concentration. Platelet 
activation leads to (a) morphological shape change via cytoskeleton rearrangement of 
the platelet which increases the platelet surface area on which thrombin generation 
can occur (b) degranulation of the platelet alpha and dense granules, releasing TXA2, 
ADP, serotonin, p-selectin and other platelet aggregatory and chemoattractant agents 
(c) increased platelet membrane expression of the GPIIβIIIα receptor followed by a 
conformational change of the receptor that enhances its affinity for fibrinogen and 
(d) platelet aggregation, in which fibrinogen binds to the activated platelet fibrinogen 
inhibitor GPIIβIIIα, causing a growing platelet plug. Part of the platelet activation 
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process is the release of platelet derived microparticle (MP formation is discussed in 
section 1.3). At the same time with platelet plug formation, activation of coagulation 
cascade occurs. Activated platelets promote coagulation by expressing phosphatidyl 
serine on their surface; an anionic phospholipid that is highly thrombogenic and a 
perfect substrate on which coagulation factors become activated. Once these clotting 
factor complexes are assembled they generate thrombin. In addition to converting 
fibrinogen to fibrin, thrombin enhances platelet recruitment and activation via the 
thrombin receptors (protease-activated receptors types 1 and 4 [PAR1 and PAR4] 
respectively) thereby promoting expansion of the platelet plug. This final step of clot 
formation is facilitated by the stabilizing effects of factor XIII. Platelet aggregation is 
the final step in the formation of the platelet haemostatic plug. GPIIb/IIIa expressed 
on the activated platelet mediates these platelet-to-platelet linkages. Divalent 
fibrinogen and multivalent vWF molecules serve as bridges and bind adjacent 
platelets together. Once bound to GPIIb/IIIa, fibrinogen and vWF trigger signals that 
augment platelet activation and result in the activation of additional GPIIb/IIIa 
receptors, creating a positive feedback loop. Because GPIIb/IIIa acts as the final 
effector in platelet aggregation, it is a logical target for potent antiplatelet drugs. 
Fibrin, the ultimate product of the coagulation system, tethers the platelet aggregate 
together and fix them to the site of injury. Therefore, an orchestrated response of 
activated platelets and coagulation cascade occur that results in fibrin network 
formation from thrombin action which helps anchoring the platelet-fibrin net plug 
formation at the site of injury. Activated platelets also release adhesive proteins, such 
as vWF, thrombospondin, and fibronectin which amplify platelet adhesion at sites of 
injury, as well as growth factors, such as platelet-derived growth factor (PDGF) and 
transforming growth factor-β (TGF-β) both which promote wound healing. 
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1.1.2 P-selectin and platelet activation 
P-selectin belongs to the selectin family of transmembrane proteins. It has a 140 KDa 
weight and is stored in the Webel-Palade bodied of the platelets and the endothelial 
cells (8). P-selectin consists of three domains: N-terminal, trans-membrane and  
cytoplasmic domains (9). Upon activation, endothelial cells and platelets express P-
selectin on their surface which binds to the P-selectin ligand (PSGL-1) on the 
leukocytes through which P-selectin exerts its biological activities. P-selectin 
mediates platelet-leukocyte interaction via the P-selectin-PSGL-1 bond which leads 
to leukocyte activation and recruitment at the site of inflammation (10). Hahne et all 
have shown that inflammatory mediators like as tumour necrosis factor-α (TNF-α), 
lipopolysaccharide (LPS) and interleukin-4 (IL-4) increase P-selectin production 
from endothelial cells in addition to upregulating P-selectin at the cell surface within 
minutes after stimulation with TNF-α, both the above effects are additive (11). 
Soon after P-selectin is expressed on the platelet or endothelial cell membrane, it 
undergoes enzymatic cleavage at the junction between the N-terminal portion and the 
transmembrane domain. The N-terminal domain is released in the circulation and 
represents the soluble P-selectin (s-P-selectin) (12;13). It has been shown that soluble 
P-selectin has the same biological activities as the attached to the cells P-selectin 
(14). P-selectin plays an essential role in the initial recruitment of leukocytes to the 
site of injury during inflammation. Endothelial cells activated by molecules such as 
histamine or thrombin during inflammation express P-selectin on the endothelial cell 
surface. P-selectin then interacts with PSGL on the monocytes/and leukocytes 
facilitating the recruitment and activation of inflammatory cells (15). P-selectin is 
also very important in the recruitment and aggregation of platelets at areas of 
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vascular injury promoting platelet aggregation and activation through platelet-fibrin 
and platelet-platelet binding. 
 
1.1.3 Platelet activation and coronary thrombosis in acute coronary syndrome 
Although the pathophysiology of acute coronary syndrome (ACS) is multifactorial, 
atheromatous plaque rupture or erosion with superimposed thrombus is the most 
common cause of ACS. Other coexisting pathophysiologic processes contributing to 
the development of ACS include 1) dynamic obstruction of the epicardial coronary 
artery due to a) artery spasm in the presence of surplus, in the ACS setting, of 
vasoconstrictive and prothrombotic molecules released from the activated platelets, 
b) peripheral embolization of debris and c) endothelial dysfunction which almost 
always exist in these patients 2) severe luminal narrowing caused by progressive 
coronary atherosclerosis 3) restenosis after coronary interventions 3) intracoronary 
and systemic inflammation 4) coronary ischaemia related to decreased oxygen 
supply (anaemia) or increased oxygen demand (fever and tachycardia) of the 
myocardium. The following observations support the central role of coronary artery 
thrombosis in the pathogenesis of ACS: (a) the frequent finding of thrombus with 
coronary angioscopy (b) the demonstration with coronary angiography, intravascular 
ultrasound and optical coherence tomography of plaque ulceration or irregularities 
suggesting a ruptured plaque or thrombus (c) autopsy findings that coronary artery 
thrombi usually localized at the site of the ruptured or eroded coronary plaque (16) 
(d) the elevation of several serum markers of platelet activation and fibrin formation 
and (e) antiplatelet and antithrombotic therapy improves the clinical outcomes. 
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1.2 Platelet-monocyte interactions 
1.2.1 Platelet monocyte aggregate formation  
Activated platelets accumulate at the sites of atheromatous plaque rupture (17) via 
interaction with the vWF of the subendothelial collagen as described above. During 
platelet activation, P-selectin expression on their surface facilitates platelet binding 
and interaction with leukocytes, via the PSGL-1 on the leukocyte surface, leading to 
platelet-monocyte aggregate formation (PMA). This interaction between activated 
platelet and leukocyte may alter leukocyte migration, recruitment and activation 
patterns (18). It has also been shown that activated platelets lose their surface P-
selectin despite the fact they continue to circulate and function (19). Therefore PMA 
measurement may represent a more robust marker of platelet activation than 
detection of P-selectin on their surface (20-22). 
 
1.2.2 The pathophysiologic significance of platelet-monocyte aggregate 
formation in coronary heart disease 
The role of PMA formation in the pathophysiology of coronary heart disease (CHD) 
remains unknown. Whether PMA formation is just a bystander of the inflammatory 
and thrombotic process occurring in the setting of ACS or whether the PMA is an 
effector of disease remains unclear. Nevertheless P-selectin on the surface of 
activated platelets induces monocyte TF expression and binding of P-selectin to 
monocytes in the setting of a ruptured atheromatous plaque during ACS which may 
trigger or contribute to the cascade of thrombosis (23). In addition, pro-inflammatory 
cytokines e.g. TNF-α and IL-1 also partially regulate the expression of TF on 
endothelial cells and monocytes (24).  
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Neumann et al showed that in patients with acute myocardial infarction (AMI) 
thrombin stimulated platelets induce monocyte cytokines, IL-1β, IL-8, and monocyte 
chemotactic protein-1 (MCP-1) expression, a process that is regulated by NF-kB 
activity. It has also been shown that secretion of these chemokines is not, however, 
directly signalled by P-selectin. Instead, tethering of the monocytes by P-selectin is 
required for their activation by a platelet chemokine, RANTES (25). Weyrich et al 
have demonstrated that adhesion of human monocytes to P-selectin, the most rapidly 
expressed endothelial tethering factor, increased the secretion of MCP-1 and TNF-α 
by the leukocytes when they were stimulated with platelet-activating factor (PAF). 
Increased cytokine secretion was specifically inhibited by G1, an anti P-selectin mAb 
that prevents P-selectin from binding to its ligand, PSGL-1, on myeloid cells (25).  
Activated platelets also express CD40 ligand (CD154), a molecule critical to 
adaptive immune responses, which has been implicated in platelet-mediated 
modulation of innate immune responses and inflammation. Binding of CD40L to 
CD40 on monocytes leads to monocyte activation and secretion of pro-inflammatory 
cytokines including IL-6 which is associated with unstable angina (26;27),  and often 
associated with increased C-reactive protein (CRP) (28). Binding of non-activated 
platelets does not affect receptor expression, cytokine production, NF-kB activation, 
chemotactic responses, or apoptosis. In contrast binding of activated platelets does 
trigger pro-inflammatory responses in monocytes. Bournazos et al, in line with the 
above, showed that in the absence of overt platelet activation P-selectin-PSGL-1 
dependent monocyte-platelet interaction represents a normal physiological process 
with little impact on the potential of monocytes to cause vascular injury (29). They 
concluded that high levels of P-selectin on the surface of activated platelets or 
binding of multiple platelets per monocyte are required to trigger monocyte 
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activation via the P- selectin-PSGL-1 pathway. In addition they also suggest that 
release of a range of cytokines, including IL-1ß, IL-6 and IL-12 after platelet 
activation might provide additional signals that lower the threshold for monocyte 
responsiveness. 
The extent of PMA formation depends mainly on platelet activation status rather than 
the monocyte activation (30). It has been shown that prevention of platelet adhesion 
to monocytes by interfering with the binding of platelet P-selectin to PSGL-1 reduces 
inflammation (31). Platelet binding to monocytes via the P-selectin dependant 
pathway increases the adhesive properties of monocytes by up-regulating the 
expression and functionality of beta1 and beta2 integrins (32;33). This process is 
facilitated by the presence of RANTES and CXCL10 chemokines produced by 
platelets on to the monocytes (34). Binding of platelets to monocytes induce TF 
expression on the monocyte surface in addition to increasing the release of pro-
inflammatory chemokines. P-Selectin-PSGL-1 interaction is important but not 
exclusively responsible for this process. TF expression on the PMA is found to be 
reduced by a P-selectin blocking antibody (35). 
In summary, activated platelet-monocyte interaction leads to monocyte activation 
which consequently transforms the monocyte into a more pro-inflammatory cell 
through the production of chemokines such as IL-6 and TNF-α and more pro-
coagulant cell, via TF expression on the monocyte surface. 
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1.2.3 Clinical significance of platelet-monocyte aggregate in coronary heart 
disease 
Increased PMA levels have been observed in patients with stable CHD compared 
with normal control subjects (36). Furman et al have also found higher circulating 
PMA in patients with AMI who presented within 4 hours of symptoms compared to 
unstable angina patients concluding that PMA formation is an early marker of AMI 
(37). Similarly Sarma et al studied 13 patients with AMI, twelve patients with 
unstable angina and 27 patients with non-cardiac chest pain. They found significantly 
elevated PMA in patients with AMI and unstable angina compared with those with 
non-cardiac chest pain. They also reported that calcium independent PMA formation 
is significantly higher in AMI group (38). 
Ray et al demonstrated elevated markers of platelet activation including PMA and 
soluble P-selectin in patients with CHD prior to percutaneous coronary intervention 
(PCI) (20). Furthermore increased levels of PMA before PCI were associated with 
increased expression of P-selectin on the platelet. They found that patients with 
higher levels of PMA prior to PCI were more likely to develop an elevation of 
cardiac troponin I during the first 24h after PCI and that PMA levels may identify 
patients at risk for troponin elevation following PCI (20). 
PMA have also been studied in patients with ACS who underwent PCI with 
concurrent administration of Glycoprotein IIb/IIIa inhibitors (20;39). Both studies 
have shown that inhibition of platelet-platelet adhesion and activation via 
glycoprotein IIb/IIIa inhibitors leads to PMA formation reduction in addition to the 
reduction of platelet activation and degranulation.  
Suboptimal angiographic results following coronary interventions, where PCI 
achieves epicardial coronary perfusion but not myocardial perfusion occurs in a 
 25 
proportion of patients and is called ‘no-reflow phenomenon’. No reflow phenomenon 
is a poorly understood complication of PCI and is defined as transient cessation of 
blood flow, due to microvascular obstruction, in the epicardial coronary artery during 
PCI despite the removal of the luminal obstruction. Recently experimental and 
clinical data have shown that no-reflow phenomenon occurs after reperfusion with a 
variable prevalence ranging between 5 to 20% (40). 
Notably the incidence of post-AMI complications including arrhythmias, adverse left 
ventricular remodelling with heart failure and overall mortality is higher in patients 
with no reflow phenomenon. No reflow phenomenon has a multifactorial 
pathogenesis including distal embolization, ischemia injury, reperfusion injury and 
individual predisposition of coronary microcirculation to injury. Distal embolization 
can occur either from coronary thrombus formed in-situ or debris from the ruptured 
atherosclerotic plaque during ACS (41). Ischemia related injury involves endothelial 
cells swelling and protrusion in the artery lumen, myocardial cells swelling and 
interstitial oedema. All the above factors lead to compromise of coronary 
microcirculatory flow (42;43). 
Reperfusion myocardial injury is mediated via leukocytes and platelets infiltrating 
the injured reperfused myocardium which become activated. Activated neutrophils 
release a variety of cytotoxic agents (i.e. oxygen free radicals, proteolytic enzymes) 
and pro-inflammatory mediators that cause tissue and endothelial damage. Activated 
platelets also bind leukocytes forming PMA which can cause mechanical plugging of 
the capillaries blocking the flow (44;45). Additionally activated platelets, endothelial 
cells and monocytes release vasoconstrictive substances contributing to local 
vasoconstriction of the coronary microcirculation compromising further the 
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perfusion (46). Activated platelets express P-selectin on their surface which bind to 
monocyte via the p-selectin ligand as described earlier in this chapter. 
PMA formation of at the site of plaque rupture with subsequent monocyte activation 
and cytokine release may play an unfavourable role in the restoration of 
microcirculatory flow. Ko et al have found increased levels of soluble CD40 ligand, 
IL-6, serotonin, TF and factor VII in the culprit coronary artery compared to those in 
peripheral blood (47). Also a positive relationship between inflammatory markers 
(IL6 and CRP) and markers of platelet activation like P-selectin and PMA has been 
demonstrated by Wang et al (48). Therefore the possibility that PMA may contribute 
in the pathophysiology of microvascular dysfunction via exaggerating and sustaining 
the coagulation cascade in addition to perpetuating local coronary inflammation 
exist. 
Takahashi et al have showed that neutrophilia on admission is associated with 
impaired microvascular reperfusion and poor functional recovery in patients with 
STEMI treated with primary PCI. Similar finding were found by Sezer et al (49). In 
this study the authors studied 41 patients with anterior STEMI treated with primary 
PCI. They assessed the MvD invasively using Coronary Flow Reserve (CFR), the 
index of Microvascular Resistance (IMR) and coronary wedge Pressure (Pw). 
Thermodilution-derived technique and a pressure-temperature sensor-tipped guide-
wire in the left anterior descending artery, within 48 h after primary PCI, was used to 
calculate the CFR and IMR. Increased neutrophil count and higher mean platelet 
volume are found to be associated with higher IMR lower CFR and higher coronary 
wedge pressure. Therefore the association of mean platelet volume (MPV) and 
impaired microvascular perfusion can represent platelet-leukocyte complex and 
platelet-platelet aggregate mediated microvascular injury and endothelial dysfunction 
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in coronary arterioles and capillaries. Individual predisposition of coronary 
microcirculation to no-reflow can be genetic and/or acquired. Particularly diabetes 
mellitus has been associated with impaired microvascular reperfusion after primary 
PCI, while hypercholesterolemia in the animal model aggravates reperfusion injury 
by enhancing endothelial oxidative stress (50). 
 
1.2.4 Differential expression of platelet-monocyte aggregate in the coronary 
artery and peripheral circulation 
PMA formation is increased in CHD in both stable angina and unstable coronary 
syndromes as discussed above (36;51). In addition patients who have had coronary 
interventions, there is increased PMA expression (20). It has been suggested that 
increased platelet-monocyte interaction at the site of the ruptured atheromatous 
plaque may well be a contributing factor in the pathogenesis of no-reflow 
phenomenon. Botto et al have demonstrated increased platelet-monocyte interaction 
and PMA formation in blood samples aspirated from the infarct related artery (IRA) 
compared with the peripheral circulation in patients presented with AMI (52). The 
concept of an active involvement of PMA in ACS has been supported with the 
observations by Patel et al who demonstrated trans-coronary gradient of platelet-
leukocyte formation in patients with ACS. They found increased PMA level in the 
coronary sinus samples compared to the aortic samples in both patients with ACS 
and stable angina (21). The increment was 22% in ACS group and 16% in the stable 
angina group.  
In conclusion PMA is a sensitive marker of platelet activation but also may be the 
link between platelet activation, thrombosis and inflammation via monocyte 
activation in patients with CHD. The downstream effect of the increased expression 
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of PMA at the site of the ruptured plaque appears to be the link between platelet 
activation, thrombosis and coronary inflammation in patients with CHD. 
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1.3 Microparticles 
1.3.1 Introduction 
Microparticles (MP) were first described in 1967 when Wolf reported platelet 
membrane fragments in human plasma (53). He called these fragments ‘platelet dust’ 
which are essentially cell vesicles with diameter of less than 0.1µm. MP are 
submicron membrane vesicles 100-1000nm derived from virtually any eukaryotic 
cell during biological processes like cell activation, differentiation and apoptosis. 
Microparticles differ in size and membrane formation including the phospholipids 
and protein composition and their biological effects depend on the initial stimulus 
which led to their formation. Mounting evidence indicates that MP are potent pro-
coagulant molecules affecting vascular endothelial function and regulate the 
inflammatory process (54;55). In healthy individuals MP formation represents a 
physiological process, a fine balance between MP formation and clearance. However 
a variety of diseases, mainly thrombotic, disorders including atherothrombosis (56), 
diabetes mellitus, preeclampsia and systemic inflammatory conditions are associated 
with elevated circulating MP in the peripheral blood (57;58).  The question as to 
whether MP is implicated in the pathogenesis of atherothrombotic diseases or just a 
bystander in these clinical disorders remains to be answered. Platelet derived 
microparticles (PMP) represent 70-80% of circulating MP (59). Endothelial derived 
(EMP), neutrophil derived (NMP), monocyte derived (MMP), and red blood cells 
account for the rest of the MP population. While many questions about the function 
of MP remained to be answered, in general MP propagates the actions of their 
parental cells, the activated platelets in the case of PMP.  
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1.3.2 Microparticle formation 
The initial step in MP formation is plasma membrane budding. This step requires a 
disruption of the asymmetrical distribution of lipids between the inner and outer 
surface of the plasma membrane and cytoskeleton protein reconstruction (60). At rest 
the predominant phospholipids of the outer surface of the cell membrane is 
phosphatidylcholine and sphingomyelin whilst phosphatidylserine (PS) is located in 
the inner monolayer of the cell membrane (61). During cell activation or apoptosis, 
the combination of the activation of the ‘floppase’ protein’ and the inhibition of the 
‘flippase’ protein’ of phospholipid transporters (62) triggered by the increased 
concentration of the intracellular calcium, lead to a rapid and overwhelming 
externalization of the PS (63). The ‘floppase’ (an ATP-dependent trans-membrane 
protein that specifically transfers PS from the inner to exterior surface) mediates the 
rapid outward translocation that is directly responsible for the disruption of 
asymmetry when cells are activated (64). ‘Flippase’ is a trans-membrane protein 
which maintains the normal resting phospholipid distribution with PS being the main 
phospholipid of the inner membrane and phosphatidylcholine and sphingomyelin the 
phospholipids of the external layer of the membrane (65). The above step has been 
named as the flip-flop phenomenon and is the most crucial step in the MP formation 
cascade. In addition, the integrity of the cell membrane, supported by the sub-
membrane cytoskeleton, is believed to contribute to the maintenance of its 
asymmetry and therefore the cell shape. Cytoskeleton reorganization could therefore 
help membrane budding and MP formation. Proteolytic cleavage of the cytoskeleton 
proteins via calcium-activated enzymes (calpains in activated cells or caspases in 
apoptotic cells) results in membrane destabilization and eventually MP formation 
(66). The combined membrane phospholipids and cytoskeleton reconstruction in 
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response to cell activation has been labelled as ‘membrane remodelling’. Membrane 
remodelling of the cells undergoing activation or apoptosis with PS exposure appears 
to be a universal feature and an underlying feature of MP release by these cells (67). 
It is important to underline that the flip-flop phenomenon with rapid externalization 
of PS is a naturally pro-coagulant process. PS borne by MPs provides an excellent 
substrate for the assembly of the pro-thrombinase complex (which consists of the 
coagulant factors Xa the cofactor Va and calcium), leading to thrombin generation 
and clot formation (68). 
As discussed above MP release from activated cells is generally a pro-coagulant 
process. Whether PS negative MP without pro-coagulant activity exists or not is a 
matter of debate. It has been reported that the majority of platelet-derived MPs 
circulating in the platelet poor plasma (PPP) of healthy donors fail to bind AnnexinV 
(AnV) and as such lack phospholipid-dependent pro-coagulant activity (69). 
Nevertheless the nature of the platelets or endothelial cells derived AnV negative MP 
detected by flow cytometry (69;70) and the mechanisms facilitate their release is 
poorly understood. These findings suggest that cell-derived MPs are not only potent 
procoagulant effectors in atherothrombosis but can also convey a variety of different 
molecules, such as, cytokines, enzymes, bioactive lipids and mRNA to the 
neighbouring cells.  
 
1.3.3 Microparticle composition 
MP composition is an important determinant of their biological effects. MP lipid and 
protein composition may vary depending on the parental cell and the stimulus which 
triggered their formation. For example, the phospholipid composition of MPs 
isolated from patients with chronic inflammatory arthritis differs from that of MPs 
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from platelet poor plasma (PPP) of healthy subjects (71). In addition, the degree of 
phospholipid oxidation varies depending on the stimulus initiating the MP release 
(72). 
 
1.3.4 Biological effects of microparticles 
Coagulation, inflammation and endothelial dysfunction are the main biological 
effects of MP. Those mechanisms also play a central role and contribution to the 
evolution of the atheromatous plaque in patients with CHD. Besides the above 
mentioned deleterious MP effects, MP can transfer biological information in the 
form of proteins, adhesion molecules [receptors and integrins], nucleic acids and 
lipids. For those reasons they have been recently described as protagonists of 
intercellular communications and signalling (57;58;73). In addition MP are involved 
in the “cellular waste process” because they contain increased (compared with 
parental cell) concentrations of chemotherapeutics, oxidized phospholipids, or 
caspase 3 (58). Caspase 3, an intracellular cleavage enzyme, accumulates in 
endothelial cells. EC which undergo apoptosis release caspases 3–containing MP 
(74) indicating that the release of MP is part of a protective mechanism to prevent the 
intracellular accumulation of caspase 3 at dangerously high levels (75). 
 
1.3.4.1 Coagulation 
The procoagulant effect of cell-derived MP is the most described characteristic. The 
negatively charged phospholipids layer of the MP (mainly phosphatidylserine) 
provides an excellent substrate for the assembly of the prothrombinase complex 
(which consists of the coagulant factors Xa the co-factor Va and calcium), leading to 
thrombin generation and clot formation. Interestingly, PMP surfaces have 50- to 100-
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fold higher pro-coagulant activity compared with the normal platelet surface (76). 
Also circulating TF bearing MP can initiate and propagate the TF-dependant 
coagulation cascade (77;78). The TF exposed on the MP appears to be in an inactive, 
non-coagulant form as Damiant et al showed in patients with type 2 DM (79). 
However this inactive form of TF may become procoagulant after the contact of TF-
bearing MP with the developing thrombus (80), an interaction which is believed to 
be mediated by P-selectin, expressed on the activated platelets (81). This is supported 
by the finding that those patients with ST-elevation ACS who had the highest plasma 
level of TF-exposing MP were characterized by a procoagulant phenotype, as 
reflected by increased plasma levels of thrombin-antithrombin complexes (82). The 
complexity of the involvement of MP in the coagulation cascade is supported by 
evidence showing the divergent coagulant effects of MP. For example in healthy 
individuals PPP derived MP exert an anticoagulant activity via activation of protein 
C, which, in turn, inhibits additional thrombin generation by inactivating the 
coagulation factors Va and VIIIa (83). Contrary to the above anti-thrombotic effects 
of MP in the healthy population, in pathological situations the observed increased 
levels of TF-bearing MP eliminates their anticoagulant effect resulting in a net 
procoagulant effect.   
 
1.3.4.2 Inflammation 
It is now widely accepted that atherosclerotic disease is a chronic inflammatory 
process (84). Patients with high inflammatory markers like CRP including those with 
diabetes mellitus, metabolic syndrome and chronic inflammatory arthritis (psoriatic 
or rheumatoid arthritis) are at high risk of developing CHD (85). The exact 
mechanisms are not well understood however the evidence suggest various pathways 
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through which MP formation may act as an inflammatory mediator. For instance in 
vitro leukocytes derived MP can stimulate the expression of pro-inflammatory genes 
in endothelial cells, leading to the formation of leukocyte– endothelial cell adhesion 
molecules and pro inflammatory cytokines, like IL-6 (86). Also platelet-derived MP 
delivers arachidonic acid (AA) in the endothelial cells leading to up-regulation of 
ICAM-1 (intercellular adhesion molecule-1, CD54) which mediates monocyte-
endothelial cells adhesion (87). In addition oxidative stress is a well-recognized 
phenomenon in atherosclerosis and coronary heart disease. Oxidized modification of 
low density lipoproteins (LDL) appears to play a key role during all the stages of 
atherosclerosis via activation, migration and transformation of monocytes into 
macrophages and scavenger cells within the atheromatous plaque (72). It has been 
shown that MP derived from oxidative stress-treated-endothelial cells contains 
oxidized phospholipids which can activate monocytes and neutrophils and adherence 
with EC via expression of adhesion molecules. The exact mechanism by which 
oxidized phospholipids are involved in this process is not clear however PAF 
receptors expressed on leukocytes and platelets has been postulated as a possible 
pathway (87). 
 
1.3.4.3 Endothelial dysfunction 
Endothelium is a multifunctional organ. Apart from being the mechanical barrier 
between the blood cells and the subendothelial tissue preventing the coagulation 
cascade activation, endothelial cells exert a variety of characteristics including anti-
inflammatory, vascular tone control, vessel wall permeability and cell growth (87). 
The above functions render endothelium an important player in the pathophysiology 
of CHD. Impaired endothelial function has been reported in cardiovascular diseases 
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like atherosclerosis (84;88) ACS (89), heart failure (90), hypertension (91) and pre-
eclampsia and eclampsia syndromes (92). Mechanism by which MP may cause 
endothelial dysfunction include a) alteration of the endothelial nitric oxide (NO) 
synthase activity and the balance between NO availability and reactive oxygen 
species production and 2) the post-receptor NO transduction pathway. The latter has 
been shown by Boulanger et al. who found that circulating MP from patients with 
acute MI cause severe endothelial dysfunction in healthy blood vessels by affecting 
the post-receptor nitric oxide (NO) transduction pathway  (93). Mostefai et al showed 
in vitro that MP from T-lymphocytes decrease NO production and increase oxidative 
stress in endothelial cells (94). These effects are associated with a reduction of 
endothelial NO synthase activity, which depends on phosphatidylinositol-3-kinase 
(PI3K), extracellular signal–regulated kinase 1/2, and nuclear factor-B pathways 
(94). In vivo data also indicate that circulating MP from patients with type II DM 
(95) and chronic renal failure (96) are associated with vascular endothelial 
dysfunction. 
Interestingly, in contrast to the above findings, in some situations MP can improve 
endothelial dysfunction. The protective role of MP has been shown by Mostefai and 
co-workers providing evidence that increased circulating MP are protective against 
vascular hypo-reactivity accounting for hypotension in patients with septic shock 
(97).  In line with these findings Soriano et al have shown that elevated levels of 
EMP and PMP predict a more favourable outcome in severe sepsis in terms of 
mortality rate and organ dysfunction (98). 
In summary, MP can have both detrimental and favourable effects on endothelial 
function by altering the balance between NO and ROS production and release 
depending on the clinical setting. It appears that the expression of those effects 
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depends on the specific stimulus underlying the release of MP by their parent cells 
(75). 
 
1.3.4.4 Angiogenesis 
As mentioned above atherosclerosis is a chronic inflammatory process of the 
vascular wall with monocyte infiltration, lipid accumulation and modification with 
subsequent focal thickening of the intima of arteries. Evolution of the atheromatous 
plaque leads to vulnerable atherosclerotic plaques prone to rupture. Those vulnerable 
plaques are characterized by an enlarged necrotic core containing apoptotic 
macrophages, increased number of vasa vasorum, and more frequent intra-plaque 
haemorrhage (99). Researchers have found that MPs isolated from human 
atherosclerotic lesions express CD40L and stimulate endothelial cells after CD40 
ligation promoting in vivo angiogenesis. Therefore, MPs could represent a major 
determinant of intra-plaque neovascularisation and plaque vulnerability (100). 
Circulating angiogenic cells (CACs) are believed to represent a cell population 
enriched in monocytes and exert their angiogenic effects via paracrine and signalling 
mechanisms (101).  Recent reports suggested that the neo-vascularization-related 
capacities of CACs are impaired in atherosclerotic patients. Also PMPs were 
reported to augment the re-endothelialization capacity of CACs (102). Ohtsuka et al 
isolated mononuclear cells and PMPs from peripheral blood of patients with 
atherosclerotic heart disease. They generated PMP-pretreated CACs (PMP-CACs) by 
co-culturing of the mononuclear cells and PMPs. They found that although the 
migration capacity of PMP-CACs was similar to that of CACs, the adhesion capacity 
of PMP-CACs was greater. This augmented adhesion and neo-vascularization 
capacities by PMP-CACs were canceled out by a RANTES neutralizing antibody. 
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They concluded that PMP-secreted RANTES may play a role in the augmenting 
adhesion and neo-vascularization capacities of CACs (102). 
 
1.3.5 Clinical significance of microparticle formation in patients with coronary 
heart disease 
Clinical studies in patients with CHD or conventional risk factors for CHD have 
shown that MP levels are elevated compared with healthy volunteers (56;103;104).    
Endothelial dysfunction is the main contributing factor in the pathophysiology of 
atherosclerosis and subsequently stable or unstable CHD. Also in ACS, where 
platelet activation and thrombus formation dominates, markers of platelet activation 
like total MP and PMP are expected to be markedly elevated. Therefore the 
interactions between a dysfunctional endothelium, activated platelets and monocytes 
may play an important role in the pathogenesis of ACS. Singh et al studied the PMP 
level in 6 patients with UA. Blood samples were drawn from the patients every 4 h 
over a 24 h period and PMP were estimated using flow cytometry. There was a 
marked, six-fold increase of PMP levels in the unstable angina patients (p=0.001) 
compared with 6 healthy, volunteers (105). Stepien et al determined the levels of 
PMP, EMP, MMP and s-P-selectin in 12 AMI patients, 10 stable angina (SA) 
patients and 9 healthy controls. They found that patients with AMI displayed higher 
levels of total MP, PMP and  TF+MP than patients with SA (104). In addition 
Bernal-Mizrachi et al found that CD31+EMP and CD51+EMPs were significantly 
higher in ACS than SA. Among patients with first MI, CD31+EMP was higher in 
patients with MI than in patients with UA and was significantly higher than in 
patients with recurring MI. CD51+EMP did not discriminate ACS from SA and 
PMPs did not discriminate patients with SA from control subjects (106).  
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Whether elevated MP levels play a contributory role to the pathophysiology of CAD 
or the consequence of CAD or even represent a bystander is still matter of debate. 
Several clinical studies have shown a correlation between MP levels and total 
mortality, cardiovascular mortality, major cardiac and cerebro-vascular events, 
myocardial damage and indices of myocardial dysfunction (107-111). Montoro-
Garcia et al compared MP (total MP, PMP, EMP and MMP) levels in patients with 
STEMI, NSTEMI, SA and healthy individuals. They found that in NSTEMI patients, 
EMP and MMP were independently predictive for future admissions related to heart 
failure. They concluded that small-size MP could be potentially implicated in the 
modulation of the post-ACS reparative response to injury, with prognostic 
implications (111). Sinning et al determined the number of CD31+EMP in 200 
patients with stable CHD and their correlation with cardiovascular outcomes. The 
median follow-up for major adverse cardiovascular and cerebral event (MACCE)-
free survival was 6.1 years. MP levels were significantly higher in patients with 
MACCE compared to patients without MACCE (p=0.004). In multivariate analysis 
high MP levels were associated with a higher risk for cardiovascular death (HR 4.0; 
p=0.04), the need for revascularization (HR 2.4; p=0.005), and the occurrence of a 
first MACCE (HR 2.3; p=0.001). Inclusion of the MP level into a classical risk factor 
model substantially increased c-statistics from 0.637 to 0.702 (p=0.03). They 
concluded that the level of circulating AnV+CD31+EMP is an independent predictor 
of cardiovascular events in stable CHD patients and may be useful for risk 
stratification (108). Amabile and his team examined whether or not increases in 
circulating MP levels could predict the all-cause and cardiovascular mortality (fatal 
myocardial infarction, stroke, acute pulmonary edema and sudden cardiac death) in 
81 stable haemodialysed patients with end-stage renal disease (ESRD). Kaplan-
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Meier analysis demonstrated significantly higher probability of all-cause (p<0.001) 
and cardiovascular mortality (p<0.0001) between the lower and upper EMP tertiles 
even after adjustment for confounding factors. They concluded that increased plasma 
levels of EMP is a robust independent predictor of severe cardiovascular outcome in 
end-stage renal failure patients (107). Jung et al tried to correlate the levels of EMP 
or PMP in 36 patients with STEMI with the myocardium at risk and infarct size 
which were determined by cardiac MRI (CMR) imaging one week after the index 
event. They found that EMP and PMP correlated to myocardium at risk, but not to 
infarct size suggesting that MP levels reflect the severity of the endothelial injury and 
platelet activation during myocardial ischemia (109). Biasucci et al looked at the 
AnV+MP, EMP and PMP levels in 33 patients with SA and 43 patients with ACS 
undergoing PCI. They found that in the ACS group, Day 2 AnV+ MP correlated with 
peak Troponin T levels (112). In line with the above findings Mavroudis et al 
showed a positive correlation between systemic arterial total MP and EMPs with 
markers of myocardial damage in patients with STEMI treated with pPCI (113). 
Recently Porto et al studied 78 STEMI patients undergoing successful pPCI 
following STEMI. They measured the systemic (aortic) and local (in the culprit 
coronary artery) levels of PMP and EMP and their relation to indices of 
microvascular obstruction (MVO) like Thrombolysis in myocardial infarction (TIMI) 
flow, thrombus score (TS), corrected TIMI frame count (cTFC), myocardial blush 
grade (MBG). Both PMP and EMP levels were significantly higher in the 
intracoronary than in the aortic blood samples. They found that intracoronary EMP 
and both systemic and intracoronary PMP levels correlated with TS. Moreover, the 
correlation of intracoronary MP with indices of microvascular dysfunction suggests a 
possible direct role of MP in the pathogenesis of MVO in addition to the role of MP 
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as markers of ongoing thrombosis (110). Endothelial derived MPs have been also 
correlated with angiographically high risk coronary artery lesions. Bernal-Mizrachi 
et al studied 43 patients undergoing coronary angiography. Fifteen had presented 
with AMI, 20 with unstable angina (UA), 5 with SA and 3 with congestive heart 
failure. Coronary angiography was reviewed and coronary lesions were classified 
using the Ambrose classification as high or low risk. They found that high EMP was 
associated with high-risk angiographic lesions like eccentric, multiple irregular or 
thrombotic lesions. They concluded that EMP may be a useful marker in detecting 
endothelial injury and risk of ACS as defined by angiography (114). The levels of 
circulating MP have also been linked with the remote ischemic conditioning. Nagy et 
al found that PMP level is significantly elevated in patients treated electively with 
PCI compared to subjects with diagnostic catheterization alone. They showed that at 
15 minutes after the completion of PCI the levels of PMPs, the platelet P-selectin 
expression and the ratio of platelet-monocyte heterotypic aggregates were 
significantly (p<0.05) elevated in the PCI group compared to the non-stented 
subjects, but no difference was found in soluble P-selectin values. They concluded 
that the observed cellular changes are early and sensitive markers to detect the 
platelet-activating effect of stent implantation (115). Jeanneteau et al hypothesized 
that the circulating MPs are the effectors of remote ischemic conditioning. Remote 
ischemic conditioning was induced by 5-min inflation and 5-min deflation of a 
blood-pressure cuff causing limb ischemia. They found that CD54+EMP and 
procoagulant AnV+MP are markedly increased after remote ischemic conditioning. 
However, MP release did not appear to be a biological vector of remote ischemic 
conditioning in their model (116).   
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1.3.6 Lifespan of circulating microparticles 
Another interesting aspect of the MP generation in stable and unstable CHD is the 
life span of these cell fragments. Skeppholm et al measured PMP levels in 51 
patients with ACS and 61 sex- and age-matched healthy controls on admission, 
within 24 hours (before coronary angiography), and six months later. Plasma 
concentrations of PMP were elevated on admission (p<0.001 compared to controls), 
decreased significantly 24 hours later following initiation of treatment with 
clopidogrel and subcutaneous anticoagulation (p<0.001), and decreased even further 
six months later (p<0.01). However, PMP were still almost 2-fold higher than in 
healthy controls (p<0.001). They concluded that PMP concentrations follow the 
pattern of platelet activation during and after an ACS. Also PMP levels decreased 
after initiation of antithrombotic treatment, but were still elevated after six months 
compared to healthy control levels (117). In line with the above findings Biasucci et 
al did serial measurements of AnV+MP, EMP and PMP in 33 patients with SA and 
43 patients with ACS undergoing PCI. They found that AnV+MP increased until 
Day 2 (P=0.001), while EMP and PMP peaked on Day 1 (p<0.01) then decreased to 
baseline values (112). 
 
1.3.7 Microparticle and inflammatory markers 
Ueba et al looked at the levels of inflammatory markers IL-6, hs-CRP and their 
correlation with PMP as a marker of platelet activation in 464 healthy Japanese 
volunteers. They found that plasma level of IL-6 was associated with plasma level of 
PMP after adjustment for diastolic blood pressure, platelet count, and high sensitivity 
C-reactive protein in men (p<0.001) and associated with plasma level of PMP after 
adjustment for platelet count in women (p<0.001) (118). Biasucci et al in 33 patients 
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with SA and 43 patients with ACS undergoing PCI found that EMP and PMP 24 
hours after the admission correlated with hs-CRP (r=0.37, p=0.04 and r=0.33, 
p=0.05; respectively) (112).  
I have described in the above paragraphs the mechanisms underlie the MP formation, 
composition and their biological effects which are mainly coagulation, inflammation 
and vascular dysfunction. Our understanding that the above processes are also crucial 
in the pathogenesis of CHD together with the correlation between elevated MP in 
individuals with CHD or risk factors for CHD with markers of platelet activation and 
inflammation, leads to the view that circulating MP are harmful, contributing to 
CHD and risk of CHD. Furthermore, whether cell-derived MP is a cause, 
consequence, or both of CHD remains to be established. Also the clinical question 
whether MP is marker of CHD risk and whether they can be used as independent 
predictors of CHD outcome remains unanswered. In addition, it is fair to state that 
the data from the clinical studies referenced, which are looking into MP levels and 
clinical outcomes in patients with clinically manifested CHD, have potentially 
important limitations as the number of patients recruited is small. As such firm 
conclusions cannot be drawn. 
Recently, the association of the Framingham risk score and numbers of platelet-, 
leukocyte- and endothelium derived MP were reported in two retrospective 
(119;120) and one prospective study (121). The addition of endothelial CD144+MP 
to the Framingham risk model improved the classification of risk and appeared as a 
significant and independent predictor of future CVD events in a high-risk population 
(121). The above results are promising, but more prospective studies are needed to 
further detail the prognostic value of cell-derived MP in individuals at high risk for 
cardiovascular disease (CVD) (75). 
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1.4 Role of inflammation in coronary heart disease  
Atherosclerosis has both chronic and acute manifestations, affects both mid and 
large-size arteries and can cause either focal or diffuse stenosis of the affected 
vessels. Over the last twenty years, data have emerged showing that immune cells are 
involved in the pathogenesis of formation and evolution of the atherosclerotic 
plaques. Understanding of the anatomic structure and function of the normal artery 
and its native cell types is essential for the understanding of the pathophysiology of 
atherosclerosis. 
 
1.4.1 Normal artery structure 
Normal artery is a tripetalous structure, the inner layer-tunica intima, the tunica 
media and the outer layer-adventitia (122). The intima consists of a monolayer of 
endothelial cells adjacent to basal lamina which is a basement membrane containing 
non-fibrillar collagen types, such as type IV collagen, laminin, fibronectin, and other 
extracellular matrix molecules. The internal elastic lamina lies between the intima 
and tunica media. The tunica media consist of smooth muscle cells (SMCs) and 
layers of extracellular matrix (123). The composition of the extracellular matrix and 
organization of the smooth muscle cells differs according to artery size. The external 
elastic lamina lies between the tunica media and the adventitia. The adventitia 
contains collagen fibrils like the intima but in a looser arrangement. It also contains 
vasa vasorum and nerve endings. The existence of SMCs in the adventitia is very 
little compared with the other layers (124). 
 
 44 
1.4.2 Endothelial cells 
Endothelial cells (EC) of the arterial intima represent the natural barrier between 
blood and the prothrombotic subendothelial matrix. Arterial endothelial cells are 
effectors of many important haemostatic mechanisms including anticoagulant, 
fibrinolytic activities and platelet inhibition. EC is the main anti-coagulant by 
regulating thrombin generation. Amongst the various mechanisms through which 
endothelial cells exert these effects are: 1) production of heparan sulphate 
proteoglycans, which bind anti-thrombin III and tissue factor pathway inhibitor 
(TFPI). Heparan sulphate-antithrombin complex increases speed the rate at which 
anti-thrombin inhibits thrombin and other coagulation enzymes (125) while TFPI is a 
natural inhibitor of coagulation after it binds heparan sulphate on the endothelial cell 
(126), and 2) Expression on the endothelial cells surface thrombomodulin (127). 
Thrombomodulin binds thrombin and this complex activates the anti-coagulant factor 
protein C and S. Activated protein C inhibits the activated factors V and VIII which 
are involved in process of thrombin generation (128). Endothelial cells also exhibit 
fibrinolytic properties by producing and releasing tissue plasminogen activator (t-
PA) and urokinase plasminogen activator (u-PA), should the clot formation cascade 
begin. Both t-PA and u-PA can initiate fibrinolysis by converting plasminogen to 
plasmin (129). Endothelium also releases type 1 plasminogen activator inhibitor 
(PAI-1), the main regulator of t-PA and u-PA. Thus, net fibrinolytic activity of 
endothelium depends on the dynamic balance between the release of plasminogen 
activators and plasminogen activator inhibitor 1 (PAI-1). As a result, healthy 
coronary arteries actively oppose platelet and clotting cascade activation and prevent 
thrombotic events (129). Endothelial cells produce and release into the blood 
prostacyclin and NO that are not only effective platelet inhibitors but also potent 
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vasodilators. In addition, endothelial cells regulate the platelet activation (130) via 
the molecule CD39, an ADPase expressed on the platelet surface. CD39 degrades 
ADP, a platelet agonist. 
1.4.3 Smooth muscle cells  
Smooth muscle cells are important cells of the normal artery wall with many pivotal 
functions contributing to the normal vascular homeostasis, and also in the 
pathogenesis of arterial diseases. SMC, apart from regulating blood flow through 
contraction and relaxation of the coronary arteries, synthesize the extracellular matrix 
that plays a crucial role in normal vascular homeostasis and in the development and 
evolution of atheromatous plaques. These cells also can migrate and proliferate, 
contributing to the formation of intima thickness, atherosclerosis and stent restenosis 
after PCI. Imbalance between synthesis by SMCs and degradation by MMPs of 
extracellular matrix can promote either stabilization or destabilization of 
atheromatous plaques. In the former case the patient will present with stable angina 
contrary to the latter where the presentation will be ACS. 
1.4.4 Initiation and evolution of atheromatous plaque 
Although the initial step in the pathophysiology in human artery atherosclerosis is 
still a matter of debate, observations of tissues obtained from young humans 
combined with the results of experimental studies in animals suggest that the first 
step in the pathophysiology of atherosclerosis is small lipoprotein particles (LDL) 
accumulation in the intima (129). These LDL particles become susceptible to 
oxidative and other chemical alterations after they bind to extracellular matrix.  
Alterations of these lipoproteins, including oxidation and glycation, promote the 
release of pro-inflammatory cytokines from SMCs. These cytokines amplify the 
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expression of leukocyte and monocyte adhesion molecules like MCP-1 and 
chemoattractant molecules that result in monocyte attachment and migration into the 
intima (131;132). MCP-1 is produced by endothelial cells and SMCs in response to 
oxidized lipoprotein and other inflammatory stimuli. MCP-1 selectively promotes the 
directed migration of monocytes. Increased levels of MCP-1 are expressed on human 
atherosclerotic lesions compared with uninvolved vessels. Several other cytokines 
including IL-8 bind on leukocytes, and interferon-γ which induces the genes 
encoding T-cell chemo-attractants (123), contribute to monocyte recruitment during 
atherogenesis. Normally there is minimum interaction between healthy endothelium 
and leukocytes. In atherogenesis, as described above, leukocyte migration, 
recruitment and accumulation within the intima is a crucial step and occurs in the 
early stages. Monocytes adhere to the endothelium and move through endothelial cell 
junctions or even can penetrate endothelial cells and enter the intima, where they 
begin to accumulate lipids and become foam cells (133). Specific leukocyte adhesion 
molecules expressed on the surface of the endothelial cell governs the interaction and 
adherence of monocytes and T cells to the endothelium (134). Those are: 1) members 
of the immunoglobulin family which mainly promote tighter adhesive interactions 
and immobilization of leukocytes; and 2) selectins which tend to promote less tight 
and rolling locomotion of leukocytes over the endothelium. The first family includes 
vascular cell adhesion molecule 1 (VCAM-1 or CD106) and ICAM-1 which are the 
main adhesion molecules mediating interaction between endothelium and leukocytes. 
CD106 plays an important role in the early stages of atherogenesis whilst the 
interaction of endothelial cells via CD54 with monocytes occurs throughout the 
whole process of atherogenesis. Selectins represent the second broad category of 
leukocyte adhesion molecules. The main representative of selectins is E-selectin 
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(CD62E), which recruits neutrophils. Other members of this family, including P-
selectin may play a greater role in leukocyte recruitment involved in atherogenesis. 
CD62P is expressed on endothelial cells overlying human atheromatous plaques. 
Experimental studies in genetically altered mice have proven roles for VCAM-1 and 
P-selectin (including both platelet- and endothelium-derived P-selectin) in 
experimental atherosclerosis (135;136). During the last decade, the combination of 
basic and clinical research has demonstrated the crucial role of inflammation in 
atherothrombosis. Cell-cell interactions play a pivotal role in the evolution of 
atheromatous plaque. Antigen-presenting cells like macrophages, dendritic cells and 
endothelial cells allow the presented antigen to interact with and activate T cells. 
Activated T cells subsequently release pro- and anti-inflammatory cytokines that can 
modulate atherogenesis. There are two types of CD4+ T cells (T helper), Th1 and 
Th2. Th1 has pro-inflammatory properties and they can secrete cytokines like 
interferon-γ (INF-γ), TNF-α and CD40 ligand. This group of cytokines can in turn 
activate immune and non-immune vascular cells and coordinate changes of the 
plaque homeostasis that can lead to plaque destabilization and susceptible to 
thrombosis. In contrast, Th2 elaborate anti-inflammatory cytokines, such as 
interleukin-10 (137). Cytotoxic T cells (CD8+ T cells) promote cytolysis and 
apoptosis of macrophages, endothelial cells and SMCs. The death or apoptosis of 
these cell types can occur within the atheromatous plaque and may contribute to 
plaque progression and complication. 
 
1.4.5 Evolution of plaque 
SMCs, under the chemoattractant effect of PDGF, migrate into the intima from the 
tunica media.  PDGF is a potent SMC attractant secreted by activated monocytes and 
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is vividly expressed in human atherosclerosis. SMCs in the atherosclerotic intima are 
involved in the progression of atheromatous plaque including SMCs proliferation. 
There are differences at sub-cellular level between SMCs of the normal arterial 
tunica media and those in the intima of an evolving atheromatous plaque (138). 
Intima SMCs contain rougher endoplasmic reticulum and fewer contractile fibres 
than the SMCs of the normal tunica media do. Intriguingly there is a non-linear 
pattern of SMCs proliferation during atherosclerosis evolution and growth of the 
intima. In fact bursts of SMCs migration and replication more likely to occur. 
Besides SMC proliferation, death or apoptosis (programmed cell death) of the SMCs 
may also be involved in the progression of the atheromatous plaque (139;140). 
Apoptosis of SMCs in the atheromatous plaque is facilitated by inflammatory cells 
and mediated by death receptors like Fas. More specifically migrated T cells express 
on their surface the Fas ligand while SMC under the influence of the pro-
inflammatory cytokines express Fas. Interaction between Fas ligand and Fas initiates 
the process of the programmed cell death (141).  
Although the anatomic and functional changes (at cellular and molecular level), 
during the evolution of the atheromatous plaque in patients with CHD, follow a 
continuous pattern (progressive disease), the clinical manifestations of each patient 
with CHD are probably determined by distinct genetic differences. Reilly et al have 
shown that specific genetic predispositions promote the development of coronary 
atherosclerosis whereas others lead to myocardial infarction in the presence of 
coronary atherosclerosis (142). Therefore, signalling pathways predisposing to 
atherosclerosis probably differ from those contributing to plaque vulnerability. That 
explains why many patients with angiographically proven CHD remain stable on 
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medical management, while in other patients myocardial infarction represents the 
first manifestation of CHD. 
 
1.4.6 Arterial extracellular matrix 
Extracellular matrix (ECM) which accounts most of the plaque volume is also 
equally important in the evolution of the atherosclerotic plaque. Collagens (types I 
and III), proteoglycans and elastin fibres are the most important extracellular matrix 
molecules of the atheromatous plaque. ECM is normally produced by the SMCs of 
atheroma and this process is part of the natural development and maintenance of the 
arterial wall. PDGF and TGF- secreted by activated platelet and other cell types in 
the atheromatous lesions are the main stimulants of SMCs for extracellular matrix 
production. Extracellular matrix turnover and maintenance is the result of the 
biosynthesis (by SMCs) on the one hand, and ECM breakdown by the 
metalloproteinase (MMPr) enzymes on the other hand. Extracellular matrix 
breakdown certainly plays a role in SMCs migration into the intima from the media. 
In injured arteries, overexpression of MMPr inhibitors (known as tissue inhibitors of 
metalloproteinases, or TIMPs) can delay smooth muscle accumulation in the intima 
of injured arteries (143). Extracellular matrix synthesis and degradation also plays a 
role in arterial wall remodelling that accompanies lesion growth. During the early 
stages of atheromatous lesion development, plaque grows outwardly, in a way that 
would lead to luminal stenosis. This outward growth of the intima leads to an 
increase in the external diameter of the entire artery and is called positive 
remodelling or compensatory enlargement. Luminal stenosis tends to occur only after 
the plaque burden exceeds some 40% of the cross-sectional area of the artery. 
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1.4.7 Angiogenesis in atheromatous plaques 
Atherosclerotic plaques develop their own microcirculation as they grow, a process 
named neovascularisation. Histologic examination with endothelial markers of the 
evolving plaque reveals a rich network of capillary vessels which develop in 
response to angiogenic factors (vascular endothelial growth factor [VEGF], placental 
growth factor [PlGF], and oncostatin M) expressed in atheromatous plaques. These 
micro-vessels within plaques have significant functional implications. They provide 
a conduit so leukocytes can enter and exit the atheromatous plaque. In advanced 
human atherosclerotic plaque, microvascular endothelium displays mononuclear-
selective adhesion molecules such as VCAM-1 much more prominently than does 
the macrovascular endothelium overlying the plaque. The neovascularisation of the 
atheromatous plaques also allow growth of the plaque by supplying oxygen and 
nutrients. Alongside with this view, administration of inhibitors of angiogenesis to 
mice with experimentally induced atherosclerosis limits the growth lesion. Also, the 
plaque micro-vessels may be friable and prone to rupture leading to in situ 
thrombosis which can promote SMC proliferation and ECM accumulation in the area 
immediately adjacent to the microvascular disruption. 
 
1.4.8 Plaque mineralization 
Plaques often develop areas of calcification as they evolve, a process which shares 
many mechanisms with bone formation. SMC subpopulations contribute to this by 
increased secretion of cytokines such as bone morphogenetic proteins, homologues 
of TGF-β. Receptor activator of NF-κB ligand (RANKL), a member of the tumour 
necrosis factor family, appears to promote SMC mineral formation through a bone 
morphogenetic protein 4 (BNP4)–dependent pathway (134). 
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1.4.9 Arterial stenoses and their clinical implications 
The sections above have considered the initiation, formation and evolution of the 
atherosclerotic plaque. These phases last many years, during which the affected 
individual is often asymptomatic. When the plaque burden exceeds the capability of 
outward remodelling, advance of the atheromatous plaque within the arterial lumen 
begins. This chronic asymptomatic or stable phase of lesion growth probably occurs 
with bursts of rapid progression and periods of relative quiescence. Ultimately, the 
stenosis may progress to a degree that limits the coronary artery flow. Lesions that 
produce more than 60% stenosis can cause flow limitation under conditions of 
increased demand. This type of atheromatous disease commonly leads to stable 
angina pectoris. However in many cases of acute myocardial infarction there is no 
history of stable angina prior to the acute event. Several clinical observations suggest 
that many myocardial infarctions result from no-flow limiting lesions. It is now 
widely accepted that many cases of acute coronary syndromes occur because of 
thrombosis complicating a non-occlusive plaque (144). This has been supported by 
studies showing that the culprit lesion in patients who had myocardial infarction was 
less than 50% during the coronary angiography months before the acute event. Serial 
angiographic studies have shown that lesions with stenosis severity more than 60% 
from a previous coronary angiography account only for approximately 15% of the 
acute myocardial infarctions. The above findings imply that mild to moderate lesions 
cause most of the myocardial infarctions. Undoubtedly high-degree stenosis cause 
myocardial infarction and critical stenoses are more likely to cause acute myocardial 
infarction than do non-occlusive lesions. 
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1.4.10 Atheromatous plaque inflammation, rupture and thrombosis 
Atherothrombosis is considered as the most important pathophysiologic mechanism 
in the progression and transition of the chronic atherosclerosis to acute coronary 
syndromes. We now recognize that disruption of the atheromatous plaque causes in 
situ coronary thrombosis (145). Although there are several mechanisms of plaque 
disruption and coronary thrombi formation, the most common mechanisms are 
fracture and erosion of the fibrous cap of the plaque. Rupture of the atheromatous 
plaque fibrous cap is the result of the dynamic balance between the forces that 
encroach on the cap and the mechanical stability and strength of the fibrous cap to 
resist. Extracellular matrix and SMCs are the factors responsible for most of the 
biomechanical resistance to disruption of the fibrous cap. Therefore, production and 
catabolism of the above ingredients probably play a main role in regulating the 
susceptibility to disruption of the plaque. Stimuli that trigger decreased collagen 
synthesis by SMCs or increase collagen metabolism can damage their capability to 
maintain the integrity of the plaque's fibrous cap. For instance, INF-γ, a lymphocyte 
derived cytokine, can effectively stop SMC collagen production. In contrast, as 
previously mentioned, inflammatory mediators like TGF-β and PDGF released from 
activated platelets increase collagen synthesis by SMCs and strengthen the plaque's 
fibrous stability. Furthermore, increased catabolism of the extracellular matrix can 
also contribute to weakening of the plaque’s fibrous cap and render it susceptible to 
rupture. Matrix metalloproteinase and cathepsins, macrophage-derived matrix-
degrading enzymes, catalyse the breakdown of the collagen and elastin of the arterial 
ECM (2;143) contributing to weakening of the fibrous cap. The result of reduced 
collagen synthesis and increased degradation is thinning of the plaque's fibrous cap, a 
feature of the so called vulnerable plaque. Histologic studies (145-149) have shown 
 53 
that rupture of atherosclerotic plaques with thin fibrous caps have caused fatal 
myocardial infarction. Another characteristic of the vulnerable atherosclerotic plaque 
and especially regions of local inflammation within the plaque is the relative scarcity 
of SMCs. As explained above, both soluble and lymphocytes associated 
inflammatory factors, can provoke programmed death of SMCs. Given that SMCs is 
the source of ECM collagen necessary to preserve the matrix of the fibrous cap, lack 
of SMCs may contribute to weakening of the fibrous cap and hence the propensity of 
that plaque to rupture (150). Another micro-anatomic characteristic of the vulnerable 
atherosclerotic plaque is the accumulation of macrophages and a large lipid pool. 
Activated macrophages produce pro-inflammatory cytokines and the matrix-
degrading enzymes responsible for the regulation of the matrix metabolism and SMC 
apoptosis. Apoptotic macrophages and SMCs generate TF-bearing MP, a potential 
trigger of coronary vascular thrombosis after spontaneous or iatrogenic plaque 
rupture. Also from a mechanical viewpoint, a large lipid pool can transmit the 
biomechanical forces on the shoulders of the plaque, which are common sites of 
disruption of the fibrous cap. The success of lipid-lowering therapy in reducing the 
incidence of acute coronary syndromes in patients at risk may result from a reduced 
accumulation of lipid in addition to decrease the inflammatory drive and plaque 
thrombogenicity. Animal studies (151;152) and monitoring of peripheral markers of 
inflammation in humans (153;154) support this concept. Therefore, the strength of 
the plaque's fibrous cap goes through a dynamic regulation, linking the inflammatory 
response in the intima, the metabolism of ECM macromolecules as the determinants 
of plaque stability, the response of the SMCs to inflammation and hence thrombotic 
complications of the atheromatous plaque.  
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1.4.11 Inflammation regulates the thrombogenicity of plaques 
Tissue factor expression by plaque macrophages appears essential in triggering 
thrombosis that complicates plaque disruption. Even though expression of tissue 
factor by a subset of plaque macrophages was well established, the stimulus to tissue 
factor expression on these cells remained uncertain (155;156). Soluble cytokines 
associated with atherosclerotic plaques, including IL-1 and TNF-α, weakly induced 
TF expression by human macrophages. CD40-ligand (CD154), a cell-surface-
associated inflammatory cytokine, promptly triggers tissue factor production by 
human monocyte/macrophages (157). 
 
1.4.12 Superficial erosion and coronary thrombosis 
Fracture of the plaque’s fibrous cap accounts for 60-70% of fatal acute myocardial 
infarctions. Around 20-25% of these events result from a superficial erosion of the 
intima rather than from true fracture of the fibrous cap but. Superficial erosion 
appears particularly important in patients with dyslipidaemia, and in women (145). 
The pathogenesis of plaque fibrous cap erosion is less well understood compared to 
that of rupture. One possible mechanism is apoptosis of the luminal endothelial cells 
exposing platelets to the prothrombotic subendothelial collagen. Potential direct 
toxins of the endothelial cells include hypochlorous acid, produced by 
myeloperoxidase (MPO). MPO is an enzyme localized in plaques and associated 
with acute myocardial infarction (158). Hypochlorous acid is also a potent trigger of 
TF production by endothelial cells. Activated endothelial and SMCs also produce 
enzymes capable of degrading extracellular matrix, including MMPr as mentioned 
above. Overproduction of active forms of the MMPr could damage the adherence of 
endothelial cells and the basement membrane, facilitating their desquamation 
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providing substrate for coronary thrombosis (143). In this regard, inflammation may 
promote superficial erosion and rupture of the plaque’s fibrous cap. 
Thus, inflammation controls not only the evolution of atherosclerosis but also the 
propensity of plaques to complicate via rupture or erosion by altering matrix 
composition through the mechanisms described above. Inflammation also increases 
the thrombogenicity of the plaque’s interior, promoting thrombus formation of the 
ruptured/eroded plaque. 
 
1.4.13 Diffuse and systemic nature of plaque vulnerability and inflammation in 
atherogenesis 
The concept that mainly vulnerable atheromatous plaques cause coronary thrombosis 
and ACS encouraged many to find ways of recognizing and treating such high-risk 
atherosclerotic coronary lesions. Recent data, though, suggest that more than one 
such high-risk plaque often exists in a given coronary tree (159;160). In addition, the 
inflammation thought to be localized in the so-called vulnerable plaques appears to 
extent in more than one lesion in many cases after careful analysis of angiograms of 
individuals with acute coronary syndromes. Studies using various imaging modalities 
have highlighted the multiplicity of such high-risk plaques (134;159). The above has 
been also shown by angioscopic studies where multiple sites of coronary thrombosis 
have been found in patients with ACS. Intravascular ultrasound, optical coherence 
tomography and computed tomographic angiography have contributed to the better 
understanding of the plaque morphology that cause acute coronary syndrome (160). 
It has been found that patients demonstrating positively remodelled coronary lesions 
on CT angiography were at a higher risk of ACS developing over time when 
compared with patients having lesions without these characteristics (161). 
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1.4.14 Inflammatory markers and myocardial necrosis in acute coronary 
syndrome 
Inflammation is defined as a complex biological response of vascular tissues to 
harmful stimuli, such as pathogens, damaged cells, or irritants (162). It is a 
stereotyped response, and therefore it is considered as a mechanism of innate 
immunity, as compared to adaptive immunity, which is specific for each pathogen 
(163). 
During ACS with or without ST-elevation there is a degree of myocardial 
damage/necrosis accompanied by ischemia reperfusion injury. Therefore, an 
immediate inflammatory response to the above stimuli which is part of the 
myocardium healing process takes place in the post-infarction period. In addition, 
and more interestingly the inflammatory process taking place within the 
atheromatous plaque as described above may well be the primary inflammatory 
triggering factor of coronary instability. Mounting evidence support an important 
association between increased circulating inflammatory markers (CRP, serum 
amyloid-A (SSA), IL-6, and IL-1 receptor antagonist) and adverse clinical outcomes, 
both in-hospital and short-term follow up (164-169). It has been demonstrated by 
Liuzzo et al that in patients with ACS who had similar ischemic burden, high serum 
CRP is discriminator of adverse short-term prognosis compared  to those patients 
with normal CRP levels (170). Also high CRP levels in ACS patients at discharge 
associated with recurrent admissions and re-infarction (167). Elevated CRP levels do 
not appear to correlate with the extent and burden of CHD as only 20% of patients 
with severe CHD have raised CRP (171;172). In contrast, patients with ACS have a 
high prevalence of elevated CRP irrespective of the CHD ischemic burden, affirming 
the specificity of systemically detectable inflammation in ACS. In line with above, 
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patients with severe enough peripheral vascular disease warranting revascularization 
have similar CRP levels to the levels observed in patients ACS and single-vessel 
CAD (173). Although high levels of CRP are not a pre-requisite for ACS and 
unstable angina, CRP is elevated on admission in virtually all patients with AMI who 
experienced unstable angina. Multiple studies have shown that various systemic 
inflammatory markers, such as CRP, increase in patients at risk for acute coronary 
syndromes. Furthermore, inflammation precedes the ACS, as shown by profiling of 
the platelet transcriptome.  Researchers have found that elevated serum levels of 
MRP-8/14 (inflammatory marker) predicts the risk of a first cardiovascular event in 
apparently healthy women, and also two of the most elevated mRNA transcripts from 
platelets of patients with ACS compared to that from patients with stable coronary 
artery disease encode proteins implicated in inflammation (174). Levels of PMA and 
CRP were significantly increased in patients with non ST-elevation ACS, especially 
in those with troponin elevation. This increase is strongly related to the risk of in-
hospital cardiac events. A panel of PMA, CRP, and Trop I may provide important 
information additional to current laboratory data for the treatment of ST-elevation 
ACS (175). Therefore, a combination of imaging studies and investigations using 
inflammatory markers supports the diffuse and systemic nature of instability of 
atheromatous plaques in individuals with or at risk of developing ACS.  
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1.4.14.1 Role of C-reactive protein in coronary heart disease  
CRP exerts a variety of pro-inflammatory and pro-coagulant effects such as 
stimulation of the production of TF by mononuclear cells (176), activation of the 
complement system (177), and interaction with low density lipoprotein and damaged 
cell membranes (178). CRP can also induce PAI-1 expression and can suppress NO 
release from the endothelial cells (179). 
Several studies have demonstrated that an elevated CRP in ACS is associated with a 
worse prognosis (27;165;171). Elevated CRP level in patients with NSTEMI is 
reported to be associated with cardiac rupture, left ventricular aneurysm and cardiac 
death at one year (180). After PCI a hyper responsive reaction of the inflammatory 
system defined by elevated CRP, IL-6 and SAA is considered to be a worse 
prognostic factor (170). This has been confirmed by showing that persistent elevation 
of CRP 72 hours after coronary artery stenting identified all patients who suffered a 
later adverse outcome. In contrast no cardiac events occurred in those with normal 
levels at one year follow up (181). 
MONICA (Monitoring Trends and Determinants in Cardiovascular Disease Study)  
showed that CRP is a strong predictor of future cardiac events in apparently healthy 
men (182). Patients with the highest quintile of CRP levels were shown to have a 2.6 
fold increased risk of suffering a fatal or nonfatal myocardial infarction or sudden 
cardiac death. Similarly in the Women’s Health Study patients with higher baseline 
hs-CRP levels than control subjects were found to be associated with cardiovascular 
events, and patients with highest baseline levels were associated with five and seven 
fold increase in any vascular events and combined  stroke or myocardial infarction 
respectively (183). 
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1.4.14.2 Role of serum amyloid antigen in coronary heart disease 
Serum amyloid antigen (SAA) may play a role in the pathophysiology of 
atherosclerosis. SAA induces IL-1 and IL-8 production in neutrophils and interferon 
gamma in lymphocytes. SAA has been shown to be chemotactic for monocytes 
(184). It also promotes monocyte adhesion and chemotaxis (185-187), induces 
matrix-metalloproteinase and activates NF-kB in CD4+ lymphocytes (188). These 
findings raise the question whether these pro inflammatory substances play any 
pathogenic local role within the coronary artery of the ACS patients. Matsubara et al 
(189) have shown that the increment of SAA across the coronary circulation 
correlated positively with the severity of coronary atherosclerosis. Higher adverse 
outcomes including myocardial infarction, revascularization and death in ACS 
patients with elevated SAA has been previously reported (171). Song et al have 
demonstrated that SAA induced higher TF activity in patients with ACS, but not 
stable angina patients, indicating that SAA may contribute to the procoagulant state 
in patients with ACS (190). These findings suggest TF response to SAA differs in 
ACS patients compared to controls, and the difference in induced TF between ACS 
and stable angina highlights the significance of the prothrombotic properties of SAA. 
SAA may contribute to the pathology of ACS via the induction of both TF and TNF-
α. Song et al have demonstrated upregulation of TNF-α mRNA in SAA-stimulated 
peripheral blood leukocytes, indicating that TNF is an early response gene product of 
SAA. They have reported, unlike TF, peripheral blood mononuclear cell-derived 
TNF-α level is similar in patients and controls, and low dose SAA only, induces 
TNF-α in cells from ACS patients (190). They concluded that SAA induces more 
TNF-α in cells from ACS patients than in cells from stable angina or controls, 
suggesting SAA may be a pro-inflammatory amplifier in ACS (190).  
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1.4.14.3 Role of IL-6 in coronary heart disease  
One of the most widely studied inflammatory markers is IL-6. IL-6 induces the 
production of CRP from the liver. It increases fibrinogen and PAI-1, and promotes 
leukocyte adhesion during myocardial reperfusion. It also exerts a negative inotropic 
effect on myocardium (191). IL-6 is produced by variety of inflammatory cell type 
and has been shown to remain elevated up to 4 weeks after a myocardial infarction. 
In patients with ACS elevated IL-6 predicts in-hospital events (192) in addition to 
future adverse coronary events (193). It has also been reported that circulating IL-6 
correlates well with left ventricular remodelling in patients with reperfused AMI 
(194). It has been reported during the first 48 h after ACS, that IL-6, CRP and TnT 
levels are high in patients who subsequently had major adverse cardiac events. 
However one week after admission, this prognostic value of IL-6 had been lost (195). 
In apparently healthy males elevated levels of IL-6 are associated with increased risk 
of future myocardial infarction which supports a role of cytokine mediated 
inflammation in the early stages of atherogenesis (196). 
 
1.4.14.4 Role of TNF-α in coronary heart disease  
TNF-α contributes to plaque instability by promoting inflammatory processes and 
inducing  matrix metalloproteinases in atherosclerotic lesions (197). TNF-α mediates 
a variety of interactions resulting in progressive inflammation, plaque destabilization 
and prothrombosis. Elevated serum TNF-α levels in CHD predict adverse coronary 
events in population studies (198). Reperfusion induces TNF-α expression in the 
coronary microcirculation and TNF-α can impair endothelium- dependent coronary 
flow reserve (199) which may adversely affect outcome. TNF-alpha can also cause 
cardiac contractility depression either directly (191) or via the inducible NO synthase 
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(i-NOS) pathway in cardiomyocytes (200). It is not entirely clear whether TNF- 
alpha is generated locally in the coronary artery or in the systemic circulation. In 
experimental and clinical (201) studies, TNF-α did not differ in paired coronary 
arterial and coronary sinus blood samples, suggesting that TNF-α is not of cardiac, 
but of peripheral origin. Increased TNF-α concentration contributes to vascular 
dysfunction. TNF-α induces the expression of cell adhesion molecules such as E-
selectin, VCAM-1 and ICAM-1 at the endothelial surface. These molecules mediate 
the adhesion and migration of leukocytes into the arterial wall. Activated leukocytes, 
following interaction with platelets, produce TNF-α which induces TF expression on 
macrophages, neutrophils, and endothelial cells (202-204) influencing the extrinsic 
pathway of the coagulation cascade via TF (205). TF mediates thrombin formation, 
leading to fibrin clot formation and intravascular fibrin deposition. 
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1.5 Microvascular dysfunction in coronary artery disease 
1.5.1 Introduction 
Microvascular dysfunction (MvD) is a powerful independent predictor of long term 
outcomes, and mortality in patients presented with ACS and revascularization after 
PCI. Despite a successful angiographically coronary artery stenting, potential 
compromise of the coronary microcirculation during or after PCI is associated with 
“slow flow” or “no flow” with subsequent impaired myocardial tissue oxygenation. 
A number of different non-invasive and invasive techniques have been developed to 
evaluate the functional reserves of the coronary microvasculature. Among the 
invasive methods in the catheter laboratory the ‘Index of microvascular resistance’ 
(IMR) which is derived using a Doppler or a pressure-temperature sensing wire, has 
emerged as a novel index for the assessment of the coronary microcirculation. This 
has been validated in the experimental model and has been shown to be reproducible. 
 
1.5.2 Coronary circulation and coronary blood flow control 
The coronary circulation plays a unique role by not only generating the required 
arterial pressure to perfuse the systemic circulation but at the same time having its 
own perfusion hindered during systolic phase of the cardiac cycle. Myocardial 
contraction is closely connected to coronary blood flow and oxygen delivery. The 
balance between myocardial oxygen supply and demand is the main determinant of 
the normal heart function. Therefore any disruption of the coronary flow will disrupt 
the oxygen-demand balance precipitating a vicious cycle, whereby ischemia-induced 
contractile dysfunction causes hypotension and further myocardial ischemia.  
Coronary arterial blood flow increases during diastole whilst at the same time 
coronary venous outflow decreases. During systole there is reduction of the diameter 
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of intra-myocardial micro-vessels (arterioles, capillaries and venules) impeding 
coronary arterial blood flow, which reaches a nadir, whereas the venous outflow 
peaks during systole (206). In contrast to other vascular beds, myocardial oxygen 
extraction is near-maximal at rest reaching close to 75% of the arterial oxygen 
content (207). As such increase in myocardial oxygen consumption happens 
predominantly by proportional increases in coronary blood flow and oxygen 
delivery. Heart rate, systolic pressure (or myocardial wall stress), and left ventricular 
(LV) contractility are the major determinants of myocardial oxygen consumption 
(208). Studies in animals have shown that at basal state subendocardial coronary 
blood flow is auto-regulated and can remain constant as coronary artery pressure 
reduces to as low as 40 mmHg of mean coronary artery pressure (or 30 mmHg of 
diastolic pressure) (208).  In contrast, the lower auto-regulatory limit for sub-
epicardial coronary flow is a mean coronary artery pressure of 25 mmHg. This 
phenomenon is termed auto-regulation.  
The resistance to coronary blood flow can be divided into three major components. 
R1 is epicardial arteries resistance, which is normally not significant (<5% pressure 
drop). R2 arises from microcirculatory resistance arteries (mainly arterioles with 
diameter 20 to 200 µm) and R3 is the compressive resistance which varies during the 
cardiac cycle that is higher in subendocardial than sub-epicardial myocardium. In 
hearts without obstructive CHD, R2 is the main contributor to the coronary blood 
flow resistance. During pharmacologic vasodilation, like intravenous administration 
of adenosine, the arteriolar resistance (R2) becomes negligible. Therefore, under the 
above circumstances, severe epicardial stenosis becomes the main contributor to 
coronary blood flow resistance. Coronary artery resistances at any segment of the 
coronary microcirculation represent the integration of anatomical, metabolic and 
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neural mediators. It has been shown by Kuo et al that the diameter of coronary 
arterioles respond to changes in local stress, a mechanism termed as flow-mediated 
vasodilation and is mediated via endothelium-derived relaxing factor (EDRF or NO) 
and endothelium-dependent hyperpolarizing factor (EDHF) (209). In addition, the 
capacity of vascular smooth muscle to oppose changes in coronary arterial diameter 
enables the coronary microcirculatory resistance arteries to relax when coronary 
arterial pressure decreases and to constrict when coronary arterial pressure increases. 
The above response has been termed as myogenic regulation and believed to be 
mediated via L-type Ca++ channels (210). Apart from the physical factors regulating 
the coronary artery resistance metabolic mediators like hypoxia, acidosis, adenosine 
and ATP-sensitive K+ channels are also important. In addition the sympathetic and 
parasympathetic innervation of the coronary arteries and arterioles affecting the 
vascular smooth muscle tone also contributes to the regulation of the coronary 
resistance. A wide variety of paracrine vasoactive factors secreted by platelets, 
endothelial cells and smooth muscle cells also modulate the coronary vascular tone. 
The most important factors are NO, EDHF, prostacyclin, serotonin, thromboxane A2, 
ADP, endothelin and thrombin. 
 
1.5.3 Physiologic assessment of epicardial coronary artery stenosis and coronary 
microcirculation 
Physiologic assessment of the epicardial coronary stenosis is an essential element in 
the clinical decision making process and management of patients with CHD (211). 
The chronic process of atherogenesis leads to atherosclerotic plaque formation and 
angiographically epicardial artery stenosis which increases the coronary resistance 
(R1). This in combination with the impaired coronary microcirculation which is also 
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common in patients with CHD or risk factors for CHD does reduce maximal 
myocardial perfusion which can also contribute to causing myocardial ischemia. 
Separating the role of a stenosis from coronary resistance vessels can be 
accomplished by simultaneously assessing coronary flow and distal coronary 
pressure using intracoronary transducers that are currently available for clinical care 
(212). The relationship between stenosis severity and pressure drop has been 
validated in animals as well as humans and can be described by the Bernoulli 
equation which essentially states that the resistance is inversely related with the 
square of the cross-sectional area at the stenosis point. As such small changes in 
luminal area can cause significant changes in the stenosis pressure-flow relationship 
and reduce distal (to the stenosis) coronary pressure which is the main determinant of 
myocardial perfusion. The length of the stenosis is another factor which contributes 
to the epicardial coronary resistance. The pressure drop (ΔP) also varies with the 
square of the flow velocity, which means increased pressure drop across a stenosis 
during vasodilation (conditions of coronary hyperaemia).  
At rest, due to coronary auto-regulation, coronary flow remains stable as stenosis 
severity increases. As such it is impossible to identify thermodynamically significant 
stenosis with resting myocardial perfusion imaging in contrast the maximally 
vasodilated pressure-flow relationship which is much more sensitive in detecting 
pressure drop and stenosis severity (it is easy to understand this from the Bernoulli 
equation). Normally there is considerable coronary flow reserve with almost a 
fivefold increment of the resting coronary flow during conditions of hyperaemia. The 
increase in epicardial coronary artery resistance is very small until stenosis severity 
progresses to a 50% internal diameter reduction (75% cross-sectional area). As a 
result, there is no significant pressure drop across a stenosis until stenosis severity is 
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more than 50% under circumstances of both resting coronary flow and coronary 
hyperaemia. As stenosis severity increases further due to the steep curvilinear 
coronary pressure-flow relationship small increases in stenosis severity will lead to 
significant increases of pressure drop across the stenosis. The curve becomes even 
steeper for stenosis >70%. Ultimately the distal coronary pressure reduces with a 
parallel decrease of the vasodilated coronary flow. In critical stenosis, coronary 
stenosis of more than 90%, the subendocardial flow reserve is diminished and under 
these circumstances coronary hyperaemia achieved by pharmacologic vasodilation 
results in reduction of the distal coronary pressure. This leads to a transmural steal 
phenomenon where there is redistribution of coronary flow towards the 
subepicardium. 
 
1.5.4 Fractional Flow Reserve 
Fractional flow reserve (FFR) is obtained by calculating the ratio of the driving 
pressure for microcirculatory flow distal to the stenosis (distal coronary pressure 
minus coronary venous pressure) to the coronary driving pressure available in the 
absence of a stenosis (mean aortic pressure minus coronary venous pressure). This 
technique is based on the principle that the distal coronary pressure measured during 
vasodilation is directly proportional to maximum vasodilated perfusion and assumes 
linearity of the vasodilated pressure-flow relationship, which is known to be 
curvilinear (213). Also it assumes that coronary venous pressure is zero. This results 
in the simplified FFR index of mean distal coronary pressure/mean aortic pressure 
(Pd/Pa). FFR measurement as a physiological assessment of a moderate degree 
stenosis can help in the decision management regarding coronary intervention and is 
unaffected by alterations in resting flow. FFR can also be used to assess the 
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functional effects of a residual lesion after PCI. A significant advantage of FFR is 
that there is now considerable prognostic information. Recent data from a large 
prospective randomized study, indicating that FFR measurements more than 0.8 are 
associated with excellent outcomes with deferred rather than prophylactic 
intervention (214). This study demonstrated that physiologically guided PCI using 
FFR versus angiographic criteria is safe and cost- effective and reduces the number 
of major adverse cardiac events at one year (13.2% versus 18.3% in angiographically 
guided treatment) (214). FFR although simple and clinically useful has several 
limitations. Contrary to CFR, FFR cannot assess the microcirculatory contribution 
but can only assess the significance of the epicardial stenosis. Also FFR 
measurement is dependent on achieving maximal pharmacologic vasodilation 
(underestimating stenosis severity if maximal vasodilation not achieved) during 
measurement. In addition the assumption that the vasodilated pressure-flow 
relationship is linear and that the venous pressure is zero FFR can underestimate the 
physiological significance of an epicardial stenosis. Besides by inserting the guide-
wire across a stenosis can in theory artifactually overestimate stenosis severity 
caused by the reduction in cross sectional area. By assessing both the physiological 
significance of epicardial stenosis with FFR and the microcirculatory flow with CFR 
using a single wire has the potential to identify circumstances where mixed 
abnormalities contribute to clinical symptoms and discriminate which one is the 
cause of patients symptoms. Left ventricular hypertrophy (LVH) and impaired 
endothelial dependant vasodilation are the two most common pathological conditions 
affecting the microcirculatory resistance independently from the severity of the 
epicardial stenosis. In the former (acquired LVH) there is increased left ventricular 
mass with the microcirculatory vessels remain unchanged (215). Also the resting 
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coronary flow per gram of myocardium remains stable and for this to happen the 
resting coronary flow increases (more flow to maintain the blood flow per 
myocardium gram constant). During maximum hyperaemia the coronary flow 
remains unchanged and as a result of this (relatively increased resting and decreased 
hyperaemic flow) the coronary flow reserve decreases.  In the latter case which is 
common in almost all risk factors for CHD like diabetes mellitus, hypertension, 
hypercholesterolemia and smoking, there is inability of the coronary microcirculation 
to maximum hyperaemia due to impaired NO-mediated endothelial vasodilation. 
Also the coronary pressure/flow curve shifts towards the right leading to an 
increment of the minimum coronary pressure required to keep coronary flow stable 
(216). The net effect of the above is an accentuation of the functional effects of 
epicardial stenosis rendering myocardium prone to ischemia at higher coronary 
pressure and less workload (217). 
 
1.5.5 Role of collaterals in coronary microcirculation 
Coronary collaterals are a complimentary source of blood supply when an epicardial 
coronary artery occlusion or stenosis jeopardizes myocardial blood supply. Several 
studies have demonstrated that collateral blood flow is sufficient to prevent ischemia 
when collateral flow calculated from mean aortic pressure (Pa), coronary wedge 
pressure (Pw) and central venous pressure (Pv) exceeds 25% (218). Also during 
coronary angioplasty and balloon occlusion, ischemia does not develop if FFR 
(based on coronary wedge pressure during occlusion minus venous pressure) is 
greater than 0.25 (219). Pressure derived collateral flow index (CFIp) is calculated as 
(Pw-Pv) / (Pa-Pv). CFI is used as an index of collateral circulation and can be easily 
measured with a pressure wire during PCI. High collateral flow has a beneficial 
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effect on the occurrence of future major ischemic events and less severe myocardial 
ischemia during PCI. On the other hand higher collateral flow also has been 
associated with increased risk of in-stent restenosis after PCI (220-222) probably due 
to competing hemodynamic forces for antegrade flow at the traumatised site. A CFI> 
0.25 indicates a circulation with good collateral support and CFI< 0.25 indicates a 
circulation with less collaterals. In a large observational study lower cardiovascular 
event rate and improved survival was observed in patients with elevated distal 
coronary pressure arising from recruitable collaterals (223). In patients with stable 
angina higher CFI indicates the presence of a good collateral circulation as in a non-
infarcted heart the pressure signals obtained distal to the occluded artery invariably 
originates from collateral channels. However, in the acute myocardial infarction 
setting CFI is unlikely to represent collateral flow but seems to increase with severity 
of microvascular dysfunction. Yamamoto et al demonstrated higher CFI in acute 
myocardial infarction is associated with poorer functional recovery. In the acute 
myocardial infarction, the observed increase in systolic coronary wedge (Pw) 
pressure may be explained by congested blood flow in the coronary microcirculation. 
In the non-infracted heart intra-myocardial blood is smoothly squeezed into the 
venous circulation in systole but this ejection of blood to the venous circulation is 
impeded owing to the extensive microvascular obstruction in the infarct zone (224). 
Collateral circulation develops in response to recurring myocardial ischemia. This is 
a process dependent on hemodynamic forces and angiogenic growth factors, mainly 
VEGF. Although several interventions like the use of recombinant growth factors or 
endothelial progenitor cells have been successful in angiogenesis of capillaries and 
improve myocardial function, randomized human clinical trials have been 
disappointing (225). It is believed that relief of ischemia might be expected to lead to 
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regression of collaterals. Several studies have suggested rapid loss of collateral 
function after PCI (226-229). Some of these results could be due the fact that during 
the estimation of CFI either central venous pressure was not measured or adequate 
hyperaemia was not achieved. Pw alone does not represent collateral flow; right 
atrial pressure and mean aortic pressure need to be considered to measure CFI 
accurately. Perera et al showed that assuming a fixed value of right atrial pressure for 
the measurement of CFI can alter the results substantially (230). The same group 
have demonstrated coronary collateral flow remains undiminished for at least 24 
hours after successful PCI and functional collateral support subsequently declines but 
does not regress completely (231). 
 
1.5.6 Coronary flow reserve 
Coronary flow reserve (CFR) is equal to the ratio of the hyperaemic (during 
maximum vasodilation) to resting coronary flow. Coronary blood flow increases 
automatically from resting to a maximum level in response to increase myocardium 
oxygen demand. CFR reflect both epicardial and microcirculatory contribution 
though it cannot discriminate the two. CFR can be obtained with non-invasive 
methods like PET or CMR and invasive methods by measuring the intracoronary 
flow (CFRDoppler) velocity or by thermodilution using a pressure-temperature sensing 
wire (CFRThermo) in the catheter laboratory. CFR quantifies the ability of coronary 
flow to increase above the resting value. In individuals without LVH and normal 
coronary circulation, CFR varies from 4 to 6. CFR values of less than 2 are 
pathological and become clinically important (219). Coronary flow reserve is altered 
by factors that either affects 1) the hyperaemic coronary flow (e.g., heart rate and 
arterial pressure, stenosis severity and also impaired microcirculatory response) or 2) 
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the resting coronary flow like haemoglobin, resting arterial pressure, heart rate, and 
the resting oxygen extraction. Because CFR quantifies the flow reserves of the 
coronary vascular bed it is impossible to extract conclusions about the importance of 
an epicardial stenosis and dissociate the magnitude of the stenosis from impaired 
microcirculatory function which are common in patients with risk factors for CHD 
like hypertension, diabetes mellitus and hypercholesterolemia. Simultaneous 
measurements of FFR and CFR give the clinician additional information about the 
respective contribution of the epicardial vessel and microvasculature to the total 
resistance to myocardial blood flow. In patients with CHD without a significant 
pressure drop along the epicardial artery (i.e. normal FFR) a low CFR value indicates 
microvascular involvement. 
 
1.5.7 Measurement of coronary flow reserve by Doppler flow wire 
A Doppler wire is placed in the distal coronary artery to obtain optimal traces. 
Continuous average peak velocity is recorded at baseline and at maximum 
hyperaemia. Angiographic views in two orthogonal planes are also taken at baseline 
and at maximum hyperaemia for measurement of coronary artery diameter. Changes 
in coronary artery diameter are calculated using an automated QCA edge detection 
system approximately 2.5 mm distal to the tip of the Doppler wire in a 2.5-5mm 
length segment. Absolute coronary flow is calculated from the product of 
corresponding average peak flow velocity (APV) values and QCA derived coronary 
artery diameter (1/2 x APV x [coronary cross-sectional area]) at baseline and 
maximal flow. The percentage change in coronary blood flow is obtained from the 
ratio of baseline and maximal blood flow values (232). Pijls et al studied 103 arteries 
from 50 patients and demonstrated a fair correlation between CFRthermo and 
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CFRDoppler (233). They found CFRthermo = 0.84 × CFRDoppler + 0.17 (r=0.80; P<0.001). 
The average absolute difference between both indexes was 17±14% (range, 0% to 
51%). In 26% of all studies the difference between the both parameters was > 20%. 
For post-stenotic coronary flow velocity reserve several studies reported strong 
correlations with myocardial stress perfusion imaging and 2D echocardiographic 
stress imaging (234). Coronary flow velocity reserve <2 corresponded to reversible 
ischemia with myocardial perfusion image and stress-induced wall motion 
abnormality. These studies had high sensitivity (86% to 92%), specificity (89% to 
100%), predictive accuracy (89% to 96%) and positive predictive value (94% to 
100%) and negative predictive value (77% to 95%) (211;212;235;236). 
FFR and CFR have excellent correlation with non-invasive stress test at cut off 
values of 0.72 to 0.75 for FFR and 1.7 to 2.0 for CFR (211;234;237). Meuwissen et 
al studied 150 intermediate coronary lesions in 126 consecutive patients with stable 
angina they found concordant outcomes in 109 lesions (73%) and discordant 
outcomes in 41 lesions (27%). Out of the 41 discordant cases 26 had FFR <0.75 and 
CFR >2; 15 had FFR≥ 0.75 and CFR < 2. They also measured a velocity based index 
of microvascular resistance during hyperaemia (h-MRv) as a ratio of mean distal 
pressure to average peak flow velocity (APV). Between the two discordant groups h-
MRv was significantly higher in the second group in comparison to first. This 
suggests the observed variability in the microvascular resistance plays a significant 
role in the discordance between FFR and CFR. Both FFR and CFR are influenced by 
the combination of coronary artery stenosis and microvascular resistance. In absence 
of coronary stenosis variability of h-MRv will have little effect on FFR but it will be 
reflected in CFR (238). 
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1.5.8 Limitations of coronary flow reserve 
As CFR represents a ratio between peak hyperaemic and resting coronary flow, CFR 
measured by thermodilution has some limitations such as dependency on heart rate, 
blood pressure, myocardial contractility, previous myocardial infarction, valvular 
heart disease, LV hypertrophy, age, individual variability between persons and 
dependency on achieving true hyperaemic coronary blood flow (233;239-241). A 
previous study (240) has shown that CFRDoppler is significantly reduced by 
tachycardia and by increased contractility. Although these different methods for 
assessment of the coronary microcirculation have methodological flaws, the 
influence of different confounding clinical factors and sometimes poor 
reproducibility represented limitations for their routine use in clinical practice. With 
the introduction of a pressure wire with temperature and pressure sensors assessment 
of coronary microvasculature has become much easier. With the single wire it is now 
possible to measure CFR, FFR and IMR. IMR has emerged as a novel index of 
measuring the microcirculation (233;242). This saves the need for a separate Doppler 
flow wire which is needed to measure the h-MRv. 
 
1.5.9 Measuring the index of microvascular resistance and coronary flow 
reserve with pressure-temperature sensor wire 
IMR and CFR can be measured by a commercially available 0.014 inch floppy 
pressure wire (pressure wire 3, Radi Medical system) by using the thermodilution 
technique. The pressure wire has a microsensor at a location 3 cm from the floppy 
tip, which measures simultaneously pressure and temperature at the location of the 
sensor with an accuracy of 0.20 C. The shaft of the wire can be used as an additional 
thermistor, providing the input signal at the coronary ostium of any fluid injection 
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with a temperature difference from blood. All signals can be displayed on the regular 
catheter laboratory recording system or at a suitable interface (Radi analyzer). In this 
way the mean transit time of the injected saline down the coronary artery can be 
calculated from a coronary thermodilution curve. Thermodilution curves in the 
coronary artery are obtained by short manual injections of 3 mls 0.9% saline at room 
temperature. Measurements of transit time are calculated 3 times at base line and 3 
times at maximum hyperaemia. The mean transit time at baseline and maximum 
hyperaemia are calculated. Maximum hyperaemia is achieved by adenosine infusion 
through the femoral vein at a rate 140 microgram/kg/minute. Distal coronary 
pressure (Pd) is recorded from the pressure wire. Mean aortic pressure (Pa) is 
measured from the coronary catheter and central venous pressure (Pv) is measured 
from the right heart catheter at maximum hyperaemia. Coronary wedge pressure 
(Pw) is also measured at maximum hyperaemia by inflating a semi-compliant 
balloon (1mm smaller that the vessel diameter) in the coronary artery and the IMR is 
calculated. In absence of epicardial stenosis (and therefore collaterals) and assuming 
Pv is close to zero, IMR is calculated as hyperaemic distal coronary pressure divided 
by inverse of hyperaemic mean transit time (Tm) (a correlate to absolute flow). This 
can be represented in a simplified manner as a product of distal coronary pressure 
and mean hyperaemic transit time (Pd × Tm). Fearon et al demonstrated there was 
significant correlation between mean IMR (distal coronary pressure/Inverse of mean 
hyperaemic transit time) and true microcirculatory resistance (TMR calculated as a 
ratio of distal coronary artery pressure and hyperaemic flow measured with external 
ultrasonic Doppler) in experimental animals (243). Coronary collaterals, in the 
presence of a coronary epicardial stenosis, might lessen the drop in distal coronary 
pressure without a change in coronary blood flow and also may increase the coronary 
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Pw. The combination of the above in turn can lead to an increase in the measured 
coronary microvascular resistance (243). Therefore, in presence of a coronary 
stenosis with collaterals, myocardial flow is not equal to coronary flow but exceeds 
the coronary flow because of collateral flow. Tm is no longer representative of 
myocardial flow and the contribution of collaterals needs to be considered and the 
IMR= Pa × Tm × [(Pd-Pw) ÷ (Pa-Pw)] (assuming Pv=0). This could be again 
represented by IMR=Pa × Tm × FFRcor. In the presence of abnormal Pv the equation 
should be represented as IMR= (Pa-Pv) × Tm × [(Pd-Pw) ÷ (Pa-Pw)] (Pa=Aortic 
pressure, Pv =Right atrial pressure, Pw=coronary artery wedge pressure, Pd=distal 
coronary pressure, all the above measurements during maximum hyperaemia). 
Clearly the presence of functional collaterals will increase Pw, but there is an 
argument that Pw below 25 mmHg implies the presence of hemodynamically 
insignificant collaterals. The cut off of 25mmHg is in line with previous clinical 
studies found that collateral flow is essentially absent when Pw is lower than 25 
mmHg as discussed above. (213;244-247) The vascular volume of the epicardial 
artery between the ostium and the location where pressure and temperature are 
measured should remain constant throughout the measurements. This can be 
achieved by prior administration of 200mcg of intracoronary nitroglycerine. It is of 
paramount importance to position the sensor at the same distance from the ostium of 
the coronary artery while measuring the transit time because more distal the sensor is 
the longer the transit time will be. CFR  can be calculated as a ratio of average transit 
time at baseline and average transit time at maximum hyperaemia provided that the 
time for analysis of the thermodilution equals at least one cardiac cycle, and 
variability between values of  the 3 transit times < 20%. Flow equals V/Tm, where V 
represents the vascular volume between injection site of the indicator (tip of the 
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guiding catheter and the location of sensor). Previous studies have demonstrated 
transit time of intracoronary room temperature saline derived from thermodilution 
curves is inversely proportional to coronary flow (233;242;248). Pijls et al, in an 
experimental model found a strong correlation between the inverse of mean transit 
time and absolute flow. Using this technique CFR can be measured as a ratio 
between resting mean transit time and hyperaemic mean transit time and this 
correlates well with standard CFR measurement (241). 
 
1.5.10 Reproducibility and independence of the index of microvascular 
resistance from epicardial artery stenosis 
The main advantage of IMR over other indices of microcirculatory dysfunction is 
that it is independent of epicardial artery stenosis, so it reflects true microcirculatory 
function. Fearon et al in an experimental animal model showed that after collateral 
flow is taken into account, the microvascular resistance assessed by the IMR is not 
affected by increasing the epicardial artery stenosis (249). Also Aarnoudse et al 
studied thirty patients with stable angina scheduled for PCI. They created 10%, 50% 
and 70% artificial stenosis in the successful stented segment of the coronary artery, 
by inflating a short compliant balloon with a diameter 1 mm smaller than the stent 
with increasing pressures. They measured IMR at each degree of stenosis and 
demonstrated when contribution of collateral flow is properly accounted for, IMR 
does not change with the epicardial artery stenosis severity (250). Similarly Leyland 
et al studied forty patients with stable angina undergoing PCI. They showed that 
when collateral supply is accounted for, epicardial stenosis does not increase 
microvascular resistance in patients with stable angina (251). Interestingly, Verhoeff 
et al have shown that Pw adjusted coronary microvascular resistance calculation 
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(Doppler guided calculation) overestimates the effect of potential collateral flow and 
is not needed for the assessment of coronary flow-limiting stenosis characterized by 
a FFR between 0.6 and 0.8 or for non-significant lesions (252). 
 
Compared to CFR, IMR is more reproducible and is independent of hemodynamic 
perturbations. Ng MKC et al assessed CFR and IMR in 15 patients at baseline and 
under different hemodynamic conditions like right ventricular pacing at 110 bpm, 
intravenous nitroprusside injection, and intravenous dobutamine injection. They 
demonstrated intrinsic variability of IMR is much less in comparison to the CFR. Co-
efficient of variation for IMR was 6.9± 6.5% where as for CFR it was 18.6 ± 9.6% 
(p<0.01). Under hemodynamic stress CFR decreased during pacing and dobutamine 
infusion compared to baseline while IMR remained similar throughout all the above 
hemodynamic conditions. IMR values during pacing had a significant correlation 
with the baseline value. As a consequence of increased resting coronary flow with 
dobutamine infusion CFR values were significantly lower than those at baseline 
whereas IMR values remained unchanged (253). 
 
1.5.11 Clinical implications of measurement of the index of microvascular 
resistance 
Despite adequate epicardial artery reperfusion a number of patients with STEMI 
have a poor prognosis because of microvascular damage. IMR helps in assessing the 
microvascular damage in the setting of pPCI in STEMI patients. Fearon et al 
demonstrated (254) positive correlation of IMR measured immediately following 
pPCI for STEMI with peak CK. They also demonstrated that IMR predicted left 
ventricular function and recovery of left ventricular function, assessed by wall 
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motion score measured by echocardiography at 3 months follow up. Sezer et al 
measured IMR two days after pPCI and demonstrated intracoronary streptokinase 
administration following pPCI was associated with significantly lower IMR 
compared with the patients who did not receive intracoronary streptokinase 
following the pPCI. (16.29± 5.06 U vs 32.49 ± 11.04 U. p= <0.002). However at 6 
months there was no significant difference in LV size or function between these two 
groups (255). Payne et al measured at the end of pPCI the IMR in 108 patients 
presented with STEMI. They found that microvascular resistance measured during 
pPCI significantly predicts myocardial salvage, infarct characteristics, and left 
ventricular ejection fraction in patients with STEMI (256). Similar findings were 
found more recently in patients with anterior STEMI after pPCI (257). Also 
McGeoch showed that  IMR measured acutely was an independent predictor of LV 
function and infarct volume in patients with STEMI treated with pPCI (258).  
In patients with stable angina direct stenting has been suggested to reduce 
periprocedural microcirculatory injury compared with the stenting that follows pre-
dilation of the lesion. Cuisset et al has demonstrated in patients with stable angina 
who had elective PCI that direct stenting was associated with significantly lower 
IMR compared to the patients who had pre-dilation with balloon (IMR 13 ± 3 U vs 
24± 14 U, p=<0.01). They have also demonstrated that patients who had post PCI 
troponin release had significantly higher IMR compared to the patients who did not 
have post PCI troponin release (259). In addition measurement of IMR in patients 
electively admitted for PCI may allow prospective identification of patients at risk of 
periprocedural myocardial infarction. Pre-PCI IMR was also the strongest predictor 
of post-PCI troponin release (260). 
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1.5.12 Conclusions 
Among the different invasive methods of assessing the coronary microcirculation in 
the catheter laboratory, IMR has emerged as the most robust and independent index. 
The main advantage of IMR over the other indices is that it exclusively reflects the 
microcirculatory state and can be measured with a simple technique with the help of 
a pressure wire. It is also independent of epicardial artery stenosis. IMR is 
reproducible and is less influenced by the hemodynamic perturbations. Studies have 
shown worse microcirculatory function assessed by IMR is a predictor of poor LV 
function in patients with ST elevation myocardial infarction. 
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1.5 AIMS OF THIS THESIS 
The aims of this study were: 
 
1. To investigate the expression of the total AnV+ microparticles (MPs) and their 
cell-specific phenotype in patients presenting with symptomatic CHD, either ACS or 
stable angina. The possibility of a trans-myocardial gradient between coronary and 
periphery of MP release was explored by determining MP levels in the local 
intracoronary (CO) artery distal to the culprit lesion and in the right atrium (RA) as 
representative of the systemic circulation. 
 
2. To explore the relationship between local coronary and systemic MP levels, 
circulating markers of inflammation, and extent of myocardial necrosis in patients 
with ACS or stable angina undergoing PCI.  
 
3. To compare coronary artery and systemic circulating levels of platelet activation 
markers, and MPs in patients with symptomatic ACS or SA treated with PCI. 
 
4. To assess the relationship between microvascular dysfunction and the level of 
PMA expression, intracoronary and systemic (aorta and right atrium) in patients 
presenting with NSTEMI or stable angina treated with PCI. 
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Chapter 2: Patients and Methods 
 
2.1 Coronary heart disease patients 
 
2.2 Identification of platelet-monocyte aggregates 
 
2.3 Isolation and analysis of total Annexin V positive microparticle and 
microparticle subpopulations 
 
2.4 Estimation of the inflammatory markers and Soluble P Selectin 
 
2.5 Measuring the Index of microvascular resistance, coronary flow reserve and 
coronary wedge pressure 
 
2.6 Recruitment limitations and practical considerations 
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2.1 Coronary heart disease patients 
Eleven patients with stable angina (SA) admitted for coronary angioplasty, fourteen 
patients presented with non-ST-elevation myocardial infraction (NSTEMI) and 
twenty one patients presented with ST-elevation myocardial infraction (STEMI) 
were recruited for the study. 
 
2.1.1 Stable angina patients 
Eleven patients with symptoms of stable angina (SA) pectoris who electively 
admitted for coronary angiography and percutaneous coronary angioplasty (PCI) 
were recruited for the study. SA patients had been reviewed in the cardiology 
outpatient clinic with a diagnosis of angina pectoris based on typically ischaemic 
sounding chest pain and a positive non-invasive test such as exercise tolerance test, 
stress echocardiography or myocardial perfusion scan (MPI). All SA patients were 
treated with anti-angina medications and aspirin 75mg od. The decision for 
diagnostic angiography was made by a cardiologist. SA patients were also treated 
with Clopidogrel 75mg od per day for 7 days prior to the angioplasty as per hospital 
protocol. All patients were treated with weight adjusted unfractionated heparin 
before the intervention to achieve an activated clotting time (ACT) between 200 and 
250 sec. Informed consent was obtained prior to the procedure from 25 stable angina 
patients outside the cardiac catheterisation laboratory. However, only eleven stable 
angina patients were studied as the other nine had non-significant CHD from the 
diagnostic coronary angiogram. Ethical permission was granted by the local ethics 
committee of the Royal Free Hospital, and all participants provided fully informed 
written consent. 
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2.1.2 Non ST elevation myocardial infarction patients. 
Fourteen patients presented with non-ST elevation myocardial infarction (NSTEMI) 
and were treated with PCI were recruited for the study. The diagnosis of NSTEMI 
was based on the history of cardiac chest pain at rest with or without ischemic ECG 
changes and a 12 hour troponin T value > 0.03 ng/l (261). On arrival at our hospital 
all NSTEMI patients were treated with 300 mg of Aspirin and 600 mg of Clopidogrel 
and weight adjusted low molecular weight heparin (enoxaparin 1mg/kg twice daily). 
Angiography was performed in all NSTEMI patients within 72 hours of onset of 
chest pain. All NSTEMI patients also received weight adjusted unfractionated 
heparin in the catheter laboratory before PCI to maintain the ACT between 200 and 
250 sec. Informed consent was obtained prior to the procedure from all NSTEMI 
patients outside the cardiac catheterisation laboratory. Ethical permission was 
granted by the local ethics committee of the Royal Free Hospital, and all participants 
provided fully informed written consent. 
 
2.1.3 ST elevation myocardial infraction patients. 
Twenty three consecutive patients presented with ST elevation myocardial infarction 
(STEMI) were recruited for the study. Standard diagnostic criteria were followed for 
the diagnosis of STEMI according to current guidelines (262). All patients with acute 
STEMI were treated immediately with primary PCI as the preferred and 
recommended method of treatment for acute myocardial infarction. All STEMI 
patients were given 300 mg of Aspirin by the ambulance paramedics and received 
600 mg of Clopidogrel on arrival outside the catheterisation laboratory. Intravenous 
morphine was administered to alleviate symptoms of chest pain as necessary. 
Patients were given weight adjusted unfractionated heparin to keep the ACT between 
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200- 250 sec duration pPCI. Informed consent was obtained prior to the procedure 
from all STEMI patients outside the cardiac catheterisation laboratory. Ethical 
permission was granted by the local ethics committee of the Royal Free Hospital, and 
all participants provided fully informed written consent. 
 
2.1.4 Exclusion criteria 
Patients with renal failure, prior coronary artery bypass grafts and who had received 
Glycoprotein IIb/IIIa antagonists prior to sampling were excluded. 
 
2.1.5 Percutaneous coronary interventions (angioplasty) 
Standard techniques were followed for the diagnostic coronary angiography via the 
right femoral artery through a 6F sheath. A 6F venous sheath was also inserted via 
the right femoral vein. Left coronary artery angiography was performed with a 5F 
Judkin’s left 4 (JL4) diagnostic catheter (Cordis ®, internal diameter 0.11 cm). Right 
coronary angiography was performed with a 5F Judkin’s right 4 (JR4) diagnostic 
catheter (5F Cordis ®, internal diameter 0.11 cm). Through the femoral vein a 5F 
multipurpose catheter (5F, Cordis ®, internal diameter 0.11cm) was been placed in 
the right atrium. Following the diagnostic angiography the culprit lesion was 
identified and weight adjusted unfractionated heparin was given prior to the PCI. 
After identification and wiring of the culprit lesion an aspiration catheter (Medtronic 
® Export catheter, internal diameter 0.10 cm) was advanced distal to the culprit 
lesion and 10 ml blood sample was aspirated through the aspiration catheter with a 
syringe. In the SA and NSTEMI groups blood samples (10 ml from each site) were 
sequentially aspirated through the diagnostic 5F catheter from the right atrium and 
the ascending aorta prior to sampling the coronary artery. However in the STEMI 
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group due to the clinical priority of restoring the coronary blood flow in the infarct 
related artery, the coronary artery was sampled first and then the right atrium and 
aorta. In order to maintain similar shear stress during aspiration of the blood samples 
from the three compartments and minimise shear stress related in vitro platelet 
activation blood samples from the different sites were aspirated carefully through 
catheters of similar internal diameter. In NSTEMI and stable angina patients if the 
advance of the aspiration catheter was difficult initially due to technical reasons, pre-
dilation of the lesion with a semi compliant balloon was performed prior to the 
sampling. All the samples were collected before patients were treated with GP 
IIb/IIIa antagonists. Angioplasty was performed according to standard procedures 
following collection of samples.  
Blood samples collected from the three sites were used for estimation markers of 
platelet activation i.e. s-P selectin, platelet-monocyte aggregates (PMA), P-selectin 
positive (PMA), microparticle (MP) and inflammatory parameters i.e. C-reactive 
protein (CRP), tumour necrosis alpha (TNF-α), IL-6 and serum amyloid antigen 
(SSA). Trans-culprit lesion gradient of the above parameters was calculated by the 
difference between the median values from coronary artery and the right atrium. 
 
2.2 Identification and analysis of platelet-monocyte aggregates 
2.2.1 Collection of whole blood for platelet-monocyte aggregate estimation 
Ten millilitre of whole blood was collected from the coronary artery and right 
atrium. Four mls out of the 10mls was poured into a separate sterile vacutainer tubes 
containing a combination of 3.2% sodium citrate and EDTA for flow cytometric 
analysis of total PMA and P-selectin positive PMA (CD62P+PMA). Sodium citrate 
was added to EDTA to stop in vitro calcium dependent PMA formation. Samples 
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were immediately put onto ice and transferred to the haematology laboratory for 
preparation for flow cytometry. P-selectin positive PMA implies the presence of 
activated platelets, expressing p-selectin on their surface, within the PMA. 
Difference between the median values of the coronary artery and right atrium were 
calculated to obtain a trans-culprit lesion gradient of the above mentioned 
parameters. 
 
2.2.2 Preparation of whole blood for platelet-monocyte aggregates estimation 
Blood samples collected from the two samples were immediately transferred to the 
haematology laboratory and prepared for flow cytometry and PMA estimation. 
Analysis of all the samples was complete within 2 hours of collection. Five µl of 
anti-CD61 FITC, anti-CD14 PerCP and anti-CD62P PE were added in the two (one 
tube for each compartment) round bottom polystyrene tubes (BD Falcon 12 x75 mm 
style). One hundred µl of whole blood was aliquoted into each of the tubes. The 
samples were incubated in a dark place at room temperature for 20 minutes. After 
that erythrocytes were lysed by addition of 2 mls of easy lyse™ solution (Dako) (1 in 
10 dilution) for 15 minutes at room temperature in dark place. Red blood cells were 
washed with addition of 1ml of FACS flow and centrifuged at 300g for 5 minutes. 
After that the supernatant was discarded and the cells resuspended in 500µl of FACS 
flow for immediate flow cytometric analysis (FACS Calibur equipped with Cell 
Quest ® software – BD Biosciences, Oxford, UK). 
 
2.2.3 Flow Cytometric identification of platelet-monocyte aggregates  
Events were acquired on a 2D dot plot arraying CD14 (logarithmic scale abscissa) 
and SSC height (linear scale ordinate). Monocytes were identified as CD14 positive 
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events and distinctive intermediate side scatter height as shown in Figure 2.1. A 
minimum of 5000 CD14 positive events were acquired from each sample. The 
monocyte population was gated and named as analysis region (R1). Events within R1 
plotted again on a 2D dot-plot arraying CD 61 signal width (linear scale abscissa) 
and CD14 signal height (logarithmic scale abscissa). To exclude false-positive PMA 
arising from co-incident analysis of free platelets adjacent but not interacting with 
monocytes, the events with a narrow CD61 width was drawn (R2 in Fig 2.1b). 
Events falling within both R1 and R2 regions were subsequently plotted onto another 
2D dot-plot arraying CD61 FITC signal height (logarithmic scale abscissa ) and CD 
62 PE (logarithmic scale ordinate) (Fig 2.1c). Co- incident cells demonstrate longer 
time of flight to pass through the laser and can be distinguished by eliciting signals 
which lasts longer than the single complex. This was reflected in the wider width of 
the signal. Double positive CD14+ and CD61+ events were consider as PMA were 
expressed as percentage of the total monocytes. Out of the total PMA the events 
which were expressing CD62P were identified as P-selectin positive PMA and were 
expressed as percentage of the total PMA. The process was standardised in our 
laboratory with the percentage of PMAs in the peripheral circulation of normal 
healthy individuals was found to be 2.57± 0.31 (CV 13.96± 8.30 %). 
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Figure 2.1 Identification of PMA and CD62P+ PMA with flow cytometry 
 
a. Monocyte population was identified by CD14 positivity and distinctive 
intermediate side scatter. R1 analysis region was drawn around the monocyte 
population. 
b. Events within R1 were plotted again on a 2D dotplot arraying CD61 signal 
width (linear scale abscissa) and CD14 signal height (logarithmic scale 
abscissa). To exclude false-positive PMC arising from co-incident analysis of 
free platelets and monocytes, a region R2 was drawn  around the cells with 
 89 
narrow CD61 width. Cells with wider CD61 width (R3) were identified as co- 
incidents. 
c. Events falling within both R1 and R2  were subsequently plotted onto another 
2D dotplot arraying CD6-FITC signal height (logarithmic scale abscissa ) and 
CD62P-PE (logarithmic scale ordinate) (Fig 2.1c). Double positive events for 
CD14 and CD61 were identified as PMA. PMA positive for CD62P were 
identified as P-selectin positive complexes (CD62P+ PMA) (right upper 
quadrant figure- 2.1c). 
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2.3 Isolation and analysis of total Annexin V positive microparticle and 
microparticle subpopulations 
2.3.1 Preparation of platelet poor plasma  
3.5 mls of whole blood was collected into bottles containing 3.2% trisodium citrate 
(Becton Dickinson). Platelet poor plasma (PPP) was obtained by immediate 
centrifugation of the whole blood at 5000G for 5 minutes twice. PPP was then stored 
at –80o Celsius for later analyses of microparticle (MP) estimation and enzyme-
linked immunosorbent assay (ELISA) studies (see below). 
 
2.3.2 Isolation of microparticles from platelet poor plasma 
Platelet poor plasma was defrosted in a water bath at 37 o Celcius. Exact volumes of 
plasma (200 microlitres) were then centrifuged at 17000 G for 60 minutes and the 
supernatant decanted to obtain the microparticle (MP) pellet. The MP were then 
reconstituted in 280 microlitres of annexin V buffer (Becton Dickinson), and divided 
into seven 40-microlitre aliquots plated onto the first 7 wells of a 96 well U-
bottomed plate. 
 
2.3.3 Labelling of microparticles with annexin V and monoclonal antibodies  
The labelling and quantification of MP was achieved as follows. 5 microlitres of a 1 
in 10 dilution of FITC-conjugated (or PE-conjugated for Tissue factor positive 
monocyte derived MP (TF+MMP) Annexin V in buffer (Becton Dickinson) was 
added to every well. In addition, antibodies against platelet, endothelial, neutrophil 
and monocyte surface markers conjugated to red (PE) or far-red (PerCP-Cy5) 
fluorochromes were used to identify MP of different cell origin. Platelet markers 
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examined were the constitutively expressed platelet marker CD42a (mouse IgG1 
anti-human CD42a-PerCP-Cy5, Becton Dickinson), and the platelet activation 
marker P-selectin (mouse IgG1 anti-human CD62P-PE, Becton Dickinson). 
Endothelial surface markers examined were E-selectin (mouse IgG1 anti-human 
CD62E-PE Becton Dickinson); CD105 (“Endoglin”; mouse anti-human IgG1 
CD105-PE, Invitrogen); ICAM-1 (mouse IgG1 anti-human CD54-CYC, Becton 
Dickinson); and PCAM-1 (mouse IgG1 anti-human CD31-PE, Becton Dickinson). 
Neutrophil surface marker examined was Integrin Alpha M (mouse IgG1 anti-human 
CD66b-PE, eBioscience). Monocyte surface markers examined 
were lipopolysaccharide receptor (LPS-R) (mouse IgG1anti-human CD14- PerCP-
Cy5, AbD Serotec) and tissue factor (mouse IgG1 anti-human CD142-FITC, 
American Diagnosis). Five microlitres of a 1:10 dilution of each antibody was added 
to individual wells. The final volume of each well was 55 microliters and the final 
dilution for each of the conjugated antibodies was 1:55. MP were incubated with the 
labelled antibodies and annexin V for 10 minutes at room temperature with gentle 
shaking. The incubation was then terminated by adding 200 microlitres of annexin V 
buffer to each well, and the samples transferred to tubes prior to flow cytometry. 
Using this methodology it was possible to define the following types of 
microparticles thus: total AnV+ MP, platelet derived MP (PMP; AnV+CD42a+), 
endothelial derived MP (EMP; dual positive for AnV+ and CD62E or CD105; or 
AnV+CD42a-CD31+), neutrophil derived MP (NMP; AnV+CD42a-CD66b+) and 
tissue factor positive monocyte derived MP (MMP; AnV+CD14+TF+). 
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2.3.4 Flow cytometric analysis of microparticles 
All analysis was performed on a FACS Calibur flow cytometer equipped with Cell 
Quest ® software (BD Biosciences, Oxford, UK). To obtain optimal forward and 
side scatter instrument settings for MP, 1 micrometer and 3 micrometer latex beads 
(Sigma) were run and logarithmic forward and side scatter plots (Fig 2.2a) obtained 
(263). Gates were then set to include particles less than approximately 1.5 
micrometers, but to exclude the first forward scatter channel containing maximal 
noise. Optimal compensation was set for green, red and far-red fluorescence. 
Specific binding for each antibody was determined using isotype control antibodies 
with equal protein: fluorochrome ratios, and at the same final dilution as per 
manufacturer recommendation. Since annexin V is a protein and not an antibody 
(and hence no isotype control antibody exists), the threshold for annexin V binding 
was determined by using the fluorescence threshold established for MP in the 
absence labelled annexin V. Particles less than 1.5 micrometers in size and binding 
annexin V were then gated (Fig 2.2b), and histograms obtained for this gated 
population for binding to individual monoclonal antibodies to determine the cell of 
origin of the MP (Fig 2.2c). MP samples were run at medium flow rate with a cut-off 
time of 30 seconds. 
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Fig 2.2 Flow cytometric identification and analysis of AnV+ microparticles 
a. Logarithmic forward and side scatter plot obtained after cytometric 
acquisition of a coronary artery stained sample from a patient with NSTEMI.  
b. Microparticles were identified, as Annexin V-FITC (Fluorescein 
Isothiocyanate) (FL1-H) positive events, and gated. 
c. Particles less than 1.5 micrometers in size and binding annexin V were then 
gated and histograms obtained for this gated population for binding to 
individual monoclonal antibodies (FL2-H and FL3-H colours) to determine 
the cell of origin of the microparticle. 
d. 3 micrometer latex beads were run concurrently with the microparticle 
samples for conversion of the flow cytometer counts to an estimate of the 
number of microparticle per ml of plasma. 
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2.3.5 Determination of absolute microparticle number per ml of plasma 
To convert flow cytometer counts to an estimate of the number of MP per ml of 
plasma, a predetermined number (always 200000, calculated as per manufacturer 
recommendations) of 3 micrometer latex beads (Sigma) were run concurrently with 
the microparticle samples (Fig 2.2d). The absolute number of annexin V binding 
microparticles per ml of plasma was then determined by using the proportion of 
beads counted and the exact volume of plasma from which the microparticles were 
analysed, as described by (263). The following equation was thus derived to convert 
flow cytometer counts to an estimate of the number of MP per ml of plasma (Figure 
2.3). 
Since samples from each individual were run 7 times, microparticle counts from 
individual subjects were expressed as the mean number per ml of plasma, with 
standard error of the mean based on 7 measurements. To determine the absolute 
number of MP derived from different cellular populations (i.e. platelet, or 
endothelial) the absolute number of total MP derived from the above equation was 
multiplied by the percentage positivity for that particular marker. 
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Figure 2.3 Conversion equation for calculation of MP number from flow cytometer 
counts 
Total number of MP/ ml of plasma = 
 
(200 000   /   no. of beads counted) X (no. of MP counted per well) X 7 
 
 
Number of mls of plasma 
 
Number of beads added per well 
 
Usually 7000-9000 beads 200L 
 
The number of wells into 
which the sample was 
divided 
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Cellular source 
of MPs 
Marker Alternative 
name 
Clone Isotype Company 
      
Platelets      
 CD42a- 
PerCP-Cy5 
GPIX Beb1 IgG1  BD 
 CD62P-PE P-selectin AK-4 IgG1  BD 
Endothelial 
cells 
     
 CD31-PE PCAM-1 WM59 IgG1  BD 
 CD105-PE Endoglin SN6 IgG1 Invitrogen 
 CD62E-PE E-selectin 68-5H11 IgG1  BD 
 CD54-PE ICAM HA58 IgG1  BD 
Neutrophils      
 CD66b-PE Integrin alpha 
M 
CBRM1/5 IgG1  eBioscienc
e 
Monocyte      
 CD14-
PerCP-Cy5 
LPS-R 61D3 IgG1 AbD 
Serotec 
 CD142-FITC Tissue Factor    
Isotype 
controls 
     
 PE IgG1  MOPC-21  BD 
 PECy5 IgG1  MOPC21 IgG1  BD 
 PerCP  X40 IgG1  BD 
      
 Annexin V FITC   BD 
      
Other reagents: 
 
10 x Annexin-V binding buffer (BD Cat NO: 66121E) 
 
96-Well U-bottom Multiplate (Greiner, polypropylene, Cat 650201) 
 
FACS insert tube (Greiner Cat NO: 101101) 
 
Sarstedt screw cap micro-centrifuge tubes (Simport T338-4S) 
 
Latex beads (Sigma 3 µm:LB30; 1.1 µm: LB11; 0.3 µm: LB3) 
 
 
Table 2.1 Cell specific monoclonal antibodies and other reagents used  
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2.4 Estimation of inflammatory markers and soluble p-selectin 
2.4.1 Collection and preparation of blood samples  
3.5 mls of whole blood was collected into bottles containing 3.2% trisodium citrate 
(Becton Dickinson). PPP was obtained by immediate centrifugation of the whole 
blood at 5000G for 5 minutes twice. PPP was then stored at –80o Celcius for later 
analyses of IL-6 and TNF-α, s P-selectin with ELISA (R&D systems); hs-CRP and 
SAA using a high sensitivity automated microparticle enhanced latex turbidimetric 
immunoassay (COBAS MIRA; Roche Diagnostics GmbH). 
 
2.4.2 ELISA 
2.4.2.1 Estimation of TNF-α and IL-6  
TNF-α and IL-6 were measured using a quantitative enzyme immunoassay technique 
(R&D Systems). Monoclonal antibobies specific for TNF-α or IL-6 were precoated 
onto a microplate. Standards and samples were pipetted into the wells and any TNF-
α or IL-6 present was bound by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for TNF-α or 
IL-6 was added to the wells. Following a wash to remove any unbound antibody-
enzyme reagent, a substrate solution was added to the wells and colour developed in 
proportion to the amount of TNF-α or IL-6 bound in the initial step. The colour 
development was stopped and the intensity of the colour was measured. 
A standard curve was constructed by plotting the mean absorbance for each standard 
on the y axis against the concentration on the x-axis and a best fit curve was drawn 
through the points on the graph. The data was linearized by plotting the log of TNF-α 
or IL-6 concentrations versus the log of optical density and the best fit line was 
determined by the regression analysis. The CV of intraassay precision of this 
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particular TNF-α kit varied between 4.6% and 5.2% and the CV of interassy 
precision varied between 5.4% and 7.4%. The mean minimal detectable dose of 
TNF-α was 1.13 pg/ml. The CV of intra assay precision of the IL-6 was between 
1.6% and 4.2% whereas CV of interassay precision varied between 3.3% to 6.4%. 
The minimal detectable dose of IL-6 was typically less than 0.06 pg/ml.    
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Figure 2.4 Standard curve for TNF-α (a) and IL-6 (b). Standard curve was produced 
by plotting the log of TNF-α (a) and IL-6 (b) concentrations (x axis) and the log of 
optical densities (y axis). The best fit line was determined by regression analysis. 
 
2.4.2.2 Estimation of soluble P-selectin 
Soluble P-selectin was assayed by the quatitative sandwich immunoassay technique 
using the R& D Systems kit. A monoclonal antibody specific for s P-selectin was 
precoated into the wells together with a polyclonal antibody specific for s-P-selectin 
which has been conjugated to horseradish peroxidase. After removal of unbound 
conjugated antibody, a substrate was added and colour was developed which was 
proportional to analyte concentration. 
A standard curve was drawn by plotting the mean absorbance for each standard on 
the y axis against the concentration on the x axis. For samples the concentration 
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determined from the standard curve was multiplied by 20 (dilution factor). The CV 
of intra assay precision of this kit was between 4.9 % and 5.6 % and the CV of 
interassay precion of this test was between 7.9% and 9.9%. Minimal detectable dose 
of s P-selectin was less than 0.5 ng/ml. Mean value from healthy individual was 29 
ng/ml (± 1sd range 18-40 ng/ml). 
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Figure 2.5 Standard curve for soluble P-Selectin (s P-selectin). Standard curve for s 
P-selectin was drawn by plotting the mean absorbance on the y axis against the 
concentration on the x axis. Values of the samples obtained from the standard curve 
were multiplied by the dilution factor of 20 to get the true s P-selectin 
concentration. 
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2.4.3 Estimation of high sensitive CRP and SAA 
CRP was measured in plasma using a high sensitivity automated microparticle 
enhanced latex turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics 
GmbH). The lower limit of detection was 0.2 mg/l with an interassay CV of 4.2% at 
4 mg/l and 6.3% at 1 mg/l. SAA was measured in plasma by latex nephelometry 
(BNII autoanalyser; Dade Behring, Marburg, Germany) (264). The lower limit of 
detection was 0.7 mg/l, with an inter-assay CV of 2.6% at15 mg/l and 3.7% at 
80 mg/l.  Standardisation of both CRP and SAA assays was based on the respective 
WHO International Reference Standards (265;266). 
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2.5 Measuring the index of microvascular resistance and coronary flow reserve 
with pressure-temperature thermistor pressure wire 
The index of microvascular resistance (IMR) and coronary flow reserve (CFR) were 
measured in 7 patients with NSTEMI and 7 patients with stable angina using a 
commercially available 0.014 inch floppy pressure wire (pressure wire 3, Radi 
Medical system) by using the thermodilution technique. The pressure wire has a 
microsensor at a location 3 cm from the floppy tip, which measures simultaneously 
pressure and temperature at the location of the sensor with an accuracy of 0.20 C. The 
shaft of the wire can be used as an additional thermistor, providing the input signal at 
the coronary ostium of any fluid injection with a temperature difference from blood. 
All signals can be displayed on the regular catheter laboratory recording system or at 
a suitable interface (Radi analyzer). In this manner the mean transit time of the 
injected saline down the coronary artery can be calculated from a coronary 
thermodilution curve. Thermodilution curves in the coronary artery are obtained by 
short manual injections of 3 ml 0.9% saline at room temperature. Measurements of 
transit time are calculated 3 times at base line and 3 times at maximum hyperaemia, 
provided that the time for analysis of the thermodilution equals at least one cardiac 
cycle and variability between the values of  the 3 transit times was <20%. The mean 
transit time at baseline and maximum hyperaemia are calculated. Maximum 
hyperaemia is achieved by adenosine infusion through the femoral vein at a rate 140 
microgram/kg/minute. Distal coronary pressure (Pd) is recorded from the pressure 
wire. Mean aortic pressure (Pa) is measured from the coronary catheter and central 
venous pressure (Pv) is measured from the right heart catheter at maximum 
hyperaemia. Coronary wedge pressure (Pw) is also measured at maximum 
hyperaemia by inflating a semi-compliant balloon (1mm smaller that the vessel 
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diameter) in the coronary artery and the IMR is calculated. In absence of epicardial 
stenosis, collaterals and assuming Pv is close to zero, IMR is calculated as 
hyperaemic distal coronary pressure divided by inverse of hyperaemic mean transit 
time (Tm) (a correlate to absolute flow). This can be represented in a simplified 
manner as a product of distal coronary pressure and mean hyperaemic transit time 
(Pd × Tm). Fearon et al demonstrated there was significant correlation between mean 
IMR (distal coronary pressure/Inverse of mean hyperaemic transit time) and true 
microcirculatory resistance (TMR calculated as a ratio of distal coronary artery 
pressure and hyperaemic flow measured with external ultrasonic Doppler) in 
experimental animals (243). Coronary collaterals, in the presence of a coronary 
epicardial stenosis, might lessen the drop in distal coronary pressure without a 
change in coronary blood flow and also may increase the coronary Pw. The 
combination of the above in turn can lead to an increase in the measured coronary 
microvascular resistance (243). Therefore, in presence of a coronary stenosis with 
collaterals, myocardial flow is not equal to coronary flow but exceeds the coronary 
flow because of collateral flow. Tm is no longer representative of myocardial flow 
and the contribution of collaterals needs to be considered and the IMR= Pa × Tm × 
[(Pd-Pw) ÷ (Pa-Pw)] (assuming Pv=0). This could be again represented by IMR=Pa 
× Tm × FFR cor. In the presence of abnormal Pv the equation should be represented 
as IMR= (Pa-Pv) × Tm × [(Pd-Pw) ÷ (Pa-Pw)] (Pa=Aortic pressure, Pv =Right atrial 
pressure, Pw=coronary artery wedge pressure, Pd=distal coronary pressure, all the 
above measurements during maximum hyperaemia). Clearly the presence of 
functional collaterals will increase Pw, but there is an argument that Pw below 25 
mmHg implies the presence of hemodynamically insignificant collaterals. The cut off 
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of 25mmHg is in line with previous clinical studies found that collateral flow is 
essentially absent when Pw is lower than 25 mmHg (213;244-247). 
 
2.6 Recruitment limitations and practical considerations 
There are several recruitment limitations with this project including the difference in 
the number of patients recruited between the three study groups. As mentioned above 
25 SA patients were consented however only 11 were studied (the reasons have been 
discussed above). Also only 14 out of the 25 ACS patients (NSTEMI and SA) were 
studied with IMR. The reason being is the fact that the procedure (blood sampling 
the sites, completing the PCI and then measuring the IMR and CFR) was long, 
becoming uncomfortable for the patient. In addition there were occasions where I 
had to stop/interrupt the procedure as a patient with STEMI was admitted and needed 
to be treated with pPCI. Also the differences in the timing of the blood sampling 
between the three study groups should be noted as potentially could have affected the 
MP results (i.e. sampling of the coronary artery in the stable angina and NSTEMI 
patients after the aorta and the right atrium as opposed to the STEMI patients where 
the coronary artery was sampled before the aorta and the right atrium). 
Lastly, power calculations were not done as the initial intentions of this study were 
exploratory. Cell derived MP in patients with clinically manifested IHD has not been 
studied in so much details i.e all cell derived MP, different clinical setting (ACS vs 
stable angina) and several sites (coronary artery, aorta and right atrium). 
 
 105 
Chapter 3: Phenotypic characterisation of local and 
systemic microparticle expression in patients with acute 
coronary syndrome and stable coronary artery disease 
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3.1 Summary 
Introduction and aims 
Inflammation plays a pivotal role in the pathogenesis of atherosclerotic disease. 
Increasing evidence indicates that microparticles (MP) are potent pro-coagulant 
molecules contributing to endothelial dysfunction and modulating inflammatory 
processes. The aim of this study was to investigate the intracoronary and systemic 
microparticle expression in patients presenting with symptomatic coronary heart 
disease (CHD). 
Methods 
Forty eight patients with CHD (23 patients with ST segment elevation myocardial 
infarction (STEMI), 14 with non-ST segment elevation myocardial infarction 
(NSTEMI), and 11 with stable angina (SA) treated with percutaneous coronary 
intervention (PCI) were recruited. Blood samples were aspirated sequentially from 
the right atrium (RA) and the coronary (CO) artery (distal to the culprit lesion). 
AnnexinV+ MP (AnV+ MP) from platelet poor plasma was measured using 
fluorescent monoclonal antibodies and flow cytometry.   
Results 
AnV+ MPs in the CO and RA were expressed as medians per ml of plasma with 
interquartile range. The absolute number of the total AnV+ MP in the STEMI group 
in the CO and RA were 5.3 (3.0-12) and 1.7 (0.6-5.7) (p=0.01) respectively. In the 
NSTEMI group the total AnV+ MP in the CO and RA were 2.8 (1.9-4.5) and 0.3 
(0.1-1.2) (p=0.004) respectively. In the SA group the total AnV+ MP in the CO and 
RA were 2.51 (0.9-2.7) and 1.1 (0.1-1.5) (p=0.03) respectively. Platelet derived MP 
(PMP), endothelial derived MP (EMP) and neutrophil derived MP (NMP) were also 
higher in the CO vs the RA site in the three groups. Total AnV+ MPs, both in the CO 
 107 
and RA, were higher in the STEMI group compared with the NSTEMI and SA. 
Index event to PCI time correlated moderately negatively with PMP and EMP in the 
NSTEMI group.   
Conclusions 
High levels of AnV+ MP occur in the coronary artery of patients with ACS. Levels 
of AnV+MP correlate with severity of the ischaemic lesion since there were higher 
MPs detected in the STEMI versus the NSTEMI and SA groups. Whether these MP 
merely reflect the severity of the ischaemic lesion, and/or are active participants in 
the pathogenesis of ACS now warrants further study. 
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3.2 Introduction and aims 
Atherosclerotic disease is a chronic inflammatory process (123). Over the last twenty 
years, data have emerged showing that immune cells are involved in the pathogenesis 
of formation and evolution of atherosclerotic plaques causing either stable angina 
(SA), or acute coronary syndrome (ACS) (267). Interactions between inflammatory 
and non-inflammatory cells within the atheromatous plaque may lead to cell 
activation and differentiation, a process that has been traditionally known to be 
mediated via interleukins and adhesion molecules (2). Microparticle (MP) release 
may occur both within the atheromatous plaque and/or systemically (81;268). MP are 
submicron membrane vesicles (100-1000nm) derived from virtually any eukaryotic 
cell and platelets during biological processes such as cell activation, differentiation 
and apoptosis (269). Microparticles differ in surface marker phenotype, and their 
biological effects depending upon the parent cell of origin and nature of the stimulus 
which led to their formation (269). Mounting evidence indicates that MP possess 
potent pro-inflammatory and pro-coagulant properties, and may themselves 
contribute to endothelial dysfunction via pro-inflammatory mechanisms (54;55). 
Clinical studies in patients with coronary heart disease CHD or conventional risk 
factors for CHD have shown that circulating MP levels are elevated compared with 
healthy volunteers (56;103;104). Also, previous studies suggest a positive correlation 
between MP levels and clinical outcomes, including: all-cause mortality; 
cardiovascular mortality; major cardiac events; markers of myocardial damage; and 
indices of myocardial dysfunction after an ACS (107-112). Whether elevated MP 
levels play a true contributory role to the pathophysiology of CHD, or represent a 
purely secondary epiphenomenon is still a matter of debate. In addition, there are 
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only limited information about MP expression in the coronary artery locally versus 
systemically in patients with ACS and SA.  
I hypothesised that: 1) AnV+MP levels are higher in the ACS versus stable angina 
patients; 2) AnV+MP expression is higher in the coronary artery versus systemically 
i.e. the main source of the circulating MP is the complicated atheromatous plaque 
and/or associated clot. The aim of my study was therefore to investigate the 
expression of the total AnV+ microparticles (MPs) and their cell-specific phenotype 
in patients presenting with symptomatic CHD, either ACS or stable angina. The 
possibility of a trans-myocardial gradient between coronary and periphery of MP 
release was explored by determining MP levels in the local intracoronary (CO) artery 
distal to the culprit lesion, and in the right atrium (RA) as representative of the 
systemic circulation. Lastly, I also studied the relationship between the index event 
(onset of symptoms/chest pain) to PCI time and MP expression in the NSTEMI 
patients.  
 
3.3 Patients and methods 
3.3.1 Study population 
Forty eight patients with CHD were prospectively recruited from our institution 
(Royal Free Hospital, London, UK) to the study. The CHD patients included 23 
consecutive patients presenting with ST segment elevation myocardial infarction 
(STEMI), 14 patients with non ST segment elevation myocardial infarction 
(NSTEMI), and 11 patients with stable angina (SA). The standard criteria for the 
diagnosis of STEMI were followed according to the European Society of Cardiology 
guidelines i.e. chest pain and ST elevation ≥ 2 mm in ≥2 contiguous chest leads, or 
≥1 mm in ≥2 contiguous limb leads on the ECG (262). All STEMI patients were 
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treated immediately with primary percutaneous coronary intervention (PCI). The 
diagnosis of NSTEMI was based on the history of chest pain with or without 
ischaemic ECG changes (other than ST elevation) and a troponin T value > 0.03 ng/l 
(261). SA patients with symptoms were admitted electively for PCI. SA patients had 
been reviewed in the cardiology outpatient clinic with a diagnosis of angina pectoris 
based on typically ischaemic sounding chest pain and a positive non-invasive test 
such as exercise tolerance test, stress echocardiography or myocardial perfusion 
scan. The decision for diagnostic angiography was made by a cardiologist as part of 
routine clinical care. Informed consent was obtained prior to the procedure from all 
recruited patients outside the cardiac catheterisation laboratory. Ethical permission 
was granted by the local ethics committee of the Royal Free Hospital, and all 
participants provided fully informed written consent. 
 
3.3.2 Exclusion criteria 
The exclusion criteria have been described in Chapter 2 (Paragraph 2.1.4) 
 
3.3.3 Coronary angiography, coronary angioplasty and blood sampling 
Diagnostic coronary angiography and percutaneous coronary intervention (PCI) were 
performed according to contemporary guidelines. A 6F venous sheath was also 
inserted via the right femoral vein. Through the femoral vein a 5F multipurpose 
catheter (5F, Cordis ®, internal diameter 0.11cm) was placed in the right atrium. Left 
and right coronary artery angiography was performed with a 5F Judkin’s Left 4 
diagnostic catheter (Cordis ®, internal diameter 0.11 cm) and 5F Judkin’s Right 4 
diagnostic catheter (5F, Cordis ®, internal diameter 0.11 cm) respectively. Blood 
samples (10 ml from each site) were aspirated through the diagnostic 5F catheter 
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from the right atrium. Following the diagnostic angiography the culprit lesion was 
identified and weight adjusted unfractionated heparin was given prior to the PCI to 
achieve an activated clotting time (ACT) between 200 and 250 seconds. After 
identification and wiring of the culprit lesion an aspiration catheter (Medtronic ® 
Export catheter, internal diameter 0.10 cm) was advanced distal to the culprit lesion 
and 10 mls blood sample was aspirated through the aspiration catheter with a 
syringe. Blood samples from the different sites were aspirated carefully through 
catheters of similar internal diameter in order to maintain similar shear stress during 
aspiration and minimise shear stress related to platelet activation. In NSTEMI and 
stable angina patients if the advance of the aspiration catheter was difficult initially 
due to technical reasons, pre-dilation of the lesion with a semi compliant balloon was 
performed prior to the sampling of the coronary artery. All the samples were 
collected before the administration of GP IIb/IIIa antagonists. Angioplasty was 
performed according to standard procedures following collection of samples. Blood 
samples from the healthy volunteers were collected from the antecubital vein using a 
19G needle. 
STEMI patients were given 300 mg of Aspirin by the ambulance paramedics and 
received 600 mg of Clopidogrel on arrival outside the catheterisation laboratory. 
Intravenous morphine was administered to alleviate symptoms of chest pain as 
necessary. NSTEMI patients were treated with 300 mg of Aspirin and 600 mg of 
Clopidogrel and weight adjusted low molecular weight heparin (enoxaparin 1mg/kg 
twice daily). SA patients were treated with anti-angina medications; aspirin 75mg od 
and clopidogrel 75mg od for 7 days prior to the angioplasty as per hospital protocol. 
The index event to PCI interval was expressed in minutes. 
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The differences in timing of blood sampling of the three sites between the three 
groups have been described in chapter 2 (section 2.1)  
3.3.4 MP identification and characterization using flow cytometry 
MPs were identified by flow cytometry as previously described. Blood was collected 
in 3.2% buffered citrate and centrifuged at 5,000 g for 5 minutes twice to obtain 
platelet-poor plasma (PPP). MPs were sedimented from 200μL of PPP after 
centrifugation at 17,000 g for 60 minutes and resuspended in An V binding buffer 
(BD PharMingen, Oxford, UK) prior to incubating with fluorescent monoclonal 
antibodies: fluorescein isothiocyanate (FITC) or Phycoerythrin (PE) labeled annexin 
V (BD PharMingen), mouse PE-labeled antihuman CD62E (clone 68-5H11, BD 
PharMingen), mouse PE-labeled antihuman CD31 (clone L133.1, BD PharMingen), 
mouse IgG1 anti-human CD66b-PE (clone G10F5, eBioscience), mouse Cy5-labeled 
antihuman CD14 (clone 61D3,AbD Serotec), mouse FITC-labeled antihuman TF 
(clone VD8, American Diagnostica), and mouse PE-labeled antihuman P-selectin 
glycoprotein ligand 1, PSGL-1 (clone KPL1, BD PharMingen). Additional labelling 
with mouse antihuman CD42a-PERCP (BD PharMingen) to exclude platelet origin 
was conducted. Using this methodology we defined the following types of 
microparticles thus: total AnV+ MP, platelet derived MP (PMP; AnV+CD42a+), 
endothelial derived MP (EMP; dual positive for AnV+ and CD62E or CD105; or 
AnV+CD42a-CD31+), neutrophil derived MP (NMP; AnV+CD42a-CD66b+) and 
tissue factor positive monocyte derived MP (MMP; AnV+CD14+TF+). Samples 
were analysed with a FACS Calibur flow cytometer (BD PharMingen).  The flow 
cytometric gating strategy is summarised in figure 2.3 (chapter 2). 
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3.3.5 Statistical analyses 
Continuous variables were expressed expressed as medians with interquartile range 
(IQR) Categorical variables were expressed as percentages with 95% confidence 
intervals (95% CIs). Comparisons of continuous variables between the three groups 
were performed using Kruskal-Wallis test followed by Mann-Whitney U test for 
intergroup analyses. Comparisons between the two compartments (CO and RA) were 
performed using the Mann-Whitney U test. Chi-square test was used for comparing 
proportions between the three groups. Spearman rank correlation factor r was used 
for correlations. Differences with a 2-sided p value <0.05 were considered to be 
statistically significant. All statistical analyses were performed with GraphPad Prism 
5 statistical software. 
 
3.4 Results 
The demographics and baseline characteristics of the study population are shown in 
table 3.1. Briefly, the majority of the study population was male (79%) median age 
(IQR). The SA patients were more likely to have medical history of hypertension 
compared to the STEMI and NSTEMI groups (p=0.01). Also the NSTEMI patients 
were more likely to have family history of CHD (p=0.04). 
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  STEMI 
(n=23) 
NSTEMI 
(n=14) 
Stable Angina 
(n=11) 
p value 
Age (median), years 60 60.5 58 0.7 
Male 17 12 9 0.7 
Female 6 2 2 0.7 
Risk Factors         
Hypertension 11 3 9 0.01 
Diabetes 6 3 2 0.8 
Dyslipidaemia 10 9 4 0.3 
Smoking 9 4 2 0.4 
Family History of CHD 7 10 4 0.04 
Angiographic characteristics       0.7 
1 vessel disease 17 8 6   
2 vessel disease 4 3 3   
3 vessel disease 2 3 2   
Culprit vessel       0.3 
Left Anterior Descending 9 5 6   
Left Circumflex 3 4 0   
Right Coronary Artery 11 5 5   
Onset of symptoms to PCI 
interval, Median (mins) 
258.5 4320 N/A <0.0001 
 
Table 3.1 Baseline characteristics, demographics and angiographic data of the study 
groups. Chi-square test was used for comparison of proportions between the three 
groups and Kruskal-Wallis test for continue variables. P values < 0.05 were 
considered significant. Coronary Heart Disease (CHD). 
 
3.4.1 AnV+ MP expression in the coronary artery in the STEMI, NSTEMI and 
SA patients 
Table 3.2 summarises the CO MP levels between the three patient groups. Total 
AnV+ MP in the CO were higher in the STEMI population compared with NSTEMI 
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(p=0.02). AnV+CD42a+ PMP and AnV+CD42a+CD62P+ PMP were also higher in 
the STEMI group compared with the NSTEMI (p=0.04 and p=0.003 respectively), 
and SA (p=0.04 and p=0.0008 respectively) groups; Fig 3.1a. Also all types of AnV+ 
EMPs were higher in the STEMI patients compared with the NSTEMI and the SA 
patients, Fig 3.1b. NMP and TF+ MMP were also higher in the STEMI population 
compared with the NSTEMI and SA groups, Fig 3.1c. 
 
 CO  
 STEMI NSTEMI SA 
Kruskal-Wallis 
test 
 Median (IQR) Median (IQR) Median (IQR) p value 
Total AnV+ MP 5.35 (3.00-12.0) 2.85 (1.96-4.50) 2.51 (0.91-5.75) 0.04 
CD42a+AnV+ PMP 2.20 (0.72-4.81) 1.05 (0.51-1.71) 0.71 (0.20-1.28) 0.04 
CD62P+CD42a+AnV+ PMP 0.95 (0.28-2.45) 0.18 (0.11-0.42) 0.08 (0.02-0.15) 0.0003 
CD62E+CD42a-AnV+ EMP 0.69 (0.18-1.70) 0.33 (0.11-0.67) 0.17 (0.07-0.67) 0.02 
CD66b+CD42a-AnV+ NMP 0.17 (0.08-0.44) 0.11 (0.04-0.21) 0.04 (0.03-0.20) 0.01 
CD54+CD42a-AnV+ EMP 0.64 (0.28-0.88) 0.20 (0.11-0.34) 0.11 (0.05-0.18) 0.0008 
CD105+CD42a-AnV+ EMP 0.76 (0.37-1.91) 0.45 (0.11-0.78) 0.38 (0.07-0.77) 0.02 
CD31+CD42a-AnV+ EMP 0.75 (0.35-1.40) 0.32 (0.09-0.47) 0.24 (0.10-0.33) 0.0005 
CD14+TF+AnV+ MMP 0.15 (0.07-0.31) 0.18 (0.07-0.25) 0.07 (0.03-0.15) 0.04 
 
Table 3.2 Differences of microparticles expression (*106 /ml of plasma) in the three 
groups in the coronary artery (CO). MP levels expressed as medians with 
interquartile range (IQR). Statistical analysis performed using Kruskal-Wallis test. 
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Figure 3.1 Differences of the total AnV+MP and MP subpopulations in the coronary 
artery (CO) between the three groups of patients. ST elevation myocardial infarction 
(STEMI), non ST elevation myocardial infarction (NSTEMI), stable angina (SA). 
 
3.4.2 AnV+MP expression in the right atrium in the STEMI, NSTEMI and SA 
patients 
Table 3.3 summarises the RA MP levels between the three patient groups. Total 
AnV+ MP in the RA were higher in the STEMI population compared with NSTEMI 
(p=0.02). AnV+CD42a+ PMP and AnV+CD42a+CD62P+ PMP were also higher in 
the STEMI group compared with the NSTEMI (p=0.02 and p=0.01 respectively) and 
SA (p=0.03 and p=0.001 respectively) groups; Fig 3.2a. Also all subtypes of AnV+ 
EMPs were higher in the STEMI patients compared with the NSTEMI and the SA 
patients; Fig 3.2b. NMP were also higher in the STEMI population compared with 
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the NSTEMI and SA groups, Fig 3.2c. TF+ MMP were higher in the STEMI group 
vs the SA but not vs the NSTEMI patients, Fig 3.2 
 
  
  
RA 
    
  STEMI NSTEMI SA 
Kruskal-
Wallis test 
  Median (IQR) Median (IQR) Median (IQR) p value 
Total AnV+ MP 1.72 (0.64-5.78) 0.29 (0.11-1.2) 1.11 (0.14-1.49) 0.058 
CD42a+AnV+ PMP 0.84 (0.26-3.97) 0.11 (0.03-0.54) 0.28 (0.02-0.60) 0.025 
CD62P+CD42a+AnV+ PMP 0.17 (0.07-0.66) 0.03 (0.005-0.14) 0.03 (0.001-0.04) 0.001 
CD62E+CD42a-AnV+ EMP 0.23 (0.06-0.44) 0.02 (0.01-0.12) 0.04 (0.009-0.07)  0.009 
CD66b+CD42a-AnV+ NMP 0.08 (0.04-0.14) 0.01 (0.004-0.09) 0.01 (0.002-0.02) 0.002 
CD54+CD42a-AnV+ EMP 0.07 (0.05-0.16) 0.04 (0.008-0.10) 
0.009 (0.004-
0.04) 0.007 
CD105+CD42a-AnV+ EMP 0.16 (0.06-0.43) 0.04 (0.01-0.09) 0.07 (0.008-0.18) 0.02 
CD31+CD42a-AnV+ EMP 0.11 (0.04-0.31) 0.04 (0.01-0.20) 0.05 (0.003-0.09) 0.1 
CD14+TF+AnV+ MMP 0.09 (0.02-0.41) 0.05 (0.01-0.13) 0.03 (0.005-0.05) 0.04 
Table 3.3 Differences of microparticles expression (106 /ml of plasma) in the three 
groups in the right atrium (RA). MP levels expressed as medians with interquartile 
range (IQR). Statistical analysis performed using Kruskal-Wallis test 
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Figure 3.2 Differences of the total AnV+MP and MP subpopulations in the right 
atrium (RA) between the three groups of patients. (ST elevation myocardial 
infarction (STEMI), non ST elevation myocardial infarction (NSTEMI), stable 
angina (SA) 
 
3.4.3 AnV+ MP expression in the coronary and right atrium in the three groups 
In the STEMI group the absolute number of the Total AnV+ MP in the CO was 
5.35x106/ml (41% PMP, 13% EMP, 3% NMP, 3% TF+ MMP and 40% other AnV+ 
MP). In the RA site the number of AnV+ MP was 1.72x106/ml (49% PMP, 8% EMP, 
5% NMP, 5% TF+ MMP and 33% other AnV+ MP). In the CO site 43% of the PMP 
were CD62+ PMP vs 20% in the RA site (p=0.0007).  
In the NSTEMI group the absolute number of the Total AnV+ MP in the CO was 
2.85*106/ml (27% PMP, 8% EMP, 3% NMP, 5% TF+ MMP and 57% other AnV+ 
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MP). In the RA the number of AnV+ MP was 0.29*106/ml (38% PMP, 10% EMP, 
4% NMP, 17% TF+ MMP and 31% other AnV+ MP). In the CO 17% of the PMP 
were CD62+ PMP vs 27% in the RA (p=0.1).  
In the SA group absolute number of the Total AnV+ MP in the CO was 2.51*106/ml 
(28% PMP, 9% EMP, 2% NMP, 3% TF+ MMP and 58% other AnV+ MP). In the 
RA site the number of AnV+ MP was 1.1*106/ml (25% PMP, 4% EMP, 1% NMP, 
3% TF+ MMP and 67% other AnV+ MP). In the CO site 11% of the PMP were 
CD62+ PMP vs 10% in the RA site (p=ns). 
Total AnV+ MP, CD42a+CD62P+ PMP, all EMP subpopulations and AnV+CD42a-
CD66b+ NMP were higher in the CO compared to the RA for all patient groups 
(table 3.4). AnV+CD42a+PMP and TF+MMP were higher in the CO site compared 
to RA in the NSTEMI group only (table 3.4). 
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3.4.4 MP expression and index event to PCI time 
The median (IQR) of the index event to PCI time (defined as time from onset of 
symptoms to PCI, expressed in minutes) in the STEMI and NSTEMI groups were 
285 (116-360) and 4320 (2100-6060) respectively (p<0.0001). In the CO of the 
NSTEMI group there was a moderately negative correlation between the the index 
event to PCI time and the expression of total and cell specific AnV+MP Fig 3.3. 
 
Fig 3.3a. Onset of symptoms to PCI time (mins)
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Figure 3.3 Negative correlations between the index event to PCI time and AnV+MPs 
in the coronary artery in the non ST segment elevation myocardial infarction group 
suggesting a time dependant mode of MP expression during acute coronary 
syndrome. 
 
3.5 Discussion 
The main novel findings of this study are 1. the demonstration of differences 
between MP levels in patients with varying severity of CHD: MP levels were overall 
highest in those with STEMI as compared with NSTEMI and SA; and 2. Differences 
in local and systemic AnV+MP expression in human coronary artery disease. It is 
highly likely that the source of these MP was the culprit lesion since total AnV+MP 
and AnV+MP subpopulations were higher in the coronary artery (CO blood sampled 
distal to the culprit lesion) compared with the systemic (RA) circulation in the three 
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study groups. There was also a differential expression of the MP subpopulations in 
the three patient groups between the CO and RA (table 3.4). Overall these 
observations confirm that MP release occurs from culprit atheromatous lesions in 
ACS, and that total AnV+MP number and subpopulation phenotype could relate to 
clinical severity of ACS. Whilst, the concept that these MP directly contribute to the 
pathogenesis of ACS cannot be inferred from this study, these findings could have 
important implications in this context since AnV+MP are known to be both pro-
inflammatory and pro-thrombotic (77;78). 
In line with previous studies PMP levels were higher compared with the other cell 
specific MP subpopulations. The above trend was more prominent with respect to the 
CD62P+PMP in the STEMI patients, especially sampled from the coronary artery. 
This observation can be explained by the fact that the hallmark of ACS is disruption 
(rupture, fissure or erosion) of the atheromatous plaque in a coronary tree, with 
subsequent platelet activation (upregulation of P selectin) and thrombus formation 
(81). The observation of high levels of AnV+CD62P+PMP in the CO raises the 
possibility that these could amplify vascular inflammation and thus contribute to 
lesion progression by further recruitment of inflammatory cells expressing P-selectin 
glycoprotein ligand (PSGL), which binds CD62P (P-selectin) (29;30).  Since high 
CO AnV+CD62E+ EMP were also detected, almost certainly derived from activated 
coronary endothelium, it is likely that E-selectin-PSGL binding could further mediate 
the interaction between inflammatory cells and activated endothelial cells and 
contribute to lesion progression (270). In addition, the high CO NMP we observed 
could further amplify vascular inflammation since NMP can bind activated 
endothelium and contribute to further endothelial activation (271). 
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As well as amplifying inflammation, MP are also prothrombotic (76). The finding of 
high CO TF+MMP could implicate their role in clot propagation, since higher levels 
were observed in STEMI and NSTEMI patients than those with SA. Expressed TF 
on activated monocytes results in the release of TF+MMP, which promote the 
clotting cascade (77). Furthermore, irrespective of TF, AnV+MP are themselves 
prothrombotic (272) and were significantly elevated in the CO of STEMI patients. 
Thus MP, either total AnV+, and/or TF+ subpopulations could contribute to clot 
progression in ACS. 
Min et al have recently demonstrated locally increased MPs in coronary arteries of 
patients with STEMI compared to controls. The data from this study now also 
strongly suggests that MP release in other symptomatic patients with CHD (NSTEMI 
and stable angina) is mainly locally driven, since CO MP levels at the site of the 
complicated plaque were higher than systemic (RA) MP levels (110;273). This 
observation does not, however, preclude the possibility that MP release also takes 
place in the systemic circulation since atheromatous vascular disease is usually 
widespread. That said, these findings support the hypothesis that the complicated 
atheromatous plaque is the predominant source of the circulating microparticles, and 
that a topographic pattern of microparticle expression appears to exist depending on 
where you sample the microparticles i.e. the closer to the culprit lesion, the higher 
the level of microparticles. 
A time dependant mode of microparticle expression appears to exist from this study. 
There was a negative correlation between the index event to PCI time and total MP, 
PMP, EMP AnV+MP release in the CO in the NSTEMI group. This suggests that, in 
line with previous studies (112;117), there is a peak in MP release during the first 24-
48 hours and thereafter MP levels fall. Arguably, earlier sampling (on admission) of 
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the NSTEMI patients would have yielded an expression of MP levels similar to that 
of the STEMI patients. Antiplatelet and anti-coagulation therapy could have in 
addition influenced MP production. 
This study has a number of limitations. Firstly, the study sample was relatively small 
making the statistical analysis and interpretation of correlations less reliable in 
addition to statistical error. Also the presence of selection bias cannot be excluded. 
Secondly, it is difficult to obtain blood samples exclusively from the coronary artery 
with aspiration catheters therefore contamination with blood from non-affected 
coronaries or the systemic circulation cannot be excluded. The effects of antiplatelet 
and anticoagulant therapy on MP production, even though standardised for all patient 
groups, was not fully analysed and needs further study. In addition sampling of the 
infarct related artery proximally to the culprit lesion or sampling of a bystander 
coronary artery could have strengthened my hypothesis that the complicated 
atheromatous coronary plaque is the predominant source of microparticle release. 
 
3.6 Conclusions 
This study demonstrates higher MP levels in patients with STEMI versus those with 
NSTEMI or SA. In addition, higher MP levels were observed in the CO versus RA in 
all three patient groups, strongly suggesting that the source of these MP is the culprit 
atheromatous lesion. We cannot yet conclude that these MP have a direct pathogenic 
role; however, data from other studies have demonstrated important pro-
inflammatory and prothrombotic effects of MP. This leads us to speculate that AnV+ 
microparticle levels may be indicative of coronary artery plaque instability, and 
could directly contribute to this pathological process. 
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Chapter 4 Microparticle expression in patients undergoing 
percutaneous coronary intervention for acute coronary 
syndrome and stable coronary heart disease: correlation 
with intracoronary inflammation and myocardial necrosis 
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4.4 Results 
 
4.5 Discussion 
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4.1 Summary 
Introduction and aims 
Inflammation plays a crucial role in the pathophysiology of acute coronary syndrome 
(ACS). Mounting evidence indicates that microparticles (MPs) released from 
activated cells are potent pro-coagulant molecules contributing to endothelial 
dysfunction and modulating inflammatory processes. The aim of this study was to 
investigate the relationship between MP expression, markers of inflammation, and 
myocardial necrosis in patients with ACS or stable angina (SA). 
Methods 
Forty eight patients with coronary heart disease (37 with ACS and 11 with SA) 
treated with coronary percutaneous coronary interventions (PCI) were studied. Blood 
samples were aspirated sequentially from the right atrium (RA) and the coronary 
artery (CO) (distal to the culprit lesion) at the time of PCI. AnnexinV+MPs 
(AnV+MPs) from platelet poor plasma were measured using fluorescent monoclonal 
antibodies and flow cytometry. AnV+ MPs in the CO and RA were expressed as 
medians per ml of plasma with interquartile range. Markers of inflammation: hs-
CRP, IL-6, TNF-α, serum amyloid A (SAA) and myocardial injury (Troponin T) 
were measured using ELISA. 
Results 
Total and cell specific AnV+MP expression was higher in the ACS versus the SA 
group in both the CO and RA. CO AnV+MP levels were higher than the RA in both 
groups. In the ACS group all inflammatory markers except IL-6 were higher in the 
RA vs CO. There were no differences in the inflammatory markers between patients 
with ACS or SA (either in the RA or the CO). In the CO and RA of the ACS group, 
but not the SA group, markers of inflammation correlated positively with AnV+MP. 
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In the CO, SAA correlated with total AnV+MP (r=0.5; p=0.01), platelet MP (r=0.5; 
p=0.02) and endothelial MP (EMP) (r=0.6; p=0.005). IL-6 also correlated positively 
with total AnV+ MP (r=0.6; p=0.004), AnV+EMP (r=0.4, p=0.04) and neutrophil 
derived AnV+MP (r=0.5; p=0.008). In the RA of the ACS group IL-6 correlated with 
AnV+EMP (r=0.5; p=0.03) and tissue factor positive AnV+MP (r=0.6, p=0.01). 
Troponin T levels correlated positively with platelet MP in both CO and RA of the 
ACS group (r=0.4 for both; p=0.04 and p=0.03 for CO and RA respectively). 
Conclusions 
During ACS inflammatory markers correlated positively with local CO AnV+MP 
levels and also to a lesser extent with peripheral circulating AnV+MP. This may 
suggest a pathogenic role for MPs as effectors of the inflammatory response and 
cellular injury in ACS. 
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4.2 Introduction and aims 
Inflammation plays a pivotal role in the pathogenesis of coronary heart disease 
(CHD) and acute coronary syndrome (ACS) (123). Inflammation controls not only 
the evolution of atheromatous plaque but also its propensity for rupture or erosion, 
by altering the matrix composition (2). In addition, inflammation, through the 
activation and differentiation of the inflammatory cells involved, increases the 
thrombogenicity of the plaque’s interior by promoting tissue factor bearing 
microparticle (MP) release with subsequent thrombus formation of the 
ruptured/eroded plaque (55;62). Patients with diseases associated with chronic 
inflammation such as diabetes mellitus and metabolic syndrome, or chronic 
inflammatory autoimmune diseases (such as psoriatic or rheumatoid arthritis) are at 
high risk of developing CHD (274). Inflammatory activity has been assessed mainly 
by measuring the levels of inflammatory markers like C-reactive protein (CRP), 
serum amyloid antigen (SAA) or pro-inflammatory cytokines such as TNF-α (tumour 
necrosis factor α)  and IL-6 (Interleukin-6). It has also been shown that increased 
levels of inflammatory markers are associated with adverse outcomes in patients with 
ACS (171;204;275;276). Whether the increased levels of these inflammatory 
markers have any causal relationship with the pathogenesis of ACS (277) is not 
clear. For instance, elevated CRP levels do not correlate with the extent and burden 
of CHD (171;172). Furthermore, whether the inflammatory markers originate solely 
from the site of plaque rupture, or represent a systemic response is still a matter of 
debate. It has been shown that IL-6 is increased locally in the coronary artery 
compared with the systemic arterial circulation in patients with ACS (278;279). 
Therefore assessment of inflammatory markers in the peripheral circulation may not 
truly reflect the burden of the intracoronary inflammatory process. Even though it is 
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believed that inflammation is a systemic effect of ACS and inflammatory markers 
are mostly synthesised in the liver, the above evidence supports the concept of an 
intracoronary production of inflammatory markers, and local paracrine inflammatory 
effects close to the culprit lesion.  
Mounting evidence indicates that microparticles (MP) released from activated cells 
and platelets are potent pro-coagulant and pro-inflammatory molecules that may 
contribute to thrombus formation (55), as well as directly causing endothelial 
activation and dysfunction (54). Locally produced MPs may therefore participate in 
the local coronary inflammatory processes involved in ACS (68;268;280), although 
the exact mechanisms are currently poorly understood. Several clinical studies have 
shown a correlation between circulating MP levels and all-cause mortality, 
cardiovascular mortality, markers of myocardial damage, and indices of myocardial 
dysfunction (108;110-112). Previous reports have also suggested a link between 
circulating pro-inflammatory cytokines and MPs in health and disease. For instance, 
plasma IL-6 correlated with plasma level of platelet MP in healthy volunteers (118). 
Furthermore, endothelial and platelet derived MPs correlated with circulating hs-
CRP levels in patients with ACS undergoing percutaneous coronary intervention 
(PCI) (112). Similarly, we have previously demonstrated that tissue factor positive 
MPs in patients with ST elevation myocardial infarction (STEMI) correlate strongly 
with circulating IL-6 levels (manuscript in preparation).  
I hypothesized that: 1. Local inflammatory processes in the coronary including MP 
production are important in the pathogenesis of ACS and 2. Local levels of 
inflammatory mediators including MP correlate with extent of myocardial necrosis. 
The aim of this study was therefore to explore the relationship between local 
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coronary and systemic MP levels, circulating markers of inflammation, and extent of 
myocardial necrosis in patients with ACS or stable angina undergoing PCI. 
 
4.3 Patients and methods 
4.3.1 Study population 
Thirty seven patients with ACS (23 patients with STEMI, 14 with NSTEMI) and 11 
patients with stable angina (SA) treated with percutaneous coronary intervention 
(PCI) were recruited for the study. The diagnosis of ACS was based on the history of 
chest pain with or without ischemic ECG changes and a troponin T value > 0.03 ng/l 
(261). Patients with STEMI underwent primary PCI and patients with NSTEMI had 
PCI 3-5 days after the hospital admission. SA patients had been reviewed in the 
cardiology outpatient clinic with a diagnosis of angina pectoris based on typically 
sounding chest pain and a positive non-invasive test such as exercise tolerance test, 
stress echocardiography or myocardial perfusion scan. SA patients admitted 
electively for PCI. The decision for diagnostic angiography was made by a 
cardiologist as part of routine clinical care. Informed consent was obtained prior to 
the procedure from all recruited patients outside the cardiac catheterisation 
laboratory. Ethical permission was granted by the local ethics committee of the 
Royal Free Hospital, and all participants provided fully informed written consent. 
 
4.3.2 Exclusion criteria 
The exclusion criteria have been described in Chapter 2 (Paragraph 2.1.4) 
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4.3.3 Coronary angiography, PCI and blood sampling 
The methodology of coronary angiography and angioplasty has been described in 
chapters 2 (section 2.1) and 3 (section 3.3). 
  
4.3.4 Preparation of platelet poor plasma (PPP) MP Cytometric identification 
and ELISA 
3.5 mls of whole blood was collected into bottles containing 3.2% trisodium citrate 
(Becton Dickinson). Platelet poor plasma was obtained by immediate centrifugation 
of the whole blood at 5000G for 5 minutes twice. PPP was then stored at –80o 
Celcius for later analyses of microparticle estimation and enzyme-linked 
immunosorbent assay (ELISA) studies (see below). 
 
4.3.5 MP identification and characterization using flow cytometry 
The methodology of MP identification and characterization has been described above 
in chapters 2 (paragraph 2.3) and 3 (paragraph 3.3). 
 
4.3.6 Estimation of TNF-α, IL-6, hs-CRP and SAA  
TNF-α and IL-6 levels were measured using a quantitive sandwich enzyme 
immunoassay technique using a kit from R&D  systems  (Europe). CRP was 
measured in plasma using a high sensitivity automated microparticle enhanced latex 
turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics GmbH). SAA was 
measured in plasma by latex nephelometry (BNII autoanalyser; Dade Behring, 
Marburg, Germany). 
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4.3.7 Statistical analyses 
Continuous variables were expressed as medians with interquartile range (IQR). 
Categorical variables were expressed as percentages with 95% confidence intervals 
(95% CIs). Comparisons between the two groups and the two (coronary and right 
atrium) compartments were performed using the Mann-Whitney U test. Fisher exact 
test was used for proportions and Spearman factor r for correlations. Differences with 
a 2-sided p value <0.05 were considered to be statistically significant. All statistical 
analyses were performed with GraphPad Prism 5 statistical software. 
 
4.4 Results 
The demographics and baseline characteristics of the study population are shown in 
the table 4.1. Briefly, the majority of the study population was male (79%). The SA 
patients were more likely to have a medical history of hypertension compared with 
the ACS group (p=0.01). Otherwise there were no significant differences between 
patients with ACS and SA. 
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  ACS SA  p value 
Number of patients (n) 37 11   
Age (mean), years 60 61 0.8 
Male 29 9 0.7 
Female 8 2 0.7 
Risk Factors       
Hypertension 14 9 0.01 
Diabetes 9 2 0.9 
Dyslipidaemia 19 4 0.4 
Smoking 13 2 0.5 
Family History of CHD 17 4 0.7 
Angiographic characteristics     0.7 
1 vessel disease 25 6   
2 vessel disease 7 3   
3 vessel disease 5 2   
Culprit vessel     0.3 
Left Anterior Descending 14 6   
Left Circumflex 7 0   
Right Coronary 16 5   
 
Table 4.1. Baseline characteristics, demographics and angiographic data of the acute 
coronary syndrome (ACS) and stable angina (SA) groups. Fisher exact test was used 
for comparison of proportions between the groups. 
 
4.4.1 High levels of local CO AnV+MP are detected in patients with ACS  
Table 4.2 summarises the CO MP levels between the two patient groups. Total 
AnV+ MP in the CO were higher in the ACS population compared with SA 
(p=0.04). AnV+CD42a+ PMP and AnV+CD42a+CD62P+ PMP were also higher in 
the ACS group compared with the SA group (p=0.03 and p=0.0008 respectively); Fig 
4.1a. Also all types of AnV+ EMPs were higher in the ACS patients compared with 
the SA patients, Fig 4.1b. NMP and TF+ MMP were also higher in the ACS 
population compared with the SA group, Fig 4.1c.  
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Table 4.2. Differences of the total AnV+MP and MP subpopulations (*10⁶/ml of 
plasma) between the acute coronary syndrome (ACS) and stable angina (SA) groups 
in the coronary (CO) and the right atrium (RA). Statistical analysis performed using 
the Mann-Whitney U test. 
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Fig 4.1 Differences of the total AnV+MP and MP subpopulations in the coronary 
artery (CO) between the two groups, acute coronary syndrome (ACS) and stable 
angina (SA). Statistical analysis performed using the Mann-Whitney U test. 
CO RA
ACS SA ACS SA
Median (IQR) Median (IQR) p value Median (IQR) Median (IQR) p value
Total AnV+ MP 5.22 (3.11-8.22) 2.51 (0.91-5.75) 0.04 1.4 (0.67-4.02) 1.11 (0.14-1.49) 0.1
CD42a+AnV+ PMP 1.61 (0.89-3.23) 0.71 (0.20-1.28) 0.03 0.67 (0.24-2.56) 0.28 (0.02-0.60) 0.02
CD62P+CD42a+AnV+ PMP 0.4 (0.2-1.7) 0.08 (0.02-0.15) 0.0008 0.17 (0.06-0.61) 0.03 (0.001-0.04) 0.001
CD62E+CD42a-AnV+ EMP 0.65 (0.225-1.06) 0.17 (0.07-0.67) 0.03 0.12 (0.03-0.42) 0.04 (0.009-0.07) 0.02
CD54+CD42a-AnV+ EMP 0.42 (0.18-0.76) 0.11 (0.05-0.18) 0.001 0.07 (0.02-0.15) 0.009 (0.004-0.04) 0.008
CD105+CD42a-AnV+ EMP 0.76 (0.29-1.01) 0.38 (0.07-0.77) 0.04 0.11 (0.04-0.38) 0.07 (0.008-0.18) 0.1
CD31+CD42a-AnV+ EMP 0.51 (0.31-1.15) 0.24 (0.10-0.33) 0.005 0.08 (0.02-0.26) 0.05 (0.003-0.09) 0.09
CD66b+CD42a-AnV+ NMP 0.14 (0.07-0.39) 0.04 (0.03-0.20) 0.04 0.08 (0.02-0.12) 0.01 (0.002-0.02) 0.004
CD14+TF+AnV+ MMP 0.17 (0.07-0.27) 0.07 (0.03-0.15) 0.02 0.07 (0.02-0.18) 0.03 (0.005-0.05) 0.02
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4.4.2 Platelet, endothelial and leucocyte MP levels are higher in the systemic 
(RA) circulation of patients with ACS compared with SA 
Table 4.2 summarises the RA MP levels between the two patient groups. There was 
no difference in the total AnV+ MP levels in the RA in the ACS group compared 
with the SA group. However, AnV+CD42a+ PMP and AnV+CD42a+CD62P+ PMP 
were higher in the ACS group compared with the SA group (p=0.02 and p=0.001 
respectively); Fig 4.2a. Also AnV+ EMPs (CD62E+ and CD54+ EMP) were higher 
in the ACS patients compared with the SA patients, Fig 4.2b. NMP and TF+ MMP 
were also higher in the ACS population compared with the SA group, Fig 4.2c.  
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Fig 4.2. Differences of the total AnV+MP and MP subpopulations in right atrium 
(RA) between the acute coronary syndrome (ACS) and stable angina (SA) groups. 
Statistical analysis performed using the Mann-Whitney U test 
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4.4.3 High coronary AnV+MP levels and IL-6 are observed in ACS patients  
The absolute numbers of the total AnV+MP and MP subpopulations were higher in 
the CO versus the right atrium in both patient groups (ACS and SA), but particularly 
so for those with ACS as shown in table 4.3.  
 
ACS SA
CO RA CO RA
Median (IQR) Median (IQR) p value Median (IQR) Median (IQR) p value
Total AnV+ MP 5.22 (3.11-8.22) 1.4 (0.67-4.02) 0.0002 2.51 (0.91-5.75) 1.11 (0.14-1.49) 0.03
CD42a+AnV+ PMP 1.61 (0.89-3.23) 0.67 (0.24-2.56) 0.01 0.71 (0.20-1.28) 0.28 (0.02-0.60) 0.06
CD62P+CD42a+AnV+ PMP 0.4 (0.2-1.7) 0.17 (0.06-0.61) 0.006 0.08 (0.02-0.15) 0.03 (0.001-0.04) 0.02
CD62E+CD42a-AnV+ EMP 0.65 (0.225-1.06) 0.12 (0.03-0.42) <0.0001 0.17 (0.07-0.67) 0.04 (0.009-0.07) 0.007
CD54+CD42a-AnV+ EMP 0.42 (0.18-0.76) 0.07 (0.02-0.15) <0.0001 0.11 (0.05-0.18) 0.009 (0.004-0.04) 0.01
CD105+CD42a-AnV+ EMP 0.76 (0.29-1.01) 0.11 (0.04-0.38) <0.0001 0.38 (0.07-0.77) 0.07 (0.008-0.18) 0.02
CD31+CD42a-AnV+ EMP 0.51 (0.31-1.15) 0.08 (0.02-0.26) <0.0001 0.24 (0.10-0.33) 0.05 (0.003-0.09) 0.007
CD66b+CD42a-AnV+ NMP 0.14 (0.07-0.39) 0.08 (0.02-0.12) 0.002 0.04 (0.03-0.20) 0.01 (0.002-0.02) 0.007
CD14+TF+AnV+ MMP 0.17 (0.07-0.27) 0.07 (0.02-0.18) 0.03 0.07 (0.03-0.15) 0.03 (0.005-0.05) 0.2  
Table 4.3. Differences of the total AnV+MP and MP subpopulations (*10⁶/ml of 
plasma) between coronary (CO) and right atrium (RA) in the acute coronary 
syndrome (ACS) and stable angina (SA) groups. Statistical analysis performed using 
the Mann-Whitney U test 
 
Table 4.4 summarizes the differences between the inflammatory markers in the CO 
and RA in the two patient groups. In patients with ACS IL-6 was higher in the CO vs 
the RA (p=0.01); in contrast, SAA, hs-CRP and TNF-α were higher in the RA vs the 
CO (p=0.003, p=0.0005 and p=0.03 respectively). In the SA patients there were no 
differences in any of the inflammatory markers between the CO and RA. 
There were also no differences in the inflammatory marker levels in the CO between 
ACS and SA patients. However, hs-CRP and SAA levels in the RA of the ACS 
group were higher than the SA group (p=0.03 for both hs-CRP and SAA 
respectively).  
TNF-α and IL-6 levels in the RA did not differ between ACS and SA groups. 
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ACS SA
RA CO RA CO
Median (IQR) Median (IQR) p value Median (IQR) Median (IQR) p value
IL-6 (pg/mL) 5.03 (1.53-13.06) 6.3 (3.7-13.6) 0.01 2.29 (1.53-6.26) 2.01 (0.38-16.1) ns
SAA (ml/L) 5.5 (2.6-12.8) 3.3 (1.8-9.5) 0.003 2.5 (1.6-2.8) 2.4 (1.1-2.72) ns
hs-CRP (mg/L) 2.8 (0.9-6.1) 2.1 (0.77-5.82) 0.0005 0.8 (0.7-2.1) 0.8 (0.57-1.55) ns
TNF-α (pg/ml) 18.77 (7.4-33.92) 14.62 (5.9-28.86) 0.03 22.77 (8.61-38.98) 9.16 (6.92-30.83) ns  
Table 4.4 Differences of the inflammatory markers (medians (IQR)) between the 
acute coronary syndrome (ACS) and stable angina (SA) patients in the coronary 
(CO) and right atrium (RA). Statistical analysis performed using the Wilcoxon test. 
IL-6 (interleukin 6), SAA (serum amyloid A), TNF-α (tumour necrosis alpha) and 
hs-CRP (high sensitivity C-reactive protein). 
 
4.4.4 Coronary inflammatory markers correlate with MP levels and troponin T 
in ACS  
In the CO markers of inflammation correlated moderately positively with total 
AnV+MP, PMP, EMP and NMP. SAA correlated with total AnV+MP (r=0.5; 
p=0.01), AnV+CD42a+PMP (r=0.5; p=0.02), AnV+CD42a-CD62E+EMP (r=0.6; 
p=0.005) and AnV+CD105+EMP (r=0.7; p=0.002), Fig 4.3. Similarly, IL-6 levels in 
the CO correlated positively with total AnV+MP, AnV+CD42a-CD62E+EMP and 
AnV+CD66b+NMP. There was also a positive correlation between troponin T and 
CO AnV+CD62P+PMP (r=0.4; p=0.03); Fig 4.3. 
 
 138 
IL-6 (pg/ml)
A
n
V
+
 M
P
 p
e
r 
m
l 
o
f 
p
la
s
m
a
0 50 100 150
0
1.0107
2.0107
3.0107
4.0107
Total AnV+ MP
AnV+CD42a-CD66b+ NMP
r=0.58; p=0.004 for total AnV+ MP
r=0.42; p=0.05 for AnV+CD42a+ PMP
r=0.42; p=0.04 for AnV+CD62E+ EMP
r=0.54; p=0.008 for AnV+CD66b+ NMP
AnV+CD42-CD62E+ EMP
AnV+CD42a+ PMP
Fig 4.3b
SAA (mg/l)
A
n
V
+
 M
P
0 10 20 30 40
0
5.0106
1.0107
1.5107
2.0107
2.5107
r=0.45; p=0.01 for total AnV+ MP
r=0.5; p=0.02 for CD42a+ PMP
r=0.6; p=0.005 for CD62E+ EMP
r=0.64; p=0.002 for CD105+ EMP Total AnV+ MP
AnV+CD42a+ PMP
AnV+CD42-CD62E+ EMP
AnV+CD42a-CD105+ EMP
Fig 4.3a
Troponin T (ng/ml)
A
n
V
+
C
D
4
2
a
+
C
D
6
2
P
+
 P
M
P
0 5 10 15 20
0
5.0106
1.0107
1.5107
r=0.36; p=0.03
Fig 4.3c
 
Fig 4.3 Positive correlation between AnV+MP and markers of inflammation (IL-6 
and SSA) and myocardial injury in the coronary in the acute coronary syndrome 
(ACS) groups. Spearman factor r was used for correlations. 
 
4.4.5 Right atrial IL-6 levels correlate with MP levels and troponin T in ACS 
In the RA of the ACS group there was a moderately positive correlation between IL-
6 and AnV+CD31+EMP (r=0.5; p=0.03) and AnV+TF+MMP (r=0.6; p=0.01). 
Troponin T levels correlated positively with RA AnV+CD62P+PMP (r=0.4; p=0.04), 
(Fig 4.4). 
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Fig 4.4 Positive correlation between AnV+MP and markers of inflammation and 
myocardial injury in the right atrium (RA) in the acute coronary syndrome (ACS) 
groups. Spearman factor r was used for correlations. 
 
In contrast to the above, in the SA patients markers of inflammation and troponin T 
levels did not correlate with total AnV+MP, or cell specific AnV+MP.  
 
4.5 Discussion 
The data from chapter 3 showed that high levels of AnV+MP occur in the coronary 
artery of patients with ACS and that levels of AnV+MP correlate with severity of the 
ischaemic lesion since the highest MPs levels were detected in the STEMI patients. 
Total AnV+MP and MP subpopulations were higher in ACS patients compared with 
SA patients in both the CO and RA. In particular, platelet, endothelial and leucocyte 
MP (NMP and MMP) levels were higher in the systemic (RA) circulation of ACS 
patients with compared with SA patients. CO IL-6 was also higher than RA IL-6 in 
ACS patients. Overall, coronary inflammatory markers correlated with MP levels 
and myocardial injury in ACS (as assessed by troponin T levels); in addition RA IL-
6 levels correlated with MP levels and troponin T in ACS. Taken together, these 
results suggest that patients with more severe ACS have higher levels of local and 
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systemic inflammation, and higher levels of local and systemic circulating MP. 
Whilst these data suggest that these indices correlate with extent of myocardial 
injury, and that it is indeed likely that these are causally linked, I cannot yet infer 
from these data that a causal association is definite.  
 
These data are in agreement with previous reports demonstrating that during ACS, 
circulating platelet and endothelial MPs are elevated (104-106). This study has also 
now demonstrated that the same is true for leukocyte (neutrophil and monocyte) MP, 
since higher levels were observed in ACS compared to SA patients. Furthermore, 
these data demonstrate that although the magnitude of MP expression occurs 
predominantly locally at the site of the culprit atheromatous plaque, there is also a 
significant systemic response with high levels of MP in the RA. The increased MP in 
the systemic circulation are likely to be derived the local culprit CO atheromatous 
lesion, with additional contribution from systemic release secondary to the systemic 
inflammatory response observed in the ACS patients. 
 
In addition to changes in MP levels, the second important finding of this study is the 
differential expression of inflammatory markers in the CO and in the systemic 
circulation during ACS. In line with previous reports (278;279) the data from this 
study has shown that during ACS, local intracoronary IL-6 is increased compared 
with the systemic circulation. This IL-6 is likely to be derived from coronary 
endothelium (281), and/ or from plaque leucocytes. The rest of the inflammatory 
markers hs-CRP, SAA and TNF-α were higher in the peripheral circulation, which is 
unsurprising since CRP and SAA are produced and released from the liver; while 
TNF-α is produced from leukocytes and therefore is likely to have a predominant 
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(although not exclusive) systemic source. In the SA group there were no differences 
of the inflammatory markers between CO and RA. In addition, the higher levels of 
SAA and hs-CRP in the RA which has been observed in the ACS group compared 
with SA group are consistent with an exaggerated systemic inflammatory response in 
ACS patients. 
   
A potentially important finding is the positive correlation between total AnV+ 
microparticles and MP subpopulation with markers of inflammation. Intracoronary 
inflammatory markers correlated with total AnV+ microparticles and MP 
subpopulations (including platelets, endothelial and leukocytes derived MP) whilst in 
the RA markers of inflammation correlated only with endothelial and monocyte 
derived TF+MMP. The fact that in SA the markers of inflammation did not correlate 
with MP formation could suggest a pivotal role of intracoronary inflammation as a 
driver of MP release from the culprit plaque in the pathogenesis of ACS. However, 
these data do not yet allow us to definitively prove a causal association. 
 
The finding of this study, that SAA correlates with PMP and EMP may also provide 
a novel explanation for the previously reported pro-coagulant and pro-inflammatory 
amplification properties of SAA (190). The association between NMP and IL6 could 
be consistent with the previous suggestion that NMP can induce endothelial IL6 
production by inducing endothelial cell activation (271). Furthermore, it has been 
shown that platelet MP deliver arachidonic acid to endothelial cells leading to the up-
regulation of the intercellular adhesion molecule-1 (ICAM-1, or CD54) which 
mediates monocyte-endothelial cell adhesion (87). Ueba et al found that plasma IL-6 
correlated with PMP levels in healthy Japanese volunteers (118). In addition 
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Biasucci et al reported a positive correlation between hs-CRP and microparticles in 
patients with ACS undergoing PCI 24 hours after the admission (112). Matsubara et 
al have shown that the increment of SAA across the coronary circulation correlated 
positively with the severity of coronary atherosclerosis (189). Higher adverse 
outcomes including myocardial infarction, revascularization and death in ACS 
patients with elevated SAA has also been previously reported (204). 
 
Another important finding from this study is the positive correlation between p-
selectin positive AnV+ PMP with marker of myocardial necrosis.  Interestingly in 
both CO and RA, troponin T correlated with P-selectin positive PMP only, 
emphasizing the crucial role of platelet activation in the pathogenesis of ACS and 
myocardial damage during ACS. These observations could therefore suggest the 
pathogenic role of MP as effectors linking inflammatory and prothrombotic 
pathways in ACS. 
 
The study limitations have been described in chapter 3 (paragraph 3.5) with the main 
one being the small number of patients. This can potentially explain the unexpected 
observation that there were no differences of the measured inflammatory markers in 
the coronary artery between ACS and stable angina patients. 
 
Conclusions 
Markers of inflammation in ACS patients, both at the site of the culprit lesion and in 
the systemic circulation, strongly correlated with total AnV+, platelet, endothelial, 
and neutrophil MP. The interaction between activated platelets and monocytes with 
endothelial cells and the subsequent formation of AnV+ MP during ACS would be 
 143 
compatible with a direct pathogenic link between inflammatory and prothrombotic 
pathways in the pathogenesis of ACS and myocardial necrosis. Future studies should 
now address potential MP mediated pathogenic mechanisms in ACS to investigate 
whether these are directly pathogenic, or merely epiphenomena. 
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Chapter 5 Microparticle expression in human coronary 
heart disease: relationship to platelet-monocyte interaction 
and platelet activation 
5.1 Summary 
 
5.2 Introduction and aims 
 
5.3 Patients and methods 
 
5.4 Results 
 
5.5 Discussion 
 
5.6 Conclusions 
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5.1 Summary 
Introduction and aims 
Platelets play a pivotal role in the pathogenesis of acute coronary syndrome (ACS). 
Mounting evidence indicates that microparticles, released from activated cells, are 
potent pro-coagulant and pro-inflammatory molecules. The aim of this study was to 
investigate the relationship between markers of platelet activation and microparticle 
(MP) expression in patients presenting with ACS or stable angina. 
Methods 
Forty eight patients with coronary heart disease (37 with ACS and 11 with stable 
angina (SA) treated with percutaneous coronary intervention (PCI) were recruited for 
the study. Blood samples were obtained sequentially from the right atrium (RA) and 
the coronary artery (CO) (distal to the culprit lesion). AnnexinV+MP (AnV+MP) and 
platelet-monocyte aggregates (PMA) were estimated using flow cytometry. Soluble 
p-selectin (s-P-selectin) was measured using ELISA.  
Results 
Total and cell specific AnV+MP were higher in the ACS versus the SA group in both 
the CO and RA. CO AnV+MP levels were higher than the RA levels in both groups. 
CD62P+PMA were higher in ACS vs the SA group in both CO (p=0.0003) and RA 
(p=0.04). S-P-selectin was also higher in ACS vs SA in the CO (p=0.01). In the CO 
and RA of the ACS group, but not the SA group, markers of platelet activation 
correlated positively with AnV+MP. In the CO s-P-selectin correlated positively 
with total AnV+MP (r=0.61; p=0.001), platelet derived AnV+CD42a+MP (r=0.6; 
p=0.002), endothelial derived AnV+CD62E+MP, (r=0.62; p=0.001) and neutrophil 
derived AnV+CD66b+MP (r=0.54; p=0.006). CD62P+PMA also correlated 
positively with platelet derived AnV+CD42a+MP and endothelial derived 
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AnV+CD62E+MP  (r=0.5; p=0.04 for both). In the RA soluble P-selectin correlated 
positively with total AnV+MP (r=0.81; p=0.001), platelet derived AnV+CD42a+MP 
(r=0.77; p=0.003), endothelial derived AnV+CD62E+MP (r=0.78; p=0.002) and 
tissue factor positive AnV+CD66b+MP (r=0.72; p=0.007). 
Conclusions 
Markers of platelet activation correlated positively with total AnV+MP, platelet, 
endothelial and leukocyte derived MP, both at the site of the culprit lesion and in the 
systemic circulation during ACS. These novel observations suggest a potential 
important interaction between activated platelets, monocytes and endothelial cells via 
MP formation. Future studies are now required to explore how MP could be directly 
involved in the pathogenesis of ACS, since these could be important, novel 
therapeutic targets.  
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5.2 Introduction and aims 
Platelets play a pivotal role in the pathogenesis of ACS, with or without ST 
elevation. Recent data has demonstrated the crucial role of platelets in the pathology 
of atherothrombosis (282;283). Atherosclerotic disease is a chronic inflammatory 
process involving complex interactions between immune (leukocytes) and non-
immune cells (platelets and endothelial cells) (283). Many traditional risk factors for 
coronary heart disease (CHD) such as diabetes mellitus, hypertension and 
hyperlipidaemia are associated with endothelial dysfunction and endothelial cell 
activation (284-288). 
 
Upon activation, endothelial cells secret P-selectin (CD62P) and von-Willebrand 
factor (vWF), both stored in Weibel-Palade bodies, mediating platelet-leukocyte and 
platelet-endothelial cell interactions respectively. In addition E- selectin (CD62E) is 
expressed early in the process of atherosclerosis on the endothelial cell surface. The 
P-selectin-PSGL-1 bond leads to platelet monocyte aggregate (PMA) formation, 
which is a sensitive marker of platelet activation (21). Leukocytes also interact with 
endothelial cells via the P-selectin-PSGL-1 pathway facilitating the inflammatory 
process within the vessel wall (10;18;289). This process of leukocyte rolling on the 
activated endothelial cells activates the leukocyte integrin Mac-1, a process mediated 
by PAF-4 (290). The above enhance the firm leukocyte adhesion to the endothelial 
cells through binding to fibrinogen, a molecule that is also bound to platelets via the 
integrin IIb/IIIa (291). This leukocyte-endothelial cell interaction and adhesion leads 
to further endothelial activation and expression of intracellular and vascular adhesion 
molecules (ICAM (CD54) (87) and VCAM (CD106) respectively (135). P-selectin 
undergoes enzymatic cleavage at the junction between the n-terminal portion and the 
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trans-membrane domain leading to release of the N-terminal domain in the 
circulation which represents the soluble P-selectin (s-P-selectin) (292;293). It has 
been shown that s-P-selectin has the same biological activities as the P-selectin 
attached to the cells (294). During the adhesion to endothelium, platelets become 
activated and, in addition to pro-thrombotic molecules, release a variety of pro-
inflammatory cytokines such as P-selectin, CD40L, RANTES protein (CCL5) and 
platelet factor 4 (PAF-4 or CCL4) (295). 
 
It is obvious from the above that platelets are important modulators of the early and 
late stages of atherosclerosis, ultimately including atherothrombosis, the hallmark of 
ACS (267;296;297). Activated and/ or apoptotic cells (platelets, endothelium and 
leukocytes) release microparticles (MP) with important pro-thrombotic and pro-
inflammatory effects (55;271;298). Consequently, mounting evidence indicates that 
MP may directly contribute to the pathogenesis of ACS by providing an important 
link between pathological thrombogenicity and vascular inflammation (299;300).  
I therefore hypothesized that: 1) markers of platelet activation and MP expression in 
patients with ACS would be higher in the coronary versus the systemic circulation; 
and 2) markers of platelet activation may correlate causally with microparticle levels. 
The aims of this study were therefore to compare coronary artery and systemic 
circulating levels of platelet activation markers, and MPs in patients with 
symptomatic ACS or SA treated with PCI. 
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5.3 Patients and methods 
5.3.1 Study population 
Thirty seven patients with ACS [23 patients with ST segment elevation myocardial 
infarction (STEMI), 14 with non-ST segment elevation myocardial infarction 
(NSTEMI)] and 11 patients with stable angina (SA) treated with percutaneous 
coronary intervention (PCI) recruited for the study. The study population has been 
described in sections 3.3.1 (chapter 3) and 4.3.1 (chapter 4). 
 
5.3.2 Exclusion criteria 
The exclusion criteria have been described in Chapter 2 (Paragraph 2.1.4) 
 
5.3.3 Coronary angiography, PCI and blood sampling 
The coronary angiography and angioplasty procedures have been extensively 
described in chapters 2 (2.1) and 3 (section 3.3).   
 
5.3.4 Preparation of whole blood for PMA Cytometric identification 
The methodology of PMA cytometric identification and analysis has been described 
in chapter 2 (section 2.2). 
5.3.5 Preparation of platelet poor plasma (PPP) MP Cytometric identification 
and ELISA 
3.5 mls of whole blood was collected into bottles containing 3.2% trisodium citrate 
(Becton Dickinson). Platelet poor plasma was obtained by immediate centrifugation 
of the whole blood at 5000G for 5 minutes twice. PPP was then stored at –80o 
Celcius for later analyses of microparticle estimation and enzyme-linked 
immunosorbent assay (ELISA) studies (see below). 
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5.3.6 MP identification and characterization using flow cytometry 
MPs were identified by flow cytometry as previously described in chapter 2 (section 
2.3), chapter 3 (section 3.3) and chapter 4 (section 4.3). 
 
5.3.7 Estimation of soluble P-selectin (s P-selectin) 
Soluble p-selectin was measured using a quantitive sandwich enzyme immunoassay 
(ELISA) technique using a kit from R&D  systems  (Europe) as described in chapter 
2 (section 2.4.2.3). 
 
5.3.8 Statistical analyses 
Continuous variables were expressed as medians with interquartile range (IQR). 
Categorical variables were expressed as percentages with 95% confidence intervals 
(95% CIs). Comparisons between the two groups and the two (coronary and right 
atrium) compartments were performed using the Mann-Whitney U test. Fisher exact 
test was used for proportions and Spearman factor r for correlations. Differences with 
a 2-sided p value <0.05 were considered to be statistically significant. All statistical 
analyses were performed with GraphPad Prism 5 statistical software. 
 
5.4 Results 
The demographics and baseline characteristics of the study population are shown in 
the table 4.1, section 4.4 (chapter 4). 
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5.4.1 High levels of local CO AnV+MP are detected in patients with ACS 
Table 4.2 in chapter 4 summarises the CO MP levels between the two patient groups. 
Total AnV+MP, AnV+PMP, AnV+EMPs, AnV+NMP and TF+MMP in the CO 
were higher in the ACS population compared with SA (Figure 4.1, chapter 4).  
 
5.4.2 Platelet, endothelial and leucocyte MP levels are higher in the systemic 
(RA) circulation of patients with ACS compared with SA 
Table 4.2 in chapter 4 summarises the RA MP levels between the two groups. There 
was no difference in the total AnV+ MP level in the RA in the ACS group compared 
with SA. However AnV+PMP, AnV+EMPs, AnV+NMP and TF+MMP in the CO 
were higher in the ACS population compared with SA (Figure 4.2, chapter 4). 
 
5.4.3 High CD62P+PMA (in both CO and RA) and high CO s-P-selectin were 
observed in the ACS group.  
Figure 5.1 illustrates the total PMA and CD62P+PMA in the two groups. 
CD62P+PMA were higher in the ACS group vs the SA group in both the CO 
(p=0.0003) and RA (p=0.04). Total PMA in the CO and RA did not differ between 
ACS and SA. Also, CD62P+PMA in the CO were higher vs the RA in the ACS 
group (p=0.001) but not in the SA group. There was no difference between total 
PMA in the CO vs the RA in both groups. 
Coronary, but not RA, s-P-Selectin was higher in the ACS group vs the SA (Fig 3). 
There was no difference between CO and RA s-P-selectin in both groups. 
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Figure 5.1. Differences in total PMA, CD62P+PMA and soluble p-selectin in the 
acute coronary syndrome (ACS) and stable angina (SA) groups. Total PMA were 
expressed as percentage of the total monocytes. P-selectin positive PMA 
(CD62P+PMA) were expressed as percentage of the total PMA. Statistical analysis 
performed using the Mann-Whitney test. 
 
5.4.4 Coronary AnV+MP correlate with markers of platelet activation in ACS 
In the ACS group markers of platelet activation in the coronary artery correlated 
moderately positive with total AnV+MP, PMP, EMP and NMP. Soluble p-selectin 
correlated with total AnV+MP (r=0.61; p=0.001), AnV+CD42a+PMP (r=0.6; 
p=0.002) and AnV+CD42a+CD62P+PMP (r=0.64; p=0.0009) Table 5.1. Similarly 
there was a moderate positive correlation between soluble p-selectin with 
AnV+CD62E+EMP, AnV+CD105+EMP, AnV+CD54+EMP and  
AnV+CD31+EMP (r=0.62; p=0.001, r=0.56; p=0.005,  r=0.48; p=0.02 and r=0.61; 
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p=0.001 respectively). There was also a positive correlation between CD62P+PMA 
and AnV+CD42a+PMP (r=0.5; p=0.04), AnV+CD42a-CD62E+EMP (r=0.5; p=0.04) 
and AnV+CD42a-CD31+EMP (r=0.5; p=0.03) Table 5.1. 
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Fig 5.2. Positive correlation between AnV+MP and markers of platelet activation 
(platelet monocyte complexes (PMA) and soluble P-Selectin) in the coronary (CO) in 
the acute coronary (ACS) group. Spearman factor r was used for correlations. 
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Coronary samples 
Soluble P-
selectin   
CD62P+ 
PMA   
  Spearman r p value Spearman r p value 
Total AnV+ MP 0.61 0.0016 0.28 0.230 
CD42a+ MP 0.60 0.0020 0.46 0.044 
CD62P+ MP 0.64 0.0009 0.40 0.089 
CD62E+ MP 0.62 0.0016 0.46 0.046 
CD66b+ MP 0.54 0.0067 0.21 0.374 
CD54+ MP 0.48 0.0202 0.15 0.513 
CD105+ MP 0.56 0.0052 0.39 0.096 
CD31+ MP 0.61 0.0018 0.49 0.030 
TF+ MP 0.22 0.3034 0.008 0.970 
 
Table 5.1. Spearman correlations between AnV+MP and markers of platelet 
activation (platelet monocyte complexes (PMA) and soluble P-Selectin) in the 
coronary (CO) in the acute coronary syndrome (ACS) group.  
 
5.4.5 Right atrial soluble P-selectin correlate with MP levels in ACS 
In the RA of the ACS group there was a strong positive correlation between soluble 
p-selectin and total AnV+MP, AnV+CD42a+PMP and AnV+CD42a+CD62P+PMP. 
(r=0.81; p=0.001, r=0.77; p=0.003 and r=0.69; p=0.01 respectively) (Fig 5.3) There 
was also a strong correlation between soluble p-selectin and the EMP (Fig 5.3). 
AnV+TF+MMP correlated positively with soluble P-selectin r=0.72; p=0.007 (Fig 
5.3). 
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Fig 5.3 Positive correlation between AnV+MP and soluble P-selectin in the right 
atrium (RA) in the acute coronary (ACS) group. Spearman factor r was used for 
correlations. 
 
In contrast to the above in the SA group markers of platelet activation (total PMA 
and soluble P-selectin) did not correlate with total or cell specific AnV+MP.  
 
5.5 Discussion 
In chapters 3 and 4, higher expression of total AnV+MP and MP subpopulations in 
patients with ACS compared with stable angina patients both locally at the site of the 
culprit lesion and in the systemic circulation have been shown. Furthermore, 
coronary inflammatory markers correlated with MP levels and myocardial injury in 
ACS (as assessed by troponin T levels); in addition RA IL-6 levels correlated with 
MP levels and troponin T in ACS. These observations suggest that patients with 
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more severe ACS have higher levels of local and systemic inflammation, and higher 
levels of local and systemic circulating MP. 
 
The novelty of the study described in this chapter is the positive correlation between 
total AnV+MP and MP subpopulations with markers of platelet activation in ACS 
patients, both at the site of the culprit lesion and the systemic circulation. Previous 
research has shown positive correlation between soluble p-Selectin and platelet, 
endothelial and monocyte derived MP in patients with hypertension and diabetes 
mellitus (301). However this is the first study to show that a positive correlation 
between MP formation and markers of platelet activation exist in both the coronary 
artery and right atrium in ACS patients but not in patients with stable angina. 
 
The role of PMA formation in the pathophysiology of CHD remains unknown. 
Activated platelets express P-selectin on their surface which mediates the platelet-
leukocyte interaction via the P-selectin-PSGL-1 bond leading to PMA formation 
with leukocyte activation, migration and recruitment at the site of inflammation 
(10;18). The platelet-monocyte interaction via the P-selectin-PSGL-1 pathway 
increases further the adhesive and pro-thrombotic properties of monocytes by up-
regulating the expression and functionality of beta1 and beta2 integrins (32;33) and 
by TF expression on the monocyte surface respectively (23;35). It has been shown 
that activated platelets lose their surface P-selectin despite the fact they continue to 
circulate and function (19). Therefore PMA measurement may represent a more 
robust marker of platelet activation than detection of P-selectin on their surface 
(21;22). Increased PMA levels have been observed in patients with stable angina 
(36;51), ACS patients (37) and also after coronary interventions (20). The extent of 
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PMA formation depends mainly on platelet activation status rather than the 
monocyte activation (30). Also a positive relationship between inflammatory 
markers (IL6 and CRP) and markers of platelet activation like P-selectin and PMA 
has been demonstrated by Wang et al (48). Studies in patients with ACS who 
underwent PCI after administration of glycoprotein IIb/IIIa inhibitors have shown 
that inhibition of platelet adhesion and activation via glycoprotein IIb/IIIa inhibitors 
leads to PMA formation reduction in addition to the reduction of platelet activation 
and degranulation (20;39). It has also been shown that prevention of platelet 
adhesion to monocyte by blocking the P-selectin-PSGL-1 interaction reduces 
inflammation (31). Patel et al have demonstrated a trans-coronary gradient of 
platelet-leukocyte formation in patients with ACS. They found increased PMA in the 
coronary sinus compared with the aortic samples in patients with ACS (21). The 
above observations support an active involvement of PMA in the pathophysiology of 
ACS possibly via exaggerating and sustaining the coagulation cascade in addition to 
perpetuating local coronary inflammation. 
 
The data from this study has shown higher CD62P+PMA in patients with ACS 
compared with SA in both CO and the RA, in addition to the fact that CD62P+PMA 
were higher in the CO vs the RA only in ACS (Fig 5.1). In contrast, there was no 
difference in total PMA expression between ACS and SA in both CO and RA sites. 
In addition, CD62P+PMA correlated with AnV+ MP (platelet and endothelial MP) 
only in the coronary sample in the ACS group. These findings arguably support the 
hypothesis that platelets can trigger a pro-inflammatory monocyte response, via 
platelet-monocyte interaction and PMA formation, only when platelets are activated 
(platelets expressing P-selectin). Also the correlation between CD62P+PMA, a 
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marker of platelet activation and a link between platelet activation and inflammation, 
and endothelial MP underlines the crucial role of endothelial cells in the 
pathophysiology of ACS. Previous reports have shown that the presence of 
hemodynamically significant coronary stenosis (lesion with fractional flow reserve 
(FFR) ≤ 0.75) does not alter platelet reactivity in patients with stable coronary artery 
disease, nor the platelet-monocyte complexes in the systemic circulation (302). In 
addition, Bournazos et al have reported that in the absence of overt platelet 
activation, P-selectin-PSGL-1 dependent platelet-monocyte interaction represents a 
normal physiological process with little impact on the potential of monocytes to 
cause vascular injury (303). They concluded that high levels of P-selectin on the 
surface of activated platelets or binding of multiple platelets per monocyte are 
required to trigger monocyte activation via the P-selectin-PSGL-1 pathway. Also, it 
has been shown that intravenous administration of a P-selectin antagonist 
(inclacumab) in patients with ACS scheduled for PCI reduces myocardial damage 
(304). They found that peak Troponin I and creatine kinase reduced by 23%. This 
raises the possibility that PMA may contribute to the pathophysiology of ACS 
possibly via exaggerating and sustaining platelet activation and coagulation cascade 
in addition to perpetuating local coronary inflammation. Therefore, targeting PMA 
formation in ACS may interrupt the platelet-monocyte interactions and limit intra-
coronary inflammation and thrombus formation. 
 
Increased levels of s-P-selectin in the plasma have been previously demonstrated in 
patients with CHD, peripheral vascular disease and hypertension, with some 
relationship to prognosis (305;306). The observations from this study have shown 
higher CO s-P-selectin and platelet MP in the ACS vs SA with a positive correlation 
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between CO s-P-selectin and platelet MP underlining the importance of 
intracoronary platelet activation in the pathophysiology ACS. Also the strong 
correlation between endothelial MP and s-P-selectin emphasizes the role of the 
activated endothelial cells and endothelial MP as inflammatory mediators in 
pathogenesis of ACS. 
 
Interestingly TF+MP is the only MP subpopulation which did not correlate with 
markers of platelet activation in the CO despite the fact that TF+MP was higher in 
ACS vs SA in both CO and RA. Nevertheless there was a positive correlation 
between TF+MP and s-P-selectin in the systemic circulation (right atrium). The 
above could be due to the fact that the interaction between activated platelet and 
monocytes via the P-selectin-PSGL-1 pathway with subsequent PMA formation and 
TF expression on the monocyte is relatively delayed as opposed with the imminent 
platelet activation and s-P-selectin in the coronary during ACS. It could also be due 
to a systematic response of the platelet activation and inflammation with PMA and 
MP formation in the systemic circulation. 
 
The above observations raise the possibility that MP and PMA may contribute to the 
pathophysiology of ACS possibly via exaggerating and sustaining platelet activation, 
coagulation and intracoronary inflammation. Therefore, targeting MP release and 
PMA formation in ACS may limit intracoronary inflammation and thrombus 
formation. 
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5.6 Conclusions 
Markers of platelet activation correlated positively with total AnV+MP, platelet, 
endothelial and leukocyte derived MP, both at the site of the culprit lesion and in the 
systemic circulation during ACS. These novel observations suggest a potential 
important interaction between activated platelets, monocytes and endothelial cells via 
MP formation. Future studies are now required to explore how MP could be directly 
involved in the pathogenesis of ACS, since these could represent important novel 
therapeutic targets. 
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Chapter 6: P-Selectin Activated Platelet Monocyte 
Aggregates and Microvascular Dysfunction in patients with 
stable angina and non-ST elevation myocardial infarction 
undergoing PCI 
 
6.1 Summary 
 
6.2 Introduction and methods 
 
6.3 Patients and methods 
 
6.4 Results 
 
6.5 Discussion 
 
6.6 Conclusions 
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6.1 Summary 
Introduction and aims 
Microvascular dysfunction (MvD) is a powerful independent predictor of outcomes 
in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary 
intervention (PCI). Activated platelets interact with leukocytes forming platelet 
monocyte aggregates (PMA). PMA represent a sensitive marker of platelet 
activation. Our aim was to assess the relationship between MvD and PMA 
expression in patients with non-ST elevation myocardial infarction (NSTEMI) and 
stable angina (SA) treated with PCI.  
Methods 
Twenty five patients (14 patients with NSTEMI and 11 patients with SA were 
recruited. Blood samples were aspirated sequentially from the right atrium (RA), 
ascending aorta (AO) and coronary artery (CO) distal to the culprit lesion. MvD was 
assessed by measuring the index of microvascular resistance (IMR), coronary flow 
reserve (CFR) and the coronary wedge pressure (PwC) in 14 patients (7 NSTEMI 
and 7 SA). Monoclonal fluorescent antibodies and flow cytometry were used for 
platelet monocyte estimation (PMA).  
Results 
Total PMA and CD62P+ PMA did not differ between CO, AO and RA in the two 
groups. CD62P+ PMA expression in the CO and AO of the ACS group was higher 
compared to the SA group (p=0.005 and p=0.03 respectively). CwP (median) was 
higher in the ACS group (52.5 mmHg) compared to the SA group (18 mmHg) p= 
0.01. IMR did not differ between ACS and SA. CwP and IMR in both groups 
correlated positively with the total PMA in the three compartments (r2=0.3; p=0.009 
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and r2=0.4; p=0.01 for CwP and IMR respectively in ACS; r2=0.2; p=0.03 and 
r2=0.3; p=0.01 for CwP and IMR respectively in SA). 
Conclusions 
Elevated CD62P+ PMA is a hallmark of ACS. PMA correlate with measured 
microvascular dysfunction in both stable angina and ACS patients. This study 
supports the hypothesis that PMA formation may be important determinants of 
platelet activation, inflammation and microvascular dysfunction in coronary disease.  
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6.2 Introduction and aims 
Microvascular dysfunction (MvD) is a powerful independent predictor of long term 
outcomes, left ventricular function and mortality in patients presenting with acute 
coronary syndrome (ACS) and undergoing revascularization with PCI. Despite 
angiographic successful coronary artery stenting potential compromise of the 
coronary microcirculation during or after PCI is associated with “slow flow” or “no 
flow” with subsequent impaired myocardial tissue oxygenation. A number of 
different non-invasive and invasive techniques have been developed to evaluate the 
coronary microvasculature. Among the invasive methods in the catheter laboratory 
the ‘Index of microvascular resistance’ (IMR) which is derived using a Doppler or a 
pressure-temperature sensing wire, has emerged as a novel index for the assessment 
of the coronary microcirculation (233;240;243). 
Activated endothelial cells and platelets express P-selectin on their surface which 
mediates the platelet-leukocyte interaction via the P-selectin-PSGL-1 bond leading to 
platelet monocyte aggregate (PMA) formation with leukocyte activation, migration 
and recruitment at the site of inflammation (10;18). It has been shown that 
inflammatory mediators such as tumour necrosis factor-α (TNF-α) and LPS increase 
P-selectin production from the endothelial cells in addition to up-regulating P-
selectin at the cell surface (11). It has also been shown that activated platelets lose 
their surface P-selectin despite the fact they continue to circulate and function (19). 
Therefore PMA measurement may represent a more robust marker of platelet 
activation than detection of P-selectin on their surface. In addition, P-selectin on the 
surface of the activated platelets, within the PMA complex, induces monocyte TF 
expression which, in the ACS setting with a ruptured atheromatous plaque, may 
trigger or contribute to the cascade of athero-thrombosis (23). The amount of PMAs, 
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both at the site of the coronary lesion and systematically, has been described as a 
sensitive marker of platelet activation and inflammation. Increased PMA levels have 
been observed in both stable angina and  (36;51) ACS patients (37). However, the 
role of PMA formation in the pathophysiology of ACS remains unknown. Whether 
PMA is just a bystander of the inflammatory and thrombotic process occurring in the 
setting of ACS or whether the PMA is an effector of the disease remains unclear. 
Also recent data suggest that platelet monocyte interaction is a normal physiological 
process in the absence of overt platelet activation with little impact on the potential 
of monocytes to cause vascular injury (29). This subpopulation of PMA was 
identified as P-selectin positive PMAs (CD62+PMAs). I hypothesized that 1) PMA 
is higher in the ACS group compared with the stable angina and 2) a positive 
correlation should exist between PMA expression and markers of microvascular 
dysfunction. The aim of my study was to assess the relationship between 
microvascular dysfunction and the level of PMA expression, intracoronary and 
systemic (aorta and right atrium) in patients presenting with NSTEMI or stable 
angina treated with PCI.  
 
6.3 Patients and methods 
6.3.1 Study population  
Twenty five patients (14 patients with NSTEMI and 11 patients with stable angina 
(SA) presenting to our hospital with symptomatic coronary heart disease and treated 
with PCI were recruited for the study. The diagnosis of NSTEMI was based on the 
history of chest pain with or without ischaemic ECG changes (other than ST 
elevation) and a troponin T value > 0.03 ng/l (261). SA patients with symptoms were 
admitted electively for PCI. SA patients had been reviewed in the cardiology 
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outpatient clinic with a diagnosis of angina pectoris based on typically ischaemic 
sounding chest pain and a positive non-invasive test such as exercise tolerance test, 
stress echocardiography or myocardial perfusion scan. The decision for diagnostic 
angiography was made by a cardiologist as part of routine clinical care. Informed 
consent was obtained prior to the procedure from all recruited patients outside the 
cardiac catheterisation laboratory. Ethical permission was granted by the local ethics 
committee of the Royal Free Hospital, and all participants provided fully informed 
written consent. 
 
6.3.2 Exclusion criteria 
The exclusion criteria have been described in Chapter 2 (Paragraph 2.1.4) 
 
6.3.3 Coronary angiography, coronary angioplasty and blood sampling 
The coronary angiography, angioplasty procedures and blood sampling have been 
extensively described in chapters 2 (2.1) and 3 (section 3.3).   
 
6.3.4 Measuring IMR and CFR with pressure-temperature sensor wire 
Thermodilution technique (233) using a 0.014 inch floppy pressure wire (pressure 
wire 3, Radi Medical system) was used to measure IMR and CFR, in 14 patients of 
the study group (7 NSTEMI and 7 SA). The pressure wire has a microsensor which 
measures simultaneously pressure and temperature at the location of the microsensor. 
The shaft of the wire can be used as an additional thermistor, providing the input 
signal at the coronary ostium of any fluid injection with a temperature difference 
from blood. In this manner the mean transit time of the injected saline down the 
coronary artery can be calculated from a coronary thermodilution curve. 
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Thermodilution curves in the coronary artery are obtained by short manual injections 
of 3 mls 0.9% saline at room temperature. Measurements of transit time are 
calculated 3 times at base line and 3 times at maximum hyperaemia. The mean transit 
time (Tm) at baseline and maximum hyperaemia were calculated. Maximum 
hyperaemia was achieved by adenosine infusion through the femoral vein at a rate 
140 µg/kg/min. Distal coronary pressure (Pd) is recorded from the pressure wire. 
Mean aortic pressure (Pa) is measured from the coronary catheter and central venous 
pressure (Pv) is measured from the right heart catheter at maximum hyperaemia. 
Coronary wedge pressure (Pw) is also measured at maximum hyperaemia by 
inflating a semi-compliant balloon (1mm smaller that the vessel diameter) in the 
coronary artery. IMR measurements were calculated after the completion of the PCI. 
Previous research has shown that Pw below 25 mmHg implies that collateral flow is 
essentially hemodynamically insignificant (213;244-247). Therefore the complete 
IMR formula, which takes into account the contribution of the coronary collaterals, 
was used to calculate the IMR i.e. IMR= Pa × Tm × [(Pd-Pw) ÷ (Pa-Pw)] as 
described before (243). All the above measurements were taken during maximum 
hyperaemia. CFR  can be calculated  as a ratio of the average transit time at baseline 
and average transit time at maximum hyperaemia provided that the time for analysis 
of the thermodilution equals at least  one cardiac cycle, and variability between 
values of  the 3 transit times < 20%.   
 
6.3.5 Flow Cytometry and PMA methodology 
The methodology of PMA cytometric identification and analysis has been described 
in chapter 2 (section 2.2) and 5 (section 5.3.4). 
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6.3.6 Statistical analysis 
Continuous variables were expressed as medians with interquartile range (IQR). 
Categorical variables were expressed as percentages with 95% confidence intervals 
(95% CIs). Comparisons between the two groups and the two (coronary and right 
atrium) compartments were performed using the Mann-Whitney U test. Fisher exact 
test was used for proportions. Linear regression was used to correlate the markers of 
microvascular dysfunction and PMA. A 2-sided p value <0.05 were considered to be 
statistically significant. All statistical analyses were performed with Graph Pad Prism 
5 statistical software. 
 
6.4 Results 
The demographics and baseline characteristics of the study population are shown in 
table 6.1. Briefly the majority of the study population was male (83%). The SA 
patients were more likely to have past medical history of hypertension compared to 
the NSTEMI group. Also the NSTEMI patients were more likely to have family 
history of CHD. The study population was well balanced with respect to other risk 
factors, diabetes mellitus, dyslipidaemia and smoking. 
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  NSTEMI Stable Angina p value 
Number of patients (n) 14 11   
Age (mean), years 62 61 0.8 
Male 11 9 0.7 
Female 2 2 0.7 
Risk Factors       
Hypertension 3 9 0.01 
Diabetes 3 2 0.8 
Dyslipidaemia 9 4 0.3 
Smoking 4 2 0.4 
Family History of CHD 9 4 0.04 
Angiographic 
characteristics 
      
1 vessel disease 8 6 0.8 
2 vessel disease 3 3 0.8 
3 vessel disease 2 2 0.9 
Culprit vessel       
Left Anterior Descending 5 6 0.8 
Left Circumflex 4 0 N/A 
Right Coronary Artery 4 5 0.8 
Onset of symptoms to PCI 
interval (median), (mins) 
4320 N/A <0.0001 
 
Table 6.1 Baseline characteristics, demographics and angiographic data of the 
NSTEMI (non ST elevation myocardial infarction) and stable angina groups. Fisher 
exact test was used for comparison of proportions between the groups. 
 
6.4.1 Total PMA expression in the CO, AO and RA sites in ACS and SA groups 
Within NSTEMI and SA groups there were no difference seen in the expression of 
total PMA and CD62P+ PMA levels between the three sites (CO, AO and RA). In 
comparing total PMA expression in the CO, AO and RA sites between the NSTEMI 
and SA groups no difference was seen (Fig 6.1). However the expression of CD62P+ 
PMA in the CO site of the NSTEMI patients was higher compared to SA patients 
(p=0.005) Fig 6.1a. Similarly in the AO site of the NSTEMI patients the expression 
of the CD62P+ PMA was higher compared to SA (p=0.03) Fig 6.1b. There were no 
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differences in the expression CD62P+ PMA in the RA site between the two groups 
Fig 6.1c.  
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Fig 6.1 Total PMA and CD62P+ PMA in the coronary artery (CO) Fig 1a, aorta 
(AO) Fig 6.1b and the right atrium (RA) Fig 6.1c (total PMA expressed as % of 
monocytes and CD62P+ PMA as % of total PMA). PMA (platelet monocyte 
complexes), ACS (acute coronary syndrome), SA (stable angina). 
 
6.4.2 IMR, CFR and Pw in the two groups 
Pw (median (IQR) was higher in the NSTEMI group [52.5 mmHg (34.2-65.5)] 
compared with the SA group [18 mmHg (17-32)] p= 0.01] Fig 2. IMR (median 
(IQR) did not differ between NSTEMI [19.6 mmHg*sec (14.4-34.2)] and SA group 
 171 
[19.9 mmHg*sec (17.6-26.8)] Fig 2. CFR also did not differ between the two groups 
(data not shown). 
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Fig 6.2 Differences of IMR and Pw in patients with NSTEMI and SA (IMR in 
mmHg*sec, Pw in mmHg). IMR (index of microvascular dysfunction), Pw (coronary 
wedge pressure), NSTEMI (non ST elevation myocardial infarction), SA (stable 
angina). 
 
6.4.3 Correlations between IMR, Pw and PMA 
Using linear regression analysis Pw and IMR in the NSTEMI correlated positively 
with the total PMA levels in the three compartments (r2=0.3; p=0.009 and r2=0.4; 
p=0.01 for Pw and IMR respectively). In addition there was a strong positive 
correlation between Pw and CD62P+ PMA (r2=0.5; p=0.007). 
 172 
Pw (mmHg)
T
o
ta
l 
P
M
A
0 20 40 60 80
0
10
20
30
40
r
2
=0.3
p=0.009
Pw (mmHg)
C
D
6
2
P
+
 P
M
A
0 20 40 60 80
0
20
40
60
80 r
2
=0.5
p=0.007
 
 
IMR (mmHg*sec)
T
o
ta
l 
P
M
A
0 10 20 30 40 50
0
10
20
30
40
r
2
=0.4
p=0.01
 
Fig 6.3 Correlation between Pw and IMR with PMA in NSTEMI patients. IMR 
(index of microvascular dysfunction), Pw (coronary wedge pressure), NSTEMI (non 
ST elevation myocardial infarction), PMA (platelet monocyte aggregates). 
 
In the SA group there was a weak to moderate correlation between Pw and IMR with 
the total PMA (r2=0.2; p=0.03 and r2=0.3; p=0.01 for CwP and IMR respectively). 
CD62P+ PMA in the SA did not correlate with Pw or IMR.  
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Fig 6.4 Correlation between Pw and IMR with PMA in SA patients. IMR (index of 
microvascular dysfunction), Pw (coronary wedge pressure), PMA (platelet monocyte 
aggregates), SA (stable angina). 
 
6.5 Discussion 
The unique finding of this study is the positive correlation between invasive markers 
of microvascular dysfunction and PMA in patients with NSTEMI or stable angina. In 
line with previous studies CD62P+ PMA in the coronary, were higher in ACS 
patients compared with stable angina. The above findings support the knowledge that 
platelet activation is pivotal in ACS and as such CD62P+ PMA which is a sensitive 
marker of platelet activation is the hallmark of ACS. It also supports the notion that 
PMA formation is dependent on platelet activation and that PMA expression and 
platelet activation follow the same pattern of expression. Furthermore these 
observations strengthen our understanding that PMA formation in the setting of acute 
coronary syndrome occurs mainly intracoronary, at the site of the ruptured plaque, 
rather than in the peripheral circulation. The fact that the NSTEMI patients were 
studied, blood sampling and IMR measurements, 2-4 days after the onset of 
symptoms whilst receiving treatment with anti-platelet and anti-coagulant 
medications may have altered the expression of total PMA and contributed to our 
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observations that total PMA did not differ between the 2 groups. This may also 
explain the fact that only Pw was higher in the ACS group compared to the SA group 
whilst IMR and CFR did not differ between the 2 groups.  
During ACS, PMA formation at the site of plaque rupture with subsequent monocyte 
activation and cytokine release may contribute to the impairment of microcirculatory 
flow. Ko et al have found increased levels of soluble CD40 ligand, IL-6, serotonin, 
TF and factor VII in the culprit coronary artery compared to those in peripheral 
blood (307). Also a positive relationship between inflammatory markers (IL6 and 
CRP) and markers of platelet activation like P-selectin and PMA has been 
demonstrated by Wang et al (48). Takahashi et al have showed that neutrophilia on 
admission is associated with impaired microvascular reperfusion and poor functional 
recovery in patients with myocardial infarction treated with primary PCI. Similar 
finding were found by Sezer et al (49) who showed that neutrophilia and higher 
mean platelet volume were found to be associated with higher IMR, lower CFR and 
higher coronary wedge pressure in patients with ACS treated with PCI. The results of 
this study are in line with the above findings. Both total PMA and CD62P+ PMA 
correlated positively with the coronary wedge pressure in the ACS patients. Also 
IMR correlated positively with total PMA. Contrary to the above, in the SA group 
IMR and Pw correlated positively with total PMA only but not with CD62P+ PMA.  
Clinical studies in animal models, with coronary artery occlusion and reperfusion, 
have shown that administration of recombinant monoclonal PSGL-1 antibodies 
targeting the P-selectin-PSGL interaction results in inhibition of leukocyte-platelet 
and leukocyte-endothelial binding with subsequent improvement of reperfusion in 
addition to the reduction of the infarct size (308-310). However in human beings 
administration of recombinant PSGL in patients with STEMI as an adjunct to 
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thrombolysis have failed to improve clinical outcomes like TIMI flow (Thrombolysis 
in myocardial infarction), infarct size and mortality (311). This can be explained by 
the fact that in both studies the recombinant antibody was given intravenously and as 
such may have failed to reach the coronary circulation. This is because the 
recombinant antibody was human antibody and as such was probably absorbed by 
the antibody receptors expressed on the macrophages in the liver and spleen. 
Recently, Tardif et al have shown that intravenous administration of a P-selectin 
antagonist (inclacumab) in patients with ACS scheduled for PCI reduced myocardial 
damage (304). They found that peak Troponin I and creatine kinase reduced by 23%. 
The findings from this study may explain the mechanism behind the above positive 
findings. This raises the possibility that PMA may contribute to the pathophysiology 
of microvascular dysfunction via exaggerating and sustaining platelet activation and 
coagulation cascade in addition to perpetuating local coronary inflammation. 
Therefore, targeting PMA formation in ACS may interrupt the platelet-monocyte 
interactions and limit intra-coronary inflammation and thrombus formation. 
 
As discussed in the chapters above the main limitation of this study is the number of 
patients making the statistical analysis and the interpretation of correlations difficult. 
Also the presence of patient’s selection bias cannot be excluded. 
 
6.6 Conclusions 
In conclusion PMA are increased in patients with ACS compared with stable angina 
with CD62P+ PMA being a hallmark of ACS. PMA and CD62P+ PMA correlated 
positively with indices of microvascular dysfunction. Hence PMA may represent a 
marker of both platelet activation and microvascular dysfunction.  
 176 
Chapter 7: General discussion and Conclusions 
 
7.1 General discussion  
 
7.2 Conclusions
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7.1 General discussion 
The studies outlined in this thesis have investigated the intracoronary and systemic 
microparticle expression in patients presenting with ACS and SA and their 
relationship with markers of inflammation, platelet activation and myocardial 
necrosis. The relationship between PMA, a marker of platelet activation, and MvD 
was also studied. 
 
There are important limitations to the data presented in this thesis many of which 
have been discussed in the chapters above in addition to many unanswered questions. 
This chapter will highlight these limitations and proposes areas of future experiments 
that may address some of these unresolved issues. There had also been many 
difficulties running this project from designing the study to recruiting and collecting 
the blood samples and preparing them for flow cytometry. 
 
The main novel findings of this study are the demonstration of: 1) differences 
between MP levels in patients with varying severity of CHD i.e. MP levels were 
overall higher in those with ACS (more specifically the highest MP levels were 
observed in the STEMI patients) compared with SA; 2. differential local and 
systemic AnV+MP expression in human coronary artery disease; 3. differential local 
and systemic expression of inflammatory markers in ACS patients; 4. differential 
local and systemic expression of markers of platelet activation in ACS patients; 5. 
positive correlation between AnV+ MP and markers of inflammation, platelet 
activation and myocardial necrosis in ACS patients both in the CO and RA; and 6. 
positive correlation between invasive markers of microvascular dysfunction and 
PMA in human coronary artery disease. 
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In chapter 3 higher levels of total AnV+MP and MP subpopulations were 
demonstrated in patients with ACS compared with SA patients in both the CO and 
RA. It is highly likely that the source of these MP was the culprit lesion since total 
AnV+MP and MP subpopulations were higher in the coronary artery (blood sampled 
distal to the coronary culprit lesion) compared with the systemic (RA) circulation in 
the study groups. Overall these observations confirm that MP release occurs from 
culprit atheromatous lesions in ACS, and that total AnV+MP number and 
subpopulation phenotype could relate to clinical severity of ACS. These findings, 
which are consistent with previous reports (110;273), strongly suggest that MP 
release in symptomatic patients with CHD is mainly locally driven, since CO MP 
levels at the site of the complicated plaque were higher than systemic MP levels. 
Whilst a causal relationship cannot be established from these data, that these MP 
directly contribute to the pathogenesis of ACS, the above findings could have 
important implications in this context since AnV+MP are known to be both pro-
inflammatory and pro-thrombotic (77;78). These observations do not, however, 
preclude the possibility that additional contribution of MP release also takes place in 
the systemic circulation since atheromatous vascular disease is usually widespread 
and a systemic inflammatory response is observed during ACS. That said the 
findings from this study support the hypothesis that the complicated atheromatous 
plaque is the predominant source of the circulating microparticles, and that a 
topographic pattern of microparticle expression appears to exist depending on where 
you sample the microparticles i.e. the closer to the culprit lesion, the higher the level 
of microparticles. 
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The limitation of this project had been discussed in chapter 3. However it is 
worthwhile mentioning in this chapter the difficulty of obtaining blood samples 
exclusively from the coronary artery distal to the culprit lesion with aspiration 
catheter. Therefore contamination with blood from non-affected coronaries or 
systemic circulation cannot be excluded. The effects of antiplatelet and anticoagulant 
therapy on MP production, even though standardised for all patient groups, was not 
fully analysed and needs further study. In addition sampling of the infarct related 
artery proximally to the culprit lesion or sampling of a bystander coronary artery 
could have strengthened my hypothesis that the complicated atheromatous coronary 
plaque is the predominant source of microparticle release. 
 
PMP levels were higher compared with the other cell specific MP subpopulations but 
particularly so in with respect to the CO P-selectin positive PMP in the STEMI 
patients. This observation can be explained by the fact that the hallmark of ACS is 
disruption of the atheromatous plaque in the coronary tree, with subsequent platelet 
activation and thrombus formation (81). The observation of high levels of 
CD62P+PMP in the CO raises the possibility that these could amplify vascular 
inflammation and thus contribute to lesion progression by further recruitment of 
inflammatory cells expressing P-selectin glycoprotein ligand (PSGL), which binds 
CD62P (P-selectin) (29;30). Since, high CO CD62E+EMP, almost certainly derived 
from activated coronary endothelium, was also detected, it is likely that E-selectin-
PSGL binding could further mediate the interaction between inflammatory cells and 
activated endothelial cells and contribute to lesion progression (270). In addition, the 
high CO NMP which were observed could further amplify vascular inflammation 
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since NMP can bind activated endothelium and contribute to further endothelial 
activation (271). 
 
As well as amplifying inflammation, MP are also prothrombotic (76). The finding of 
high CO TF+MMP could implicate their role in clot propagation, since higher levels 
were observed in ACS patients than those with SA. Expressed TF on activated 
monocytes results in the release of TF+MMP which promote the clotting cascade 
(77).  Furthermore, irrespective of TF, AnV+MP are themselves prothrombotic (272) 
and were significantly elevated in the CO of STEMI patients. Thus MP, either total 
AnV+, and/or TF+ subpopulations could contribute to clot progression in ACS. 
 
A time dependant mode of microparticle expression appears to exist from this study. 
There was a negative correlation between the index event to PCI time and total MP, 
PMP and EMP in the CO in the NSTEMI group. This suggests that, in line with 
previous studies (112;117), there is a peak in MP release during the first 24-48 hours 
and thereafter MP levels fall. Arguably, earlier sampling (on admission) of the 
NSTEMI patients would have yielded an expression of MP levels similar to that of 
the STEMI patients. Antiplatelet and anti-coagulation therapy could have in addition 
influenced MP production. 
 
In chapters 4 and 5 the study population was divided in 2 groups (ACS, which 
includes STEMI and NSTEMI patients, vs SA). The observation, that total AnV+MP 
and MP subpopulations are elevated in patients with ACS compared with SA patients 
in both the CO and RA have been extensively discussed at the beginning of this 
chapter. CO IL-6 was higher than RA IL-6 in ACS patients, contrary to the other 
 181 
inflammatory markers which were studied. Overall, coronary inflammatory markers 
correlate with MP levels and myocardial injury in ACS (assessed by troponin T 
levels); in addition RA IL-6 levels correlated with MP levels and troponin T in ACS.  
Taken together, these results suggest that patients with more severe ACS have higher 
levels of local and systemic inflammation, and higher levels of local and systemic 
circulating MP. Whilst these data suggest that these indices correlate with extent of 
myocardial injury, and that it is indeed likely that these are causally linked, I cannot 
yet infer from our data that a causal association is definite.  
 
These data are in agreement with previous reports demonstrating that during ACS, 
circulating platelet and endothelial MPs are elevated (104-106). This pattern appears 
to exist for leukocyte (neutrophil and monocyte) derived MP, since higher levels 
were observed in ACS compared to SA patients. The observed increased MP in the 
systemic circulation are likely to be derived the local culprit CO atheromatous lesion, 
with additional contribution from systemic release secondary to the systemic 
inflammatory response we observed in the ACS patients. 
 
In addition to the differences in MP expression, the second important finding from 
chapter 4 is the differential expression of inflammatory markers in the CO and in the 
systemic circulation during ACS. In line with previous reports (278;279) increased 
intracoronary IL-6 was observed during ACS, compared with the systemic 
circulation. This IL-6 is likely to be derived from coronary endothelium (281), and/or 
from plaque leucocytes. The rest of the inflammatory markers i.e. hs-CRP, SAA and 
TNF-α were higher in the peripheral circulation, which is unsurprising since CRP 
and SAA are produced and released from the liver; while TNF-α is produced from 
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leukocytes. In the SA group there were no differences of the inflammatory markers 
between CO and RA. 
 
The unexpected observation that there were no differences of the measured 
inflammatory markers in the coronary artery between ACS and stable angina patients 
have been discussed in chapter 4. 
 
Positive correlation between total AnV+ MP and MP subpopulations with markers of 
inflammation in ACS patients was also shown in chapter 4. Intracoronary 
inflammatory markers correlated with total AnV+MP and MP subpopulations 
(including platelets, endothelial and leukocytes derived MP) whilst in the RA 
markers of inflammation correlated only with endothelial and monocyte derived 
TF+MMP. The fact that in the SA patients inflammatory markers did not correlate 
with MP formation could suggest a pivotal role of intracoronary inflammation as a 
driver of MP release from the culprit plaque in the pathogenesis of ACS.  
 
The finding from this study that SAA correlates with platelet and endothelial MP 
may also provide an explanation for the previously reported pro-coagulant and pro-
inflammatory amplification properties of SAA (190). Matsubara et al have shown 
that the increment of SAA across the coronary circulation correlated positively with 
the severity of coronary atherosclerosis (189). Higher adverse outcomes including 
myocardial infarction, revascularization and death in ACS patients with elevated 
SAA has also been previously reported (204). 
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Another potentially important finding from my study is the positive correlation 
between P-selectin positive PMP with markers of myocardial necrosis both in the CO 
and RA, emphasizing the crucial role of platelet activation in the pathogenesis of 
ACS. These data could therefore suggest a pathogenic role of MP as effectors linking 
inflammatory and prothrombotic pathways in ACS. 
 
In chapter 5 a positive correlation between total AnV+MP and MP subpopulations 
with markers of platelet activation was reported in ACS patients, both at the site of 
the culprit lesion and the systemic circulation. Previous research has shown positive 
correlation between soluble p-Selectin and platelet, endothelial and monocyte 
derived MP in patients with hypertension and diabetes mellitus (301). However this 
is the first study to show that a positive correlation between MP formation and 
markers of platelet activation exist in both the coronary artery and right atrium in 
ACS patients but not in patients with stable angina. 
 
The mechanism of PMA formation, their biological effects their role in the 
pathophysiology of CHD has been extensively discussed in chapters 2, 5 and 6. 
Higher CD62P+PMA in patients with ACS compared with SA in both CO and the 
RA, in addition to the fact that CD62P+PMA were higher in the CO vs the RA only 
in ACS have been shown in this chapter. Furthermore, CD62P+PMA correlated with 
AnV+MP (platelet and endothelial MP) only in the coronary sample in the ACS 
group. The correlation between CD62P+PMA (a marker of platelet activation and a 
link between platelet activation and inflammation) and endothelial MP underlines the 
crucial role of endothelial cells in the pathophysiology of ACS. 
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Increased levels of s-P-selectin in the plasma has been previously demonstrated in 
patients with CHD, peripheral vascular disease and hypertension, with some 
relationship to prognosis (305;306). Coronary s-P-selectin was higher in the ACS vs 
SA. The positive correlation between CO s-P-selectin and MP (platelet and 
endothelial) underlines the importance of local intracoronary platelet and endothelial 
activation with MP formation as inflammatory mediators in the pathophysiology 
ACS. Interestingly TF+MMP are the only MP subpopulation which did not correlate 
with markers of platelet activation in the CO. Nevertheless there was a positive 
correlation between TF+MMP and s-P-selectin in the systemic circulation (right 
atrium). The above could be due to the fact that the interaction between activated 
platelet and monocytes via the P-selectin-PSGL-1 pathway with subsequent PMA 
formation and TF expression on the monocyte is relatively delayed compared with 
early platelet activation via s-P-selectin in the circulation.  
 
In chapter 6, a positive correlation between invasive markers of microvascular 
dysfunction and PMA in patients with NSTEMI or stable angina was observed.  
Takahashi et al have showed that neutrophilia on admission is associated with 
impaired microvascular reperfusion and poor functional recovery in patients with 
STEMI treated with primary PCI. Similar findings were found by Sezer et al (49) 
who showed that neutrophilia and higher mean platelet volume were found to be 
associated with higher IMR, lower CFR and higher coronary wedge pressure in 
patients with ACS treated with PCI. The results of this study are in line with the 
above findings. Both total PMA and CD62P+PMA correlated positively with the 
coronary wedge pressure in the ACS patients. Also IMR correlated positively with 
 185 
total PMA. Contrary to the above, in the SA group IMR and Pw correlated positively 
with total PMA only but not with CD62P+PMA. 
 
Possible explanations of the failure, of the clinical studies of recombinant PSGL 
administration in patients with STEMI as an adjunct to thrombolysis (311), to 
improve clinical outcomes like TIMI flow, infarct size and mortality have been also 
discussed in chapter 6. The observations in chapters 5 and 6 may explain the 
mechanism of the positive findings reported by Tardif et al. They have shown that 
intravenous administration of a P-selectin antagonist (inclacumab) in patients with 
ACS scheduled for PCI reduce myocardial damage (304) by 23% peak Troponin I 
and creatine kinase. This raises the possibility that PMA may contribute to the 
pathophysiology of microvascular dysfunction via exaggerating and sustaining 
platelet activation and coagulation cascade in addition to perpetuating local coronary 
inflammation. 
 
The observations from this study raise the possibility that MP and PMA may 
contribute to the pathophysiology of ACS possibly via exaggerating and sustaining 
platelet activation, coagulation and intracoronary inflammation. Therefore, targeting 
MP release and PMA formation in ACS may limit intracoronary inflammation and 
thrombus formation. 
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7.2 Conclusions 
The study described in this thesis demonstrates higher MP levels in patients with 
STEMI versus those with NSTEMI or SA. In addition, higher MP levels were 
observed in the CO versus RA in all patient groups, strongly suggesting that the 
source of these MP is the culprit atheromatous lesion. Moreover, markers of 
inflammation and platelet activation in ACS patients, both at the site of the culprit 
lesion and in the systemic circulation, strongly correlated with total AnV+, platelet, 
endothelial, and leukocyte MP. CD62P+PMA also expressed higher in patients with 
ACS compared with stable angina and correlated positively with invasive indices of 
microvascular dysfunction in both ACS and stable angina. The interaction between 
activated platelets and monocytes with endothelial cells and the subsequent 
formation of AnV+MP and PMA during ACS would be compatible with a direct 
pathogenic link between inflammatory and prothrombotic pathways in the 
pathogenesis of ACS and myocardial necrosis. I cannot yet conclude that these MP 
have a direct pathogenic role; however, data from other studies have demonstrated 
important pro-inflammatory and prothrombotic effects of MP. This leads us to 
speculate that AnV+MP levels may be indicative of coronary artery plaque 
instability, and could directly contribute to this pathological process. Also PMA may 
represent a marker of both platelet activation and microvascular dysfunction. Future 
studies are now required to explore how MP and PMA could be directly involved in 
the pathogenesis of ACS, since these could represent important novel therapeutic 
targets. 
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